0001104659-20-013529.txt : 20200210 0001104659-20-013529.hdr.sgml : 20200210 20200210163311 ACCESSION NUMBER: 0001104659-20-013529 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20200210 DATE AS OF CHANGE: 20200210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACURA PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000786947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 110853640 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10113 FILM NUMBER: 20592389 BUSINESS ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 CITY: PALATINE STATE: IL ZIP: 60067 BUSINESS PHONE: 847-705-7709 MAIL ADDRESS: STREET 1: 616 N. NORTH COURT, SUITE 120 STREET 2: . CITY: PALATINE STATE: IL ZIP: 60067 FORMER COMPANY: FORMER CONFORMED NAME: HALSEY DRUG CO INC/NEW DATE OF NAME CHANGE: 19920703 10-Q 1 tm1928371d1_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

¨	TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to____

Commission File Number 1-10113

Acura Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

New York	11-0853640
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

616 N. North Court, Suite 120, Palatine, Illinois	60067
(Address of Principal Executive Offices)	(Zip Code)

(Registrant's telephone number, including area code: (847) 705-7709

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes ¨ No x

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this charter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files): Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

¨ Large accelerated filer	¨ Accelerated filer
x Non-accelerated filer	x Smaller reporting company	¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ¨ No x

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	ACUR	OTC Pink

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date:

Common Stock, $0.01 par value

Shares outstanding as of February 10, 2020: 21,650,294

ACURA PHARMACEUTICALS, INC. AND SUBSIDIARY

TABLE OF CONTENTS

FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019

Part 1. FINANCIAL INFORMATION		Page No.

Item 1. Financial Statements (Unaudited):

	Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018	1

	Consolidated Statements of Operations for the Three and Six months Ended June 30, 2019 and 2018	2

	Consolidated Statement of Changes in Accumulated Stockholders’ Deficit for the Three and Six months Ended June 30, 2019 and 2018	3

	Consolidated Statements of Cash Flows for the Six months Ended June 30, 2019 and 2018	4

	Notes to Consolidated Financial Statements	5

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	11

Item 4.	Controls and Procedures	18

Part II. OTHER INFORMATION

Item 1.	Legal Proceedings	46

Item 1A.	Risk Factors	46

Item 6.	Exhibits	46

Signatures		48

Unless otherwise indicated or the context otherwise requires, references to the “Company”, “Acura”, “we”, “us” and “our” refer to Acura Pharmaceuticals Inc. and its subsidiary. The Acura logo is our trademark and Acura Pharmaceuticals is our registered trademark. All other trade names, trademarks and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this Quarterly Report on Form 10-Q, appear with the trade name, trademark or service mark notice and then throughout the remainder of this Quarterly Report on Form 10-Q without the trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense.

Item 1. Financial Statements

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited; in thousands except par value)

	June 30, 2019			December 31, 2018
Assets:
Cash	$	15		$	91
Royalty receivable		44			137
Receivable from related party		725			-
Prepaid expenses and other current assets		48			166
Income tax receivable		67			67

Total current assets		899			461
Income tax receivable		68			68
Property, plant and equipment, net (Note 6)		572			606
Intangible asset, net of accumulated amortization of $1,086 and $983 (Note 3)		914			1,017

Total assets	$	2,453		$	2,152

Liabilities:
Accounts payable	$	674		$	605
Accrued expenses (Note 7)		689			596
Other current liabilities		9			11
Sales returns liability		223			223
Total current liabilities		1,595			1,435

Convertible debt to related party, net of discounts (Note 8)		6,000			4,224
Accrued interest to related party (Note 8)		4			110
Total liabilities		7,599			5,769

Commitments and contingencies (Note 15)

Stockholders’ deficit:
Common stock - $0.01 par value per share; 100,000 shares authorized, 21,300 and 21,034 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively		213			210
Additional paid-in capital		382,992			380,395
Accumulated deficit		(388,351	)		(384,222	)

Total stockholders’ deficit		(5,146	)		(3,617	)

Total liabilities and stockholders’ deficit	$	2,453		$	2,152

See accompanying notes to unaudited consolidated financial statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands except per share amounts)

	Three months Ended June 30,						Six months Ended June 30,
	2019			2018			2019			2018
Revenues:
Royalty revenue	$	46		$	76		$	113		$	274

Expenses:
Research and development		262			477			575			1,127
General and administrative		406			846			843			1,789
Total expenses		668			1,323			1,418			2,916

Operating loss		(622	)		(1,247	)		(1,305	)		(2,642	)
Loss on debt extinguishment		(2,600	)		-			(2,600	)		-
Interest expense, net (Note 10)		(119	)		(14	)		(224	)		(113	)
Loss before income taxes		(3,341	)		(1,261	)		(4,129	)		(2,755	)
Provision for income taxes		-			-			-			-
Net loss		(3,341	)	$	(1,261	)	$	(4,129	)	$	(2,755	)

Net loss per share:
Basic	$	(0.15	)	$	(0.06	)	$	(0.19	)	$	(0.13	)
Diluted	$	(0.15	)	$	(0.06	)	$	(0.19	)	$	(0.13	)
Weighted average number of shares outstanding:
Basic		21,872			21,101			21,684			21,068
Diluted		21,872			21,101			21,684			21,068

See accompanying notes to unaudited consolidated financial statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT

(Unaudited; in thousands)

	Common Stock				Additional
	Number of Shares		Par Value		Paid-in Capital		Accumulated Deficit			Total
Balance at January 1, 2019		21,034	$	210	$	380,395	$	(384,222	)	$	(3,617	)
Net loss		-		-		-		(788	)		(788	)
Non-cash share-based compensation		-		-		29		-			29
Net distribution of common stock pursuant to restricted stock unit award plan		266		3		12		-			15
Balance at March 31, 2019		21,300		213		380,436	$	(385,010	)	$	(4,361	)
Net loss		-		-		-		(3,341	)		(3,341	)
Non-cash share-based compensation		-		-		29		-			29
Debt premium from debt modification		-		-		1,382		-			1,382
Issuance of warrant		-		-		1,145		-			1,145
Balance at June 30, 2019		21,300		213		382,992	$	(388,351	)	$	(5,146	)

	Common Stock				Additional
	Number of Shares		Par Value		Paid-in Capital		Accumulated Deficit			Total
Balance at January 1, 2018		20,796	$	208	$	380,145	$	(380,380	)	$	(27	)
Net loss		-		-		-		(1,494	)		(1,494	)
Non-cash share-based compensation		-		-		62		-			62
Net distribution of common stock pursuant to restricted stock unit award plan		238		2		32		-			34
Balance at March 31, 2018		21,034		210		380,239	$	(381,874	)	$	(1,425	)
Net loss		-		-		-		(1,261	)		(1,261	)
Non-cash share-based compensation		-		-		60		-			60
Balance at June 30, 2018		21,034		210		380,299	$	(383,135	)	$	(2,626	)

See accompanying notes to unaudited consolidated financial statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

	Six months Ended June 30,
		2019			2018
Cash Flows from Operating Activities:
Net loss	$	(4,129	)	$	(2,755	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		34			38
Non-cash share-based compensation		58			122
Capitalized debt discount		(13	)		(74	)
Amortization of debt discount and deferred debt issuance costs		66			34
Amortization of intangible asset		103			103
Loss on debt extinguishment		2,600			-
Changes in assets and liabilities:
Royalty receivable		93			(23	)
Receivable from related party		(725	)		-
Prepaid expenses and other current assets		118			121
Accounts payable		69			659
Refundable retainer deposits		-			(100	)
Accrued expenses		94			(144	)
Accrued interest on loan		-			75
Accrued interest on related party loans		(106	)		-
Other current liabilities		(2	)		10
Net cash used in operating activities		(1,740	)		(1934	)
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units		14			2
Proceeds from related party loans		1,650			1,500
Principal payments on loan		-			(1,220	)
Net cash provided by financing activities		1,664			282
Net decrease in cash		(76	)		(1,652	)
Cash at beginning of period		91			2,220
Cash at end of period	$	15		$	568

Supplemental disclosure of cash flow information:
Cash interest payments on loan	$	-		$	78

See accompanying notes to unaudited consolidated financial statements.

ACURA PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(Unaudited; in thousands)

Supplemental disclosures of noncash investing and financing activities:

Six months Ended June 30, 2019

The imputed interest on the below market rate element of the related party $650 loans made to the Company through June 27, 2019, amounted to $13, and was recorded in interest income with a corresponding like amount recorded as debt discount against the principal amount of the loan.

On June 28, 2019, modifications made to the related party $5,000 loan resulted in debt extinguishment. A $2,600 loss on debt extinguishment was recorded comprising $1,150 for a common stock purchase warrant issued to the related party lender, the excess fair value premium on the newly issued convertible debt of $1,380, and the write-off of unamortized debt discount of approximately $70.

Accrued interest due of $274 on the related party $5,000 loan was rolled into principal under modifications made to the loan occurring on June 28, 2019 and the related party receivable of $725 was received on July 2, 2019.

Six months Ended June 30, 2018

The imputed interest on the below market rate element of the related party $1,500 loans, amounted to $74, and was recorded in interest income with a corresponding like amount recorded as debt discount against the principal amount of the loan.

See accompanying notes to unaudited consolidated financial statements.

ACURA PHARMACEUTICALS, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2019 AND JUNE 30, 2018

NOTE 1 – OPERATIONS AND BASIS OF PRESENTATION

Principal Operations

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Our Limitx Technology is in development with immediate-release tablets containing hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate due to its large market size and its known prevalence of oral excessive tablet abuse and overdose. The technology is designed to retard the release of active opioid drug when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. US commercialization rights to LTX-03 are licensed to Abuse Deterrent Pharmaceuticals LLC (See Note 3).

Our Aversion Technology has been licensed to Zyla Life Sciences or Zyla (formerly known as Egalet Corporation) for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths (See Note 3).

Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC (MainPointe), our Impede Technology in the United States and Canada to commercialize these Nexafed products (See Note 3).

Basis of Presentation, Liquidity and Substantial Doubt in Going Concern

The accompanying unaudited consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not contain all disclosures required by generally accepted accounting principles. Reference should be made to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of the Company, all normal recurring adjustments have been made that are necessary to present fairly the results of operations for the interim periods. Operating results for the three and six month periods ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of June 30, 2019, we had cash of $15 thousand, working capital deficit of $696 thousand and an accumulated deficit of $388 million. We had a loss from operations of $1.3 million and a net loss of $4.1 million for the six months ended June 30, 2019. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We had a loss from operations of $3.92 million and a net loss of $3.84 million for the year ended December 31, 2018. We anticipate operating losses to continue for the foreseeable future. As of February 10, 2020 we had cash of approximately $800 thousand.

On June 28, 2019, we entered into with Abuse Deterrent Pharma, LLC (AD Pharma), a License, Development and Commercialization Agreement (the “AD Pharma Agreement”). AD Pharma has the right to terminate the AD Pharma Agreement for “convenience”. Under the AD Pharma Agreement, the required monthly license payments by AD Pharma will only continue until November 2020 if AD Pharma does not exercise their right to terminate the AD Pharma Agreement. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. Delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. Should AD Pharma exercise their right to terminate the AD Pharma Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma’s right to terminate the Agreement “upon convenience”, our auditors included in their report relating to our 2018 financial statements a “going concern” explanatory paragraph as to substantial doubt on our ability to continue as a going concern.

In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying consolidated balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS

New accounting standards which have been adopted on or before June 30, 2019

Leases

In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. The classification of the lease will affect the pattern of expense recognition in the income statement such that operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842)-Targeted Improvements" (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840).

The Company adopted ASC 842 using the modified retrospective transition approach during Q1 2019, which allows the Company to not adjust the comparative periods presented. The Company has elected to adopt the package of transition practical expedients and, therefore, has not reassessed whether existing or expired contracts contain a lease or the lease classification for existing or expired. The Company did not elect the practical expedient to use hindsight for leases existing at the adoption date. Upon adoption, operating leases was to be reported on the balance sheet as a gross-up of assets and liabilities, however the Company has elected, as an accounting policy, to not recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The adoption of ASC 842 did not have an impact on the Company’s financial statements as the Company has no leases with term of more than 12 months.

NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS

The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement.

AD Pharma Agreement covering LTX-03

On June 28, 2019 we entered into with Abuse Deterrent Pharma, LLC (“AD Pharma”), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"), for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™. Acura will receive a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019. AD Pharma will pay for and reimburse Acura for all outside development costs on LTX-03. If the NDA filing for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the Limitx intellectual property. AD Pharma does have the right to terminate the AD Pharma Agreement anytime for “convenience”. AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones.

We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. (See MainPointe Agreement covering Nexafed products). The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement).

On June 28, 2019 Mr. John Schutte assigned and transferred to AD Pharma his $6.0 million promissory note, the common stock purchase warrant for 10.0 million common shares, and the security agreement granting a security interest in all of the Company’s assets. (See Note 8). Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of remaining common stock purchase warrants he holds). Mr. Schutte controls MainPointe and is the principal investor in AD Pharma.

Zyla Agreement covering Oxaydo

In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded annual amortization expense of $208 thousand for each of the years 2018 and 2017. Amortization of the patent for the years 2019 through 2021 is expected to approximate $208 thousand each year and $52 thousand be quarter.

In January 2015, we and Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, entered into a Collaboration and License Agreement (the “Zyla Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Zyla Agreement, we and Zyla formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions although no meetings were held in 2019 or to date in 2020. Zyla is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Zyla will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Zyla will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion.

Zyla paid us a $5.0 million license fee upon signing of the Zyla Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Zyla Agreement expires upon the expiration of Zyla’s royalty payment obligations in all countries. Either party may terminate the Zyla Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Zyla Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Zyla Agreement with respect to the U.S. and other countries if Zyla materially breaches its commercialization obligations. Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla’s supply of Oxaydo for a transition period.

MainPointe Agreement covering Nexafed products

In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement).

The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura.

KemPharm Agreement Covering Certain Opioid Prodrugs

In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

NOTE 4 – REVENUE FROM CONTRACTS WITH CUSTOMER

Adoption of ASC Topic 606, Revenue from Contracts with Customers

The Company adopted ASC Topic 606 on January 1, 2018 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. While the timing of future revenues under ASC Topic 606 may differ from the Company’s historical accounting practices under ASC Topic 605, the cumulative effect recorded through the Consolidated Statement of Stockholders’ Deficit was zero because there was no change in timing or measurement of revenues for open contracts at January 1, 2018.

Under ASC 606, revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at June 30, 2019.

The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation.

The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract.

Sales-based Milestones and Royalty Revenues

The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Zyla and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter.

License and Collaboration Agreement Revenues

The achievement of milestones under the Company’s license and collaboration agreements will be recorded during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled, which may result in later recognition as compared to the previous accounting standards.

Disaggregation of Total Revenues

The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.

On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.

Royalty revenues by licensee are summarized below:

	Three months Ended June 30,				Six months Ended June 30,
	2019		2018		2019		2018
Egalet	$	43	$	70	$	98	$	260
MainPointe		3		6		15		14
Royalty revenues	$	46	$	76	$	113	$	274

Contract Balance and Performance Obligations

The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2019 or December 31, 2018 was $0. Contract assets may be reported in future periods under prepaid expenses or other current assets on the balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the balance sheet.

NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES

Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at June 30, 2019 or December 31, 2018.

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at June 30, 2019 and December 31, 2018 are summarized as follows:

	June 30,			December 31,
	2019			2018
	(in thousands)
Building and improvements	$	1,273		$	1,273
Scientific equipment		598			598
Computer hardware and software		107			107
Machinery and equipment		275			275
Land and improvements		162			162
Other personal property		70			70
Office equipment		27			27
Total		2,512			2,512
Less: accumulated depreciation		(1,940	)		(1,906	)
Net property, plant and equipment	$	572		$	606

We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts. Depreciation expense was $34 thousand and $38 thousand for the six month periods ended June 30, 2019 and 2018, respectively and was $17 thousand and $18 thousand for the three month periods ended June 30, 2019 and 2018. The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately $2 thousand per month.

NOTE 7 - ACCRUED EXPENSES

Accrued expenses at June 30, 2019 and December 31, 2018 are summarized as follows:

	June 30,		December 31,
	2019		2018
	(in thousands)
Cost sharing expenses under license agreement	$	300	$	237
Other fees and services		26		36
Payroll, payroll taxes and benefits		7		6
Professional services		249		132
Financed premiums on insurance policies		36		102
Clinical, non-clinical and regulatory services		44		63
Property taxes		4		7
Franchise taxes		23		13
Total	$	689	$	596

NOTE 8 – DEBT

Fully Paid Loan

In December 2013, we entered into a Loan and Security Agreement (the “Oxford Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). In October 2018 we borrowed $1.8 million from Mr. Schutte and used $1.5 million from the loan proceeds to negotiate, settle and pay-off in full the Oxford Loan for $1.5 million. We recognized a net gain of $296 thousand on the debt settlement. All security interests of Oxford with respect to the Oxford Term Loan have been released.

The Oxford Term Loan accrued interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan was due and payable in full on December 1, 2018. As security for its obligations under the initial Oxford Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Upon the execution of the Oxford Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

In January 2015, we and Oxford amended the Oxford Loan Agreement providing for the exercise price of the Warrants to be lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the Warrant modification.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses, in connection with the Oxford Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred a total $231 thousand in deferred debt issue costs. We have amortized these costs, including debt modification additional costs, into interest expense over the term of the Term Loan using the loan’s effective interest rate of 10.16%.

Related Party Convertible Loan

From January 1, 2019 and through June 27, 2019, we borrowed an aggregate of $650 thousand from Mr. Schutte and issued various promissory notes to him with the same terms and conditions from the previous loans. Because we believed the Schutte Notes’ rate of interest is below current market rates for us, we imputed interest on the below market rate element of the loans using the 10.16% interest rate under the Oxford Loan Agreement and this has aggregated to $185 thousand as of June 27, 2019. We recorded these benefits to interest income in the period we received the loan, with a corresponding like amount as debt discount against the principal amount of the loan. The debt discount will be amortized to interest expense over the term on the loans. All our assets are pledged as collateral under the Schutte Notes, including our intellectual property.

On June 27, 2019 the aggregate amount of the loans made to the Company by Mr. Schutte aggregated $5.0 million. On June 28, 2019 we entered into an agreement to borrow an additional $725 thousand from Mr. Schutte, which was received on July 2, 2019, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted principal and interest conversion rights into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the loan is convertible into 37.5 million shares of our common stock. The modifications to the loan and the method of accounting for the loan changes resulted in a $2.6 million loss on debt extinguishment. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

The events of default under the $6.0 million note are limited to bankruptcy defaults, failure to pay interest and principal when due on July 1, 2023 or upon the termination of the AD Pharma agreement covering LTX-03. The $6.0 million note may be prepaid at any time in whole or in part but only with the consent of the noteholder.

Our debt interest expense for the three and six month months ended June 30, 2019 and 2018 consisted of the following:

	Three months Ended June 30,						Six months Ended June 30,
	2019			2018			2019			2018
Interest expense:
Fully paid term loan	$	-		$	63		$	-		$	145
Related party term loans		88			8			168			8
Debt discount		34			13			66			24
Debt issue costs		-			4			-			10
Financed insurance premiums		1			-			3			-
Total interest expense	$	123		$	88		$	237		$	187
Less: imputed interest income on related party loan		(4	)		(74	)		(13	)		(74	)
Total interest expense, net	$	119		$	14		$	224		$	113

NOTE 9 – RELATED PARTY TRANSACTIONS

Private Placement with Mr. John Schutte

In July 2017, we completed a $4.0 million private placement with Mr. John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units”) of the Company, at a price of $0.4488 per Unit (the “Transaction”). Each Unit consists of one share of common stock and a warrant to purchase one fifth (0.2) of a share of common stock. The issue price of the Units was equal to 85% of the average last sale price of our common stock for the five trading days prior to completion of the Transaction. The warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s common stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933.

MainPointe Pharmaceuticals LLC

Investor is a principal of MainPointe Pharmaceuticals LLC, a Kentucky limited liability company (“MainPointe”). In March 2017, we granted MainPointe an exclusive license to our Impede Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company is receiving a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported royalty revenue for the three months ended 2019 and 2018 is $3 thousand and $6 thousand, respectively and for the six months ended 2019 and 2018 is $15 thousand and $14 thousand, respectively of royalty revenue from MainPointe (See Note 3).

As part of the closing of the Transaction, the Company and Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our common stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Investor has not designated a director as of the date of filing of this Report. Galen had not designated a director and lost that right in December 2017 when it disposed of its shares of common stock in the Company. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. An independent director has not been named to fill the seat forfeited by Galen.

Loans with Mr. John Schutte

During the period January 1, 2019 through June 27, 2019 we borrowed an aggregate of $650 thousand from Mr. John Schutte. On June 28, 2019 we borrowed an additional $725 thousand from Mr. Schutte, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted conversion rights of principal and interest into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the note is convertible into 37.5 million shares of our common stock. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

AD Pharma Agreement covering LTX-03

On June 28, 2019, we entered into a License, Development and Commercialization Agreement (the "AD Pharma Agreement") with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The AD Pharma Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03. Financial arrangements include:

Monthly license payments to Acura by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (“NDA”) for LTX-03;

Reimbursement by AP Pharma of Acura’s LTX-03 outside development expenses;

Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones; and

Acura authorizes MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength).

AD Pharma may terminate the AD Pharma Agreement at any time. Additionally, if the NDA for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the intellectual property. On July 2, 2019 we received the first monthly license payment of $350 thousand. As of February 10, 2020 we have received the required monthly license payments through January 2020.

NOTE 10 – COMMON STOCK WARRANTS

Our warrant activity for the six months ended June 30, 2019 and 2018 consisted of the following (in thousands except price data):

	Six Months Ended June 30,
	2019				2018
	Number		WAvg Exercise Price		Number		WAvg Exercise Price
Outstanding, Jan. 1		1,842	$	0.59		1,842	$	0.59
Issued		10,000		0.01		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Modification		-		-		-		-
Outstanding, Jun. 30		11,842	$	0.10		1,842	$	0.59

In connection with the issuance of the $10.0 million secured promissory notes to Oxford in December 2013, we issued a common stock purchase warrant (“warrant”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. These warrants contain a cashless exercise feature (See Note 8).

As part of our July 2017 private placement transaction with Mr. Schutte, we issued a warrant to purchase approx. 1.782 million shares of our common stock. The warrant is immediately exercisable at a price of $0.528 per share and expire five years after issuance (See Note 9).

On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance (see Note 8). The warrant was assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

NOTE 11 – FAIR VALUE MEASUREMENTS

The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than our debt, are representative of their respective fair values due to their relatively short maturities. On June 28, 2019, we modified the $5.0 million related party loan and reported the debt using fair value for the changes to the loan resulting in the recognizing a $2.6 million loss on debt extinguishment.

NOTE 12 - SHARE-BASED COMPENSATION EXPENSE

Share-based Compensation

We have four share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):

	Three months Ended June 30,				Six months Ended June 30,
	2019		2018		2019		2018
	(in thousands)
Research and development costs:
Stock options	$	2	$	11	$	4	$	24
Restricted stock units		4		7		8		14
Subtotal	$	6	$	18	$	12	$	38

General and administrative costs:
Stock options	$	4	$	19	$	6	$	53
Restricted stock units		23		29		50		51
Subtotal		27	$	48		56	$	104

Total	$	33	$	66	$	68	$	142

Stock Option Award Plans

We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2019 and 2018 is shown below:

	Six Months Ended June 30,
	2019						2018
	Number of Options (000’s)			Weighted Average Exercise Price			Number of Options (000’s)			Weighted Average Exercise Price
Outstanding, Jan. 1		1,560		$	7.38			1,494		$	12.33
Granted		-			-			-			-
Exercised		-			-			-			-
Forfeited or expired		(170	)		(30.83	)		(145	)		(46.39	)
Outstanding, Jun. 30		1,390		$	4.44			1,349		$	8.68
Options exercisable		1,158		$	5.30			1,129		$	10.26

The following table summarizes information about nonvested stock options outstanding at June 30, 2019 (in thousands except price data):

	Number of Options Not Exercisable		Weighted Average Fair Value
Outstanding, Jan. 1, 2019		232	$	0.10
Granted		-		-
Vested		-		-
Forfeited		-		-
Outstanding, Jun. 30, 2019		232	$	0.10

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity.

The intrinsic value of the option awards which were vested and outstanding at each of June 30, 2019 and 2018 was $0. The total remaining unrecognized compensation cost on unvested option awards outstanding at June 30, 2019 was $9 thousand, and is expected to be recognized in operating expense in varying amounts over the 8 months remaining in the requisite service period.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors; a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). The 2017 RSU Plan was approved by our shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. The 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of June 30, 2019 there are approximately 219 thousand shares available for award under the 2017 RSU Plan and there are no remaining shares available for award under the 2014 RSU Plan.

Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The RSU awards to our non-employee directors allow for them to receive payment in cash upon the RSU award’s distribution, instead of an exchange into our common stock, for up to 40% of each RSU award. The portion of the RSU award subject to cash settlement is recorded as a liability in the Company’s balance sheet and to either general and administrative expense or research and development expense while being marked-to-market each reporting period until the award is distributed. The liability was $9 thousand and $11 thousand at June 30, 2019 and December 31, 2018, respectively.

The compensation cost to be incurred by the Company on a granted RSU award without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized over the vesting period of the RSU award to either general and administrative expense or research and development expense and recorded as additional paid-in capital.

A summary of the grants under the RSU Plans as of June 30, 2019 and 2018, and for the six month period then ended consisted of the following (in thousands):

	Six Months Ended June 30,
	2019						2018
	(in thousands)
	Number of RSUs			Number of Vested RSUs			Number of RSUs			Number of Vested RSUs
Outstanding, Jan. 1		951			459			462			262
Granted		333			-			267			-
Distributed		(267	)		(267	)		(262	)		(262	)
Vested		-			166			-			133
Forfeited or expired		-			-			(8	)		-
Outstanding, Jun. 30		1,017			358			459			133

Information about the award activity under the RSU Plans is as follows:

In December 2017, we awarded 200 thousand RSUs to employees and such RSU awards were fully vested on December 31, 2018. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2020, 2021 and 2022. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

In January 2017, we awarded approximately 60 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2017. In January 2018, these awards were distributed and they were exchanged into 214 thousand shares of our common stock while 24 thousand RSUs were settled in cash. There were also 24 thousand RSUs exchanged into common stock from prior year awards.

In January 2018, we awarded approximately 67 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2018. In January 2019, these awards were distributed and they were exchanged into 267 shares of our common stock.

In December 2018, we awarded 492 thousand RSUs to employees and such RSU awards will vested in full on December 31, 2019. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2021, 2022 and 2023. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

In January 2019, we awarded approximately 83 thousand RSUs to each of our non-employee directors. Such awards vest 25% at the end of each calendar quarter during 2019. These awards will be distributed and exchanged into common stock will occur in one third amounts on each of January 2020 and up to 40% of the award can be settled in cash.

NOTE 13 – INCOME TAXES

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse.

Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $171.8 million gross Federal NOLs at December 31, 2018 (of which approximately $167.7 million were generated prior to 2018). Because we believe the ability for us to use these NOLs generated prior to January 1, 2018 to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382, we had estimated and recorded an amount for the likely limitation to our deferred tax asset in the fourth quarter of 2017, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million at December 31, 2017. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 to offset taxable income is less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely. Future common stock transactions, such as the exercise of common stock purchase warrants or the conversion of debt into common stock, may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs.

The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both June 30, 2019 and December 31, 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

NOTE 14 – NET LOSS PER SHARE

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to both vested Restricted Stock Units (“RSUs”) which settle in shares (See Note 12) and a stock warrant exercisable for 10.0 million shares having an exercise price of $0.01 per share (See Note 8). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2019 or 2018 as the Company reported a net loss for the three and six month periods, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common share outstanding diluted computation is not impacted during any period where the exercise price of a stock option or common stock warrant is greater than the average market price of our common stock.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):

	Three months Ended June 30,						Six months Ended June 30,
	2019			2018			2019			2018
EPS – basic and diluted
Numerator: net loss	$	(3,341	)	$	(1,261	)	$	(4,129	)	$	(2,755	)
Denominator (weighted):
Common shares		21,300			21,034			21,300			21,034
RSUs - vested		242			67			218			34
Common stock purchase warrant		330			-			166			-
Basic and diluted weighted average shares outstanding		21,872			21,101			21,684			21,068
EPS – basic and diluted	$	(0.15	)	$	(0.06	)	$	(0.19	)	$	(0.13	)

Excluded securities (non-weighted):
Common shares issuable:
RSUs – vested and nonvested		659			326			659			326
Stock options – vested and nonvested		1,390			1,349			1,390			1,349
Common stock purchase warrants		1,842			1,842			1,842			1,842
Convertible loan		37,500			-			37,500			-
Total excluded potentially dilutive shares		41,391			3,517			41,391			3,517

NOTE 15 – COMMITMENTS AND CONTINGENCIES

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

None of the plaintiffs in the lawsuits filed to date have confirmed that they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. All of these lawsuits have been effectively dismissed with the exception of less than ten pending Philadelphia cases that we expect will be finally dismissed without the need for any action by us. We expect that the Court will finally dismiss the small number of remaining Pennsylvania-based cases against us with prejudice by the end of the fourth quarter of 2019. Legal fees related to this matter have been covered by our insurance carrier. Based upon the current status and evaluation, we have not accrued for any potential loss related to these matters as of June 30, 2019.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods.

Forward-Looking Statements

Certain statements in this Report constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:

our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our Limitx™ and Impede® technologies;

the expected results of clinical studies relating to LTX-03, a Limitx hydrocodone bitartrate and acetaminophen combination product, or any successor product candidate, the date by which such studies will be complete and the results will be available and whether LTX-03 will ultimately receive FDA approval;

whether Limitx will retard the release of opioid active ingredients as dose levels increase;

whether the extent to which products formulated with the Limitx Technology deter abuse or overdose will be determined sufficient by the FDA to support approval or labelling describing safety and/or abuse deterrent features;

whether our Limitx Technology can be expanded into extended-release formulations;

our and our licensee’s ability to successfully launch and commercialize our products and technologies, including Oxaydo® Tablets and our Nexafed® products;

the pricing and price discounting that may be offered by Zyla Life Sciences’ or Zyla (formerly known as Egalet Corporation) for Oxaydo;

the results of our development of our Limitx Technology;

our or our licensees’ ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;

the market acceptance of, timing of commercial launch and competitive environment for any of our products;

expectations regarding potential market share for our products;

our ability to develop and enter into additional license agreements for our product candidates using our technologies;

our exposure to product liability and other lawsuits in connection with the commercialization of our products;

the increasing cost of insurance and the availability of product liability insurance coverage;

the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;

the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;

whether the FDA will agree with or accept the results of our studies for our product candidates;

the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter (“OTC”) Monograph standards, as applicable;

the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;

changes in regulatory requirements;

adverse safety findings relating to our commercialized products or product candidates in development;

whether the FDA will agree with our analysis of our clinical and laboratory studies;

whether further studies of our product candidates will be required to support FDA approval;

whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and whether we will be able to promote the features of our technologies; and

whether Oxaydo or our Aversion and Limitx product candidates will ultimately deter abuse in commercial settings and whether our Nexafed products and Impede Technology product candidates will disrupt the processing of pseudoephedrine into methamphetamine.

In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “indicate,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “suggest,” “target,” “will,” “would” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our 2018 Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission and in Item 1A of this Report. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Accordingly, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Company Overview

We are an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is being developed to minimize the risk of opioid overdose, our Aversion® Technology is intended to address methods of abuse associated with opioid analgesics while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, pursuant to which we exclusively licensed to Zyla worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the U. S. Food and Drug Administration, or FDA, for marketing in the United States in 5mg and 7.5mg strengths. Zyla launched Oxaydo in the United States late in the third quarter of 2015. We are not actively developing product candidates utilizing our Aversion Technology.

We launched our first Impede Technology product, Nexafed, into the United States market in December 2012 and launched our Nexafed Sinus Pressure + Pain product in the United States in February 2015. On March 16, 2017, we and MainPointe Pharmaceuticals, LLC, or MainPointe, entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology in the U.S. and Canada to commercialize our Nexafed products. The MainPointe Agreement also grants MainPointe the option to expand the licensed territory to the European Union, Japan and South Korea and to add additional pseudoephedrine-containing products utilizing our Impede technology. MainPointe is controlled by Mr. John Schutte, who became our largest shareholder pursuant to a private placement completed in July 2017.

Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. We have completed four clinical studies of various product formulations utilizing the Limitx Technology which have demonstrated proof-of-concept for the Limitx Technology and will allow us to advance a product to development for a New Drug Application, or NDA. Studies AP-LTX-400, or Study 400, and Study AP-LTX-401, or Study 401, both utilizing our LTX-04 hydromorphone formulation demonstrated the mean maximum drug concentration in blood, or Cmax, was reduced in healthy adult fasted subjects by 50% to 65% when excessive buffer levels were ingested or a situation consistent with over-ingestion of tablets. Study AP-LTX-301, or Study 301 demonstrated drug Cmax from LTX-03, a Limitx hydrocodone bitartrate and acetaminophen combination product, in healthy adult fasted subjects trended toward bioequivalence in test formulations A through E and showed an increasing reduction in Cmax for formulations F through H; in which formulations A though H had increasing incremental amounts of buffer starting with no buffer in formulation A. We believe the results of Study 301 demonstrated that LTX-03 is a formulation that optimizes the balance between effective blood levels of drug for pain relief at a single tablet dose while retarding bioavailability of drug when multiple tablets are ingested. The FDA designated the development program for LTX-04 as Fast Track, which is designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. However, we intend to advance LTX-03, which combines the hydrocodone micro-particles, acetaminophen and buffer ingredients into a single tablet, as our lead Limitx product candidate due to its larger market size and its known prevalence of oral excessive tablet abuse and overdose, and we voluntarily placed the Investigational New Drug Application, or IND, for LTX-04 on inactive status. We submitted an IND for LTX-03 to the FDA in the first quarter of 2018 in order to advance to NDA development, which became effective in April 2018.

On June 28, 2019, we entered into License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC, a Kentucky limited liability company (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03. The Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03.

According to the 2017 CDC Drug Surveillance Report, opioid analgesics are one of the largest prescription drug markets in the United States with 214 million prescriptions dispensed in 2016. Prescription opioids are also the most widely abused drugs with 12 million people abusing or misusing these products annually. Oxaydo will compete in the immediate-release opioid product segment. Because immediate-release opioid products are used for both acute and chronic pain, a prescription, on average, contains 66 tablets or capsules. According to IMS Health, in 2016, sales in the immediate-release opioid product segment were approximately 194 million prescriptions, of which approximately 95% was attributable to generic products with no known safety features. Immediate-release oxycodone tablets represent approximately 30 million of these prescriptions or almost 1.7 billion tablets. The FDA approved label for our Oxaydo product describes the unique, and we believe promotable, abuse deterrent features of our product which we believe makes prescribing our product attractive to some healthcare providers.

The CDC also reported approximately 45,000 suicide deaths in the U.S. in 2016 with poisoning being the third most prevalent route of suicide. Suicides have increased 30% in the U.S. since 1999. More than 54% of suicides had no prior indication of mental health issues. We believe a significant portion of these intentional poisonings included opioid analgesics which are known to induce respiratory depression related to overdose. An analysis of forensic data associated with hydrocodone overdose deaths suggests a median dose of sixteen 10mg hydrocodone tablets was measured in the bloodstream.

In 2014, the United States retail market for over-the-counter market, or OTC, cold and allergy products containing the pseudoephedrine oral nasal decongestant was approximately $0.7 billion. In 2014, the DEA reported 9,339 laboratory incidents involving the illegal use of OTC pseudoephedrine products to manufacture the highly addictive drug methamphetamine, or meth. According to the Substance Abuse and Mental Health Services Administration, users of methamphetamine surged in 20167 to 774,000 people up from 440,000 people in 2012. As of March 16, 2017, sales of Nexafed and Nexafed Sinus are covered under the MainPointe Agreement, for which we receive a royalty.

We conduct research, development, laboratory, manufacturing, and warehousing activities at our operations facility in Culver, Indiana and lease an administrative office in Palatine, Illinois. In addition to internal capabilities and activities, we engage numerous clinical research organizations, or CROs, with expertise in regulatory affairs, clinical trial design and monitoring, clinical data management, biostatistics, medical writing, laboratory testing and related services. Our Supply Agreements with two third-party pharmaceutical product manufacturers and packagers to supply our commercial requirements for our Nexafed and Nexafed Sinus Pressure + Pain products were assigned to MainPointe in accordance with the MainPointe Agreement.

Abuse of Prescription Opioid Products and Development of Abuse Deterrent Formulations

Prescription opioids drugs, such as morphine and oxycodone, have a long history of use for the management of pain. Because they are highly effective, they are one of the largest prescribed drug categories in the U.S. However, a side effect of high doses of opioids is euphoria, or “a high”. For these reasons, opioids are the most misused or abused prescription drugs in the U.S. Opioids are offered in a variety of dosages including immediate-release tablets (or capsules), extended-release tablets (or capsules), patches and other formats. Abusers will often manipulate or tamper with the formulations to achieve their high, including:

Oral Excessive Tablet Abuse (ETA). Generally recognized as the most prevalent route of administration by abusers, the abuser simply orally ingests more tablets (or capsules) than is recommended for pain relief.

Oral Manipulated Tablet Abuse (MTA). Extended-release tablets or patches are sometimes crushed, chewed or otherwise physically or chemically manipulated to defeat the extended-release mechanism and provide an immediate-release of the opioid for oral ingestion.

Nasal snorting. Crushed tablets are insufflated for absorption of the drug through the nasal tissues.

Injection. The opioid is physically or chemically removed from the dosage and injected into the vein using a syringe.

Poly-pharmacy. Opioids are sometimes used in conjunction with alcohol, methamphetamine, or other drugs to accentuate the high.

Abuse deterrent formulations of opioid dosages incorporate physical and/or chemical barriers or functionality in the formulations to prevent or discourage an abuser from inappropriately administering the product. The extent and manner in which any of the features of abuse deterrent opioids may be described in the FDA approved label for our pipeline products will be dependent on the results of and the acceptance by the FDA of our and our licensees’ studies for each product.

Development of our abuse deterrent products, such our Aversion (if recommenced) product candidates, will require one or more abuse deterrent studies consistent with the FDA 2015 published guidance for industry on the evaluation and labeling of abuse-deterrent opioids (the “2015 Guidance”). These studies may include in vitro laboratory studies to determine, among other things, syringeability of the formulation, extractability of the opioid, and particle size of the crushed product. It is also expected that development will include human abuse liability studies comparing the abuse liability of our product candidates to currently marketed products. Because our products use known active ingredients in approved dosage strengths, the safety and efficacy of the opioid will need to be established by a series of pharmacokinetic studies demonstrating: (a) bioequivalence to an approved reference drug, (b) food effect of our formulations, and (c) dose proportionality of our formulation. A product candidate that does not achieve satisfactory pharmacokinetic results may require a phase III clinical pain study.

Further development will likely also entail additional safety and/or efficacy assessment as may be identified by the FDA for each specific formulation during the Investigational New Drug application, or IND, or NDA phase of development. In accordance with the FDA’s 2015 Guidance, we will likely have a post-approval requirement for each of our products, if approved, to perform an epidemiology study to assess the in-market impact on abuse of our formulation.

Overdose Minimized Opioid Products and Development

A known and FDA labelled side effect of the overdose of opioids is respiratory depression. High doses of opioids can affect the respiratory center of the brain resulting in a slowing and/or shallowing of the breathing which increases carbon dioxide (CO2) in the blood stream. Opioids also impact ancillary CO2 monitoring of the blood preventing the body from taking corrective action. The increased CO2 and resulting decrease in oxygen in the blood systematically shuts down body systems and may result in death.

Abusers as well as legitimate pain patients are at risk of overdose. In some cases, overdose is accidental but anecdotal reports indicate suicide rates among pain patient are increasing presumably due to their inability to access the pain medications they need to manage their condition.

In June 2019, FDA issued a draft for public comment guidance on a Benefit-Risk Assessment Framework for Opioid Analgesic Drugs. The guidance indicates FDA will “consider the public health risks of the [opioid] drug related to misuse, abuse, opioid use disorder, accidental exposure, and overdose in both patients and nonpatients, as well as any properties of the drug that may mitigate such risks”. We intend to develop our Limitx Technology products consistent with this pending guidance and perform studies to demonstrate our drug candidates have properties to mitigate the risk of overdose. Further development will likely also entail additional safety and/or efficacy assessment as may be identified by the FDA for each specific formulation during the Investigational New Drug application, or IND, or NDA phase of development.

Limitx™ Technology

Limitx Technology is intended to address the accidental or intentional consumption of multiple tablets and provide a margin of safety against respiratory depression. We believe these benefits for opioids are consistent with FDA’s proposed direction to require all newly approved opioid products to have features of benefits that provide safety or efficacy benefits over existing available opioid therapies.

Limitx Technology Products in Development

We have the following products in development utilizing our Limitx Technology:

Limitx Technology Products	Status
Immediate-release hydrocodone bitartrate with acetaminophen (LTX-03)	Initial buffer dose ranging study completed October 2017 Follow on dose ranging study completed in January 2018 Manufacturing scale-up initiated. Formulation and manufacturing process optimized for commercial scale.
Immediate-release oxycodone HCl (LTX-01) & (LTX-02)	Formulation development in process
Immediate-release non-opioid drug (LTX-09)	Formulation development in process
Immediate-release hydromorphone HCI (LTX-04)	Two Phase I exploratory pharmacokinetic studies completed. IND no longer active.

Study 400

Study 400 was a two cohort, open label, crossover design pharmacokinetic study in healthy adult subjects. Study 400 measured the rate and extent of absorption of the active drug ingredient into the bloodstream with the maximum concentration, or Cmax, typically associated with an increase in drug abuse. Cohort 1 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 1, 2 or 3 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of two different test formulations of LTX-04 (designated as LTX-04P and LTX-04S and distinguished by their respective acid neutralizing capacity) and Purdue Pharma’s marketed drug Dilaudid® as a comparator. The 1, 2 and 3 tablets subgroups in Cohort 1 completed 8, 10 and 8 subjects, respectively.

Cohort 2 enrolled 30 subjects who were randomized into three subgroups of 10 taking either 4, 6 or 8 tablets. Each subgroup subject orally swallowed the planned number of tablets in a randomized manner taking single doses of LTX-04P and the marketed drug Dilaudid as a comparator. The 4, 6 and 8 tablets subgroups in Cohort 2 completed 8, 9 and 8 subjects, respectively.

All tablets contained 2mg of hydromorphone hydrochloride. All subjects received doses of naltrexone and there was a one week washout between doses. Blood samples were taken at pre-designated time-points after dosing and were subsequently analyzed for the concentration of hydromorphone contained in the sample. All subjects in Cohort 1 had continuous pH (a measure of acid concentration) monitoring of their gastric fluid. The objective of Cohort 1 was to determine if adequate active drug entered the blood stream when one or two Limitx tablets were swallowed and to begin assessing the ability of the Limitx Technology to start retarding the release of active ingredients when three tablets are ingested. The objective of Cohort 2 was to further explore the extent the release of the hydromorphone active ingredient from LTX-04P tablets is retarded as the dose level increases to abusive levels. A safety assessment of Limitx Hydromorphone will be made from both study cohorts.

The topline results from Study 400 demonstrated that a single tablet dose delivered a Cmax of 45% and 50% lower than the reference drug for LTX-04S and LTX-04P, respectively. For an 8 tablet dose, the Cmax for LTX-04P was 59% lower than the reference drug. Doses between 1 and 8 tablets had similar reduction in Cmax compared to the reference. The extent of drug absorption, measure by area under the curve (AUC) was consistent between the Limitx products and the reference.

On December 14, 2016, we announced that we had received advice from the FDA on the continued development of LTX-04 following the FDA’s review of summary data from Study 400. The FDA confirmed our intention to reformulate LTX-04 to provide increased drug levels following an intended 1 or 2 tablet dose, noting that a scientific bridge of bioequivalence to the reference product will support a finding of safety and efficacy. The FDA also recommended that we identify studies to measure the clinical impact on abuser behavior and overdose outcome (such as drug liking and respiratory depression) associated with the reduction in Cmax when three or more LTX-04 tablets were ingested. The FDA’s advice also identified longer term studies necessary for submitting a NDA for LTX-04, including in vitro extraction studies, drug interaction studies, additional pharmacokinetic studies assessing the impact of food and beverages, and a category 3 abuse liability study.

Study 401

Study 401, completed in June 2017, also was a two cohort, open label, crossover design pharmacokinetic study in fasted, health adult subjects. Study 401 utilized a modified LTX-04 formulation containing micro-particles intended to improve drug delivery with one and two tablet dosing (LTX-04P3). Study 401 measured the rate and extent of absorption of the active drug ingredient into the blood stream with the Cmax typically associated with an increase in drug abuse. 27 subjects completed Cohort 1 swallowing a single dose tablet of LTX-04 compared to a generic hydromorphone tablet. 13 subjects completed Cohort 2 swallowing 7 LTX-04 and generic tablets doses. 15 subjects followed an undisclosed, exploratory protocol.

All tablets contained 2 mg of hydromorphone hydrochloride. All subjects received dosages of naltrexone and/or naloxone and there was a one week washout between dosages. Blood samples were taken at pre-designated time-points after dosing and were subsequently analyzed for the concentration of hydromorphone contained in the sample. The objective of Cohort 1 was to determine if adequate active drug entered the bloodstream when one Limitx tablet was swallowed. The objective of Cohort 2 was to explore the extent to which the release of the hydromorphone active ingredient from LTX-04 tablets is retarded at a seven tablet dose (oral excess abuse levels). A safety assessment of Limitx hydromorphone would be made from both study cohorts.

The topline results from Study 401 demonstrated that Cmax for a one tablet LTX-04P3 dose was approximately 50% less than the active comparator. The Cmax for the 7 tablet LTX-04P3 dose was 65% below the comparator. Study 401 also included a 7 tablet dose of LTX-04P3 taken simultaneously with an agent known to increase gastric emptying time (i.e. increase retention time of the ingredients in the stomach) which demonstrated an increase in Tmax (time of Cmax) of over 1 hour compared to LTX-04P3 taken without this agent. Since the micro-particles used in Study 401 release drug much faster than the micro-particles used in Study 400, we have concluded that the buffer levels used in both studies were excessive and is retarding the release of drug even with a single dose. Also, given that manipulating the duration of stomach acidity with a gastric emptying agent produced a significant increase in Tmax which is indicative of a delayed release of drug from LTX-04P3, we concluded the Limitx micro-particles are working as designed in that when we neutralize the stomach acid we are slowing the release of drug and subsequent absorption of drug into the blood stream.

We believe the results from Study 400 and 401 indicate the micro-particle are working as designed but that we used too much buffer for even a single tablet and did not achieve full release of the drug at a 1 tablet dose.

Study 301

Study 301 was an open-label, parallel design pharmacokinetic study testing our LIMITx formulation LTX-03 in 72 fasted healthy adult subjects randomized into 9 groups (8 subjects per group). One group swallowed a single Norco® 10/325mg tablet, the marketed comparator or reference drug. The remaining 8 groups swallowed a single LTX-03 tablet with increasing buffering amounts starting with no buffer, LTX-03 formulations A through H, respectively. All 72 subjects completed the study and the doses were generally well tolerated with no serious adverse events. One subject in the Formulation E group was not analyzed due to emesis. LTX-03 is a combination of hydrocodone bitartrate and acetaminophen.

In Study 301 bioequivalence (BE) was examined to generate information for future registration studies. Results demonstrated a trend toward BE for both active ingredients in LTX-03 formulations A through E. Formulation E had BE ratios (log transformed) for hydrocodone of 0.89 and 0.97 for Cmax and Area Under the Curve (AUC), respectively. In this small sample size study both hydrocodone BE confidence intervals were below the acceptable lower BE range of 0.80 at 0.74 and 0.79 for Cmax and AUC, respectively. For acetaminophen, Formulation E’s BE Ratios were 1.15 and 1.03 for Cmax and AUC, respectively. While the acetaminophen AUC’s met the BE standards, the Cmax upper confidence interval of 1.61 was above the acceptable upper BE range of 1.25. We believe that bioequivalence of this formulation may be achieved by reducing data variability that can be achieved through an adequately powered crossover study design with sufficient numbers of subjects in the study. For LTX-03 Formulations F though H, the higher buffer level tablets, Study 301 demonstrated a progressively increasing reduction in hydrocodone Cmax culminating in a 34% Cmax reduction associated with Formulation H, the highest level evaluated. The Cmax for acetaminophen did not decline in Formulations F through H in Study 301.

We believe that Study 301 identified a formulation that optimizes the balance between providing therapeutic blood levels of drug for pain relief at a single tablet dose while retarding the bioavailability of drug when higher buffer levels are ingested.

Non-clinical Study APT-RDR-300

Study APT-RDR-300 was a non-clinical study of respiratory depression in which five groups of 11 Sprague-Dawley rats were orally administered doses of hydrocodone ranging from 100mg of drug per kg of body weight (mg/kg) up to 300 mg/kg. 8 subjects in each group were measured for opioid induced respiratory depression (OIRD) assessing peripheral oxygen saturation (SpO2) of the blood over a 4 hour observation period. 36 subjects were analyzed as successfully completing the dosing. The additional 3 subjects in each group provided blood samples analyzed for hydrocodone at .5, 1, 2 and 4 hours post-dosing.

In study APT-RDR-300 all doses above 100 mg/kg demonstrated with statistical significance (p<.05) SpO2 measured OIRD at all time points post-dosing. The 100 mg/kg dose was not statistically significant for OIRD at any time point post-dosing. The mortality rate was correlated with higher doses. In all animals exhibiting OIRD, OIRD was acutely evident within 30 minutes of dosing which was consistent with the Cmax of the hydrocodone dose. Increased Cmax was generally associated with an increased prevalence of acute OIRD (SpO2 ≤70%). Approximately 50% of animals reaching this acute OIRD level resulted in death Due to a high variability in the pharmacokinetics and pharmacodynamics observed in the study, no further associations were possible. Acura believes the results of this study generally support the development of opioid products with a reduction in Cmax in overdose situations.

We intend to advance LTX-03 to clinical development for a New Drug Application (NDA). Therefore, we submitted an Investigational New Drug Application, or IND with respect to LTX-03, to the FDA in the first quarter of 2018, which became effective in April 2018. We are currently conducting the scale-up of the commercial manufacturing process as to-be-marketed formulations are required for all NDA development work. Among other things, we believe we will have to demonstrate a scientific link between Cmax reductions and a reduction in the risk of respiratory depression.

AD Pharma Agreement covering LTX-03

On June 28, 2019 we announced a License, Development and Commercialization Agreement (the "Agreement") with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. AD Pharma retains commercialization rights from which Acura will receive royalties and potential sales related milestones.

The Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03. Financial arrangements include monthly license payments by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (“NDA”) for LTX-03 and reimbursement by AP Pharma of Acura’s LTX-03 outside development expenses. Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones.

AD Pharma may terminate the Agreement at any time. Additionally, if the NDA for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the Agreement and take ownership of the Limitx intellectual property.

We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength). In March 2017, we granted MainPointe an exclusive license to our IMPEDE ® Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada.

Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of warrants he holds). Mr. Schutte also controls MainPointe and is an investor in AD Pharma.

Aversion Technology

Aversion Technology incorporates gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Aversion Technology and related opioid products, like Oxaydo, are covered by claims in six issued U.S. patents, which expire between November 2023 and March 2025. Our Aversion Technology products are intended to provide the same therapeutic benefits of the active drug ingredient as currently marketed products containing the same active pharmaceutical ingredient.

Oxaydo Tablets

Oxaydo (oxycodone HCI tablets) is a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. On January 7, 2015, we entered into a Collaboration and License Agreement with Zyla pursuant to which we exclusively licensed to Zyla worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is approved in 5mg and 7.5mg strengths. Zyla commenced shipping Oxaydo in the United States in October 2015.

The 2017 market for immediate-release oxycodone products was approximately 30 million dispensed prescriptions or 1.7 billion tablets. The current market is predominately serviced by generic formulations that contain no abuse deterrent features and sell for approximately $0.10 to $0.40 per tablet, depending on strength. Immediate-release opioids are prescribed by a broad cross-section of healthcare providers including primary care physicians, surgeons and pain specialists. We believe Oxaydo, given its differentiated label compared to generic products, can offer an alternative for opioid prescribing physicians concerned with the abuse or diversion for abuse of their prescriptions even at premium pricing to generics

The safety and efficacy of Oxaydo 5mg and 7.5mg tablets was established by demonstrating bioequivalence to commercially available oxycodone immediate-release tablets in the fasted state. Oxaydo differs from oxycodone tablets when taken with a high fat meal though these differences are not considered clinically relevant, and Oxaydo can be taken without regard to food. The FDA-approved label for Oxaydo describes elements unique to our Aversion Technology, which differs from current commercially available oxycodone immediate-release tablets. The label for Oxaydo includes the results from a clinical study that evaluated the effects of nasally snorting crushed Oxaydo and commercially available oxycodone tablets, and limitations on exposing Oxaydo tablets to water and other solvents and administration through feeding tubes. The clinical study evaluated 40 non-dependent recreational opioid users, who self-administered the equivalent of 15mg of oxycodone. After accounting for a first sequence effect, the study demonstrated:

30% of subjects exposed to Oxaydo responded that they would not take the drug again compared to 5% of subjects exposed to immediate-release oxycodone;

subjects taking Oxaydo reported a higher incidence of nasopharyngeal and facial adverse events compared to immediate-release oxycodone;

a decreased ability to completely insufflate two crushed Oxaydo tablets within a fixed time period (21 of 40 subjects), while all subjects were able to completely insufflate the entire dose of immediate-release oxycodone; and

small numeric differences in the median and mean drug liking scores, which were lower in response to Oxaydo than immediate-release oxycodone.

Although we believe these abuse deterrent characteristics differentiate Oxaydo from immediate-release oxycodone products currently on the market, consistent with FDA guidance which requires epidemiology studies to support a claim of abuse deterrence, the clinical significance of the difference in drug liking and difference in response to taking the drug again in this study has not been established. There is no evidence that Oxaydo has a reduced abuse liability compared to immediate release oxycodone. We and Zyla have a post-approval commitment with the FDA to perform an epidemiology study to assess the actual impact on abuse of Oxaydo tablets.

Further, the Oxaydo product label guides patients not to crush and dissolve the tablets or pre-soak, lick or otherwise wet the tablets prior to administration. Similarly, caregivers are advised not to crush and dissolve the tablets or otherwise use Oxaydo for administration via nasogastric, gastric or other feeding tubes as it may cause an obstruction. Our laboratory studies demonstrated that the Oxaydo tablet may gel when Oxaydo is exposed to certain solvents, including water.

Zyla Agreement Covering Oxaydo

On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, now known as Zyla Life Sciences or Zyla, entered into a Collaboration and License Agreement, or the Zyla Agreement, to commercialize Oxaydo tablets containing our Aversion® Technology. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved NDA for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide, or the Territory, in all strengths, subject to our right to co-promote Oxaydo in the United States.

In accordance with the Zyla Agreement, we and Zyla have formed a joint steering committee to oversee commercialization strategies and the development of product line extensions. Zyla will pay a significant portion of the expenses relating to (i) annual NDA PDUFA program fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion.

Zyla paid us an upfront payment of $5.0 million upon signing of the Zyla Agreement and a $2.5 million milestone in October 2015 in connection with the launch of Oxaydo. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150.0 million in a calendar year. In addition, we will receive from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla’s royalty payment obligations commenced on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to the Product). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

KemPharm Agreement Covering Opioid Prodrugs

On October 13, 2016, we and KemPharm Inc., or KemPharm, entered into a worldwide License Agreement, or the KemPharm Agreement, pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities, although we may provide initial technical assistance.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the 2 prodrugs licensed, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

Aversion Technology Development Opioid Products

We have suspended further development of our Aversion hydrocodone/APAP product candidate, in order to focus our time and available resources on the development of our Limitx technology product candidates. We currently have 6 additional opioids at various stages of formulation development using the Aversion Technology which are not being actively developed.

Abuse of Pseudoephedrine Products

The chemical structure of pseudoephedrine, or PSE, is very similar to methamphetamine, facilitating a straight-forward chemical conversion to methamphetamine. OTC PSE products are sometimes purchased and used for this conversion. There are multiple known processes to convert PSE to methamphetamine, all of which are not complex and do not require specialized equipment; however, many do require readily available but uncommon ingredients. Two of the three most popular processes follow two general processing steps: (1) dissolving the PSE tablets in a solvent to isolate, by filtration, purified PSE and (2) a chemical reduction of the PSE into methamphetamine for drying into crystals. The third method, or the “one-pot” method, involves the direct chemical reduction of the PSE to methamphetamine in the presence of the tablet’s inactive ingredients. All the solvents used are ultimately dried off or otherwise removed, so a wide range of solvents are amenable to the process.

Impede 1.0 Technology

Our Impede 1.0 Technology, a proprietary mixture of inactive ingredients, prevents the extraction of PSE from tablets using known extraction methods and disrupts the direct conversion of PSE from tablets into methamphetamine.

Studies sponsored by us at an international, independent laboratory demonstrated our Impede 1.0 Technology prevents the extraction of PSE from tablets for conversion into methamphetamine using what we believe are the two most common extraction methods, each requiring extraction of PSE as an initial step. Laboratory tests conducted on our behalf by an independent Clinical Research Organization, or CRO, using the “one-pot” method demonstrated that our Impede Technology disrupted the direct conversion of PSE from the tablets into methamphetamine. The study compared the amount of pure methamphetamine hydrochloride produced from Nexafed and Johnson & Johnson’s Sudafed® tablets. Using one hundred 30 mg tablets of both products, multiple one-pot tests and a variety of commonly used solvents, the study demonstrated an average of 38% of the maximum 2.7 grams of pure methamphetamine hydrochloride was recovered from Nexafed. Comparatively, approximately twice as much pure methamphetamine hydrochloride was recovered from Sudafed tablets. Both products yielded a substantial amount of additional solids such that the purity of the total powder provided contained approximately 65% methamphetamine hydrochloride.

Impede 2.0 Technology

We have previously developed a next generation, or Impede 2.0 Technology to improve the meth-resistance of our technology. We have previously completed one-pot, direct conversion meth testing performed by our CRO on the following commercially available products and on our Nexafed Impede 2.0 extended-release product, with the following results:

Product/Formulation	Meth Resistant Technology	Meth Recovery¹	Purity²
Sudafed® 30mg Tablets	none	67%	62%
Nexafed 30mg Technology	Impede® 1.0	38%	65%
Zephrex-D® 30mg Pills	Tarex®	28%	51%
Nexafed 120mg Extended-release tablets	Impede® 2.0	17%	34%

¹Total methamphetamine HCl recovered from the equivalent of 100 PSE 30mg tablets divided by the maximum theoretical yield of 2.7 grams.

²Total methamphetamine HCl recovered from the equivalent of 100 PSE 30mg tablets divided by the total weight of powder recovered.

We have previously demonstrated in a pilot clinical study the bioequivalence of a formulation of our Nexafed extended release tablets utilizing our Impede 2.0 Technology to Sudafed® 12-hour Tablets.

Nexafed Products and the MainPointe Agreement

Nexafed and Nexafed Sinus Pressure + Pain, consist of immediate release tablets. Nexafed is a 30mg pseudoephedrine tablet which until the third quarter of 2017 incorporated our patented Impede 1.0 technology and commencing in such quarter incorporated our Impede 2.0 technology. Nexafed Sinus Pressure + Pain is a 30/325mg pseudoephedrine and acetaminophen tablet which incorporates our Nexafed 1.0 technology. PSE is a widely-used nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products. While the 30mg PSE tablet is not the largest selling PSE product on the market, we believe it is the most often used product to make meth due to: (a) its relatively low selling price and (b) its simpler formulation provides better meth yields.

We have demonstrated that our Nexafed 30mg tablets are bioequivalent to Johnson & Johnson’s Sudafed 30mg Tablets when a single 2 tablet dose is administered. Commencing in 2006, the CMEA, required all non-prescription PSE products to be held securely behind the pharmacy counter, has set monthly consumer purchase volume limits, and has necessitated consumer interaction with pharmacy personnel to purchase PSE-containing products.

On March 16, 2017, we and MainPointe entered into a License, Commercialization and Option Agreement, or the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize our Nexafed products in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement and controls the marketing and sale of our Nexafed products.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million plus approximately $425 thousand for inventory and equipment being transferred. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths), including the product candidate Loratadine with pseudoephedrine (following termination of the Bayer Agreement). ). MainPointe has assigned and transferred its option rights to a Nexafed 12-hour formulation to AD Pharma. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. . On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength) and waived the $500 thousand option fee.

Impede Technology Products in Development

Given the fragmented nature of the PSE market with products containing multiple active ingredients, we have developed additional products for our Nexafed franchise:

Impede Technology Products	Status
Extended-release formulation utilizing Impede 2.0 Technology	Pilot pharmacokinetic testing demonstrated bioequivalence to Sudafed® 12-hour Tablets. Pre-IND meeting held with the FDA No imminent development planned
Extended-release combination products	No imminent development planned
Loratadine with pseudoephedrine	No imminent development planned

In July 2015, we had a pre-IND meeting with the FDA to discuss the results from our pharmacokinetic and meth-resistance testing studies to determine the development path for our extended-release development product. The FDA acknowledged the potential value of the development of risk-mitigating strategies for new formulations of pseudoephedrine products while also recognizing an approved “meth-deterrent” extended release pseudoephedrine product would be novel in the over-the-counter (OTC) setting. The FDA did not make a formal determination whether “meth-resistant” claims would be appropriate but is open to consider such an appropriately worded, evidence-based claim directed to the consumer and/or retailer. As recommended by the FDA, we have submitted additional “meth-resistant” testing information to the FDA for review prior to submitting an IND. In October 2016, we received FDA recommendations on our meth-resistant testing protocols for our Nexafed extended release tablets. We can now scale-up our manufacture batch size at a contract manufacturer which allows us to submit an IND to the FDA for our Nexafed extended release tablets, however, we have not yet committed to that level of development.

In March 2017, we completed a pilot pharmacokinetic study for the PSE and loratadine combination product using our Impede 1.0 technology. The study in 24 healthy adult subjects demonstrated sufficient, but not bioequivalent blood levels of PSE to the comparator while the second active ingredient achieved bioequivalence. Based on the product profile, we believe this formulation can be moved into final development for a 505(b)(2) NDA submission. The Company has upgraded a portion of this formulation with its Impede 2.0 Technology.

U.S. Market Opportunity for Impede PSE Products

PSE is a widely-used nasal decongestant available in many non-prescription and prescription cold, sinus and allergy products. PSE is sold in products as the only active ingredient in both immediate and extended-release products. In addition, PSE is combined with other cold, sinus and allergy ingredients such as pain relievers, cough suppressants and antihistamines. PSE also competes against phenylephrine, an alternate nasal decongestant available in non-prescription products. In 2014, a data service reported approximately $0.7 billion in retail sales of non-prescription products containing PSE. The top retail selling PSE OTC cold/allergy products in 2014 were:

Reference Brand¹	Brand Company	Active Ingredient(s)	2014 Retail Sales ($ Millions)
Claritin-D	Bayer	PSE & Loraditine²	$208.0
Allegra-D	Chattem	PSE & Fexofenadine²	$101.3
Zyrtec-D	Pfizer	PSE & Ceterizine²	$101.7
Advil Sinus	Pfizer	PSE & Ibuprofen	$58.4
Sudafed 12 Hour	J&J	PSE²	$82.3
Sudafed 30mg	J&J	PSE	$70.4

¹ Branded product only. Does not include store brand sales.

² Extended release PSE formulations

The 2014 market for 30mg PSE tablets, including store brands was approximately 470 million tablets or 19 million boxes of 24 tablets. MainPointe controls the price of Nexafed and Nexafed Sinus under the terms of the MainPointe Agreement.

The market for cold, sinus and allergy products is highly competitive and many products have strong consumer brand recognition and, in some cases, prescription drug heritage. Category leading brands are often supported by national mass marketing and promotional efforts. Consumers often have a choice to purchase a less expensive store brand. Store brands contain the same active ingredients as the more popular national brands but are not supported by large marketing campaigns and are offered at a lower price. Non-prescription products are typically distributed through retail outlets including drug store chains, food store chains, independent pharmacies and mass merchandisers. The distribution outlets for PSE products are highly consolidated. According to Chain Drug Review, the top 50 drug, food and mass merchandising chains operate approximately 40,000 pharmacies in the U.S., of which 58% are operated by the four largest chains. Stocking decisions and pharmacists recommendations for these chain pharmacies are often centralized at the corporate headquarters.

Product Labeling for Impede Technology Products

Nexafed and Nexafed Sinus Pressure + Pain products are marketed pursuant to the FDA’s OTC Monograph regulations, which require that our product have labeling as specified in the regulations. Marketing for the Nexafed products includes advertising the extraction characteristics and methamphetamine-resistant benefits of these products which is supported by our published research studies.

We expect that any of our other Impede Technology products will be marketed pursuant to an NDA or ANDA and will be subject to a label approved by the FDA. We expect that such a label will require submission of our scientifically derived abuse liability data and we intend to seek descriptions of our abuse liability studies in the FDA approved product label, although there can be no assurance that this will be the case.

U.S. Market Opportunity for Opioid Analgesic Products

The misuse and abuse of opioid analgesics continues to constitute a dynamic and challenging threat to the United States and is the nation’s fastest growing drug problem. During 2017, the US Government declared opioid abuse as an epidemic and national health emergency. According to the 2017 Centers on Disease Control Drug Surveillance Report, 11.8 million Americans aged 12 and over abused or misused prescription opioids in 2016. Further, this Report calculates that, on average, 115 Americans die every day from an opioid overdose. The majority of drug overdose deaths (66%) involve an opioid. Immediate release, or IR, opioid products comprise the vast majority of this abuse compared with extended release, or ER, opioid products.

It is estimated that more than 75 million people in the United States suffer from pain and the FDA estimates more than 61 million people receive a prescription for the opioid hydrocodone annually. For many pain sufferers, opioid analgesics provide their only pain relief. As a result, opioid analgesics are among the largest prescription drug classes in the United States with over 214 million tablet and capsule prescriptions dispensed in 2016 of which approximately 194 million were for IR opioid products and 204 million were for ER opioid products. However, physicians and other health care providers at times are reluctant to prescribe opioid analgesics for fear of misuse, abuse, and diversion of legitimate prescriptions for illicit use.

We expect our Aversion and Limitx Technology opioid products, to compete primarily in the IR opioid product segment of the United States opioid analgesic market. Because IR opioid products are used for both acute and chronic pain, a prescription, on average, contains 66 tablets or capsules. According to IMS Health, in 2016, sales in the IR opioid product segment were approximately $2.7 billion, of which ~98% was attributable to generic products. Due to fewer identified competitors and the significantly larger market for dispensed prescriptions for IR opioid products compared to ER opioid products, we have initially focused on developing IR opioid products utilizing our Aversion and Limitx Technologies. A summary of the IR opioid product prescription data for 2016 is provided below:

IR Opioid Products⁽¹⁾	2016 US Prescriptions (Millions)⁽²⁾	% of Total
Hydrocodone	90	43%
Oxycodone	55	26%
Tramadol	43	21%
Codeine	15	7%
4 Others	5	3%
Total	208	100%

¹Includes all salts and esters of the opioid and opioids in combination
with other active ingredients such as acetaminophen.

²IMS Health, 2016

Despite considerable publicity regarding the abuse of OxyContin® extended-release tablets and other ER opioid products, U.S. government statistics suggest that far more people have used IR opioid products non-medically than ER opioid products. These statistics estimate that nearly four times as many people have misused the IR opioid products Vicodin®, Lortab® and Lorcet® (hydrocodone bitartrate/acetaminophen brands and generics) than OxyContin®.

Product Labeling for Opioid Products Using Our Technologies

In April 2015, the FDA published guidance for industry on the evaluation and labeling of abuse-deterrent opioids. While the 2015 FDA Guidance is non-binding on the FDA, it outlines FDA’s current thinking on the development and labeling of abuse-deterrent products. The 2015 FDA Guidance provides for three distinct levels of pre-marketing studies that are potentially eligible for inclusion in the labeling: (1) laboratory-based in vitro manipulation and extraction studies, (2) pharmacokinetic studies, and (3) clinical abuse potential studies. The 2015 FDA Guidance further prescribes additional post-approval or epidemiology studies to determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting, which can also be included in the labeling. FDA notes “the science of abuse deterrence is relatively new. Both the technologies involved and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving. For these reasons, FDA will take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent opioid products”.

We or our licensee may seek to include descriptions of studies that characterize the safety features of our technologies in the label for our Aversion and Limitx Technology products in development. Although the FDA approved label for Oxaydo contains limitations on exposing Oxaydo tablets to water and other solvents and administration through feeding tubes, the FDA approved Oxaydo label does not contain a description of the I.V. injection studies we performed to characterize the abuse deterrent properties of Oxaydo. Zyla has committed to the FDA to undertake epidemiological studies to assess the actual consequences of abuse of Oxaydo in the market. Under the terms of the Zyla Agreement, we share a minority portion of the fees and expenses relating to such FDA required epidemiological studies, provided Zyla complies with the sections of the agreement relating thereto. The extent to which a description of the abuse-deterrent properties or results of epidemiological or other studies will be added to or included in the FDA approved product label for our products in development will be the subject of our discussions with the FDA as part of the NDA review process, even after having obtained approval of Oxaydo. Further, because the FDA closely regulates promotional materials, even if FDA initially approves labeling that includes a description of the abuse deterrent properties of the product, the FDA’s Office of Prescription Drug Promotion, or OPDP, will continue to review the acceptability of promotional labeling claims and product advertising campaigns for our marketed products.

Patents and Patent Applications

We have the following issued patents covering, among other things, our Limitx Technology:

Patent No. (Jurisdiction)	Subject matter	Issued	Expires
9,101,636 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	Aug. 2015	Nov. 2033
9,320,796 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	Apr. 2016	Nov. 2033
9,662,393 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	May 2017	Nov. 2033
10,441,657 (US)	Abuse deterrent products wherein the release of active ingredient is retarded when 3 or more doses are consumed	Sep 2019	Nov. 2033
2,892,908 (CAN)	Abuse deterrent products wherein the release of active ingredient is retarded when excessive doses are consumed	Apr. 2016	Nov. 2033
5,922,851 (JAPAN)	Abuse deterrent products wherein the release of active ingredient is retarded when excessive doses are consumed	Apr. 2016	Nov. 2033

We have the following issued patents covering, among other things, Oxaydo and our Aversion Technology:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
7,201,920 (US)	Pharmaceutical compositions including a mixture of functional inactive ingredients and specific opioid analgesics	Apr. 2007	Mar. 2025
7,510,726 (US)	A wider range of compositions than those described in the 7,201,920 Patent	Mar. 2009	Nov. 2023
7,981,439 (US)	Pharmaceutical compositions including any water soluble drug susceptible to abuse	July 2011	Aug. 2024
8,409,616 (US)	Pharmaceutical compositions of immediate-release abuse deterrent dosage forms	Apr. 2013	Nov. 2023
8,637,540 (US)	Pharmaceutical compositions of immediate-release abuse deterrent opioid products	Jan. 2014	Nov. 2023
9,492,443 (US)	Pharmaceutical compositions of immediate-release abuse deterrent opioid products	Nov. 2016	Nov. 2023

We have the following additional issued patents relating to our Aversion Technology:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
7,476,402 (US)	Pharmaceutical compositions of certain combinations of kappa and mu opioid receptor agonists and other ingredients intended to deter opioid analgesic product misuse and abuse	Jan. 2009	Nov. 2023
8,822,489 (US)	Pharmaceutical compositions of certain abuse deterrent products that contain polymers, surfactant and polysorb 80	July 2014	Nov. 2023
2,004,294,953 (AUS)	Abuse deterrent pharmaceuticals	Apr. 2010	Nov. 2024
2,010,200,979 (AUS)	Abuse deterrent pharmaceuticals	Aug. 2010	Nov. 2024
2,547,334 (CAN)	Abuse deterrent pharmaceuticals	Aug. 2010	Nov. 2024
2,647,360 (CAN)	Abuse deterrent pharmaceuticals	May 2012	Apr. 2027
175,863 (ISR)	Abuse deterrent pharmaceuticals	Nov. 2004	Nov. 2024
221,018 (ISR)	Abuse deterrent pharmaceuticals	Nov. 2004	Nov. 2024
1694260 (EUR)	Abuse deterrent pharmaceuticals	Nov. 2004	Nov. 2024

We have the following issued patents covering, among other things, our Nexafed product line and Impede 1.0 and 2.0 technologies:

Patent No. (Jurisdiction)	Subject Matter	Issued	Expires
8,901,113 (US)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Dec. 2014	Feb. 2032
9,757,466 (US)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Sept. 2017	Feb. 2032
10,004,699 (US)	Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	Jun. 2018	Dec. 2035
2010300641 (AUS)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jun. 2016	Sept. 2030
2,775,890 (CAN)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jun. 2016	Sept. 2030
2,488,029 (EUR)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Mar. 2016	Sept. 2030
218533 (ISR)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Jan. 2016	Sept. 2030
2015274936 (AUS)	Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	Sept. 2018	June 2035
13102020.5 (HK)	Pharmaceutical compositions suitable for reducing the chemical conversion of precursor compounds	Oct. 2016	Sept. 2030

In addition to our issued patents listed above and additional unlisted issued patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our Impede 1.0 and 2.0 Technologies and filed U.S. patent applications for our Limitx Technology. Except for the rights granted in the Zyla Agreement, the KemPharm Agreement, and the MainPointe Agreement and in the patent infringement settlement agreements described below, we have retained all intellectual property rights to our Aversion Technology, Impede Technology, Limitx Technology and related product candidates.

In 2012 and 2013, we received Paragraph IV Certification Notices from five generic sponsors of ANDAs for a generic drug listing our Oxaydo product as the reference listed drug. The Paragraph IV Notices referred to our 920, 726 and 439 Patents, which cover our Aversion® Technology and our Oxaydo product. We filed suit against each of such generic sponsors, Watson Laboratories, Inc., Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc. and Ranbaxy Inc., in the United States District Court for the District of Delaware alleging infringement of our 726 Patent listed in the FDA’s Orange Book. Our litigation against Watson Laboratories was dismissed by us following Watson Laboratories’ change of its Paragraph IV Certification to a Paragraph III Certification, indicating it would not launch its generic product until the expiry of our applicable Patents. Our litigation against each of the remaining generic sponsors was settled during the period October 2013 through May 2014 on an individual basis, upon mutual agreement between us and such generic sponsors. None of such settlements impacted the validity or enforceability of our Patents. See “Item 1A. Risk Factors – Generic manufacturers are using litigation and regulatory means to seek approval for generic versions of Oxaydo, which could cause Zyla’s sales to suffer and adversely impact our royalty revenue” for a discussion of the settlements and license grants relating to such patent litigation. Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

In April, 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc., or collectively Purdue, commenced a patent infringement lawsuit against us and our Oxaydo product licensee Zyla in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007, or the 007 Patent. In April 2016, Purdue commenced a second patent infringement lawsuit against us and Zyla in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s then newly issued U.S. Patent No. 9,308,171, or the 171 Patent. The actions regarding the 007 Patent and the 171 Patent are collectively referred to as the “Actions”. On April 6, 2016, we filed a petition for Inter Parties Review, or IPR Review, with the USPTO seeking to invalidate Purdue’s 007 Patent.

On May 20, 2016, we, Purdue and Zyla entered into a settlement agreement to settle the Actions and the IPR Review. Under the settlement agreement the parties dismissed or withdrew the Actions, requested that the USPTO terminate the IPR Review and exchanged mutual releases. No payments were made by the parties under the settlement agreement.

Reference is made to the Risk Factors contained in our Annual Report on Form 10-K for the year ended December 31, 2018 for a discussion, among other things, of patent applications and patents owned by third parties, including claims that may encompass our Aversion Technology and Oxaydo tablets, and the risk of infringement, interference or opposition proceedings that we may be subject to arising from such patents and patent applications.

Company’s Present Financial Condition

At June 30, 2019 we had $15 thousand of cash and at December 31, 2018 we had cash of $0.1 million. We had an accumulated deficit of $388 million at June 30, 2019. We had loss from operations of $1.3 million and net loss of $4.1 million for the six months ended June 30, 2019 and we had a net loss from operations of $3.92 million and a net loss of $3.84 million for the year ended December 31, 2018.

On June 28, 2019, we entered into License, Development and Commercialization Agreement (the Agreement) with Abuse Deterrent Pharma, LLC. The Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03. Financial arrangements include monthly license payments by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (NDA) for LTX-03 and reimbursement by AD Pharma of Acura’s LTX-03 outside development expenses. Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones. However, if the NDA application for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the Agreement and take ownership of the intellectual property.

The Agreement allows AD Pharma to terminate the Agreement “for convenience”. Should AD Pharma exercise their right to terminate the Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma’s right to terminate the Agreement “upon convenience”, our independent auditors have included in their report relating to our 2018 financial statements a “going concern” explanatory paragraph as to substantial doubt of our ability to continue as a going concern.

Also, the required monthly license payments by AD Pharma cease at November 2020 at which time the Company will need to have additional capital to fund operations until such time as LTX-03 is approved and royalty payments commence. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company’s ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations.

In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Our future sources of revenue, if any, will be derived from licensing fees, milestone payments and royalties under the AD Pharma Agreement, the Zyla Agreement, the KemPharm Agreement, the MainPointe Agreement and similar agreements which we may enter into for our Limitx products in development with other pharmaceutical company partners, for which there can be no assurance.

The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to the development and commercialization of our product candidates.

Three months Ended June 30, 2019 Compared to Three months Ended June 30, 2018

	June 30
	2019			2018			Increase (decrease)
					$000’s					Percent
Revenues:
Royalty revenue	$	46		$	76		$	(30	)	(40	)%

Expenses:
Research and development		262			477			(215	)	(45	)
General and administrative		406			846			(440	)	(52	)
Total operating expenses		668			1,323			(655	)	(50	)
Operating loss		(622	)		(1,247	)		(625	)	(50	)

Loss on debt extinguishment		(2,600	)		-			2,600		-
Interest expense, net		(119	)		(14	)		105		750
Loss before income taxes		(3,341	)		(1,261	)		2,080		165
Provision for income taxes		-			-			-		-
Net loss	$	(3,341	)	$	(1,261	)	$	2,080		165	%

Revenue

Royalty Revenue

In connection with our agreement with Zyla for Oxaydo tablets, we earn a royalty based on Oxaydo net sales. We recognized $43 thousand and $70 thousand of royalty revenue during the three months ended June 30, 2019 and 2018, respectively.

In connection with our agreement with MainPointe for the Nexafed products, we earn a royalty of 7.5% on net sales. We recognized $3 thousand and $6 thousand of royalty revenue during the three months ended June 30, 2019 and 2018, respectively.

Expenses

Research and Development

Research and development expense is primarily associated with our Limitx Technology development activity. Included in each of June 30, 2019 and 2018 reported quarterly expenses are share-based compensation expenses of approximately $6 thousand and $18 thousand, respectively. Excluding the share-based compensation expense, our research and development expenses decreased by $203 thousand between reporting periods primarily in the categories of salaries, company insurance premiums and outside clinical and development expenses.

General and Administrative

Our general and administrative expenses primarily consisted of legal, audit and other professional services, corporate insurance, and payroll. Included in each of the June 30, 2019 and 2018 quarterly results are share-based compensation expenses of approximately $39 thousand and $48 thousand, respectively. Excluding this share-based compensation expense, our general and administrative expenses decreased by $431 thousand between reporting periods, resulting primarily in the categories of salaries, company insurance premiums, patent and general legal activities, director compensation, and investment and accounting consulting fees.

Loss on Debt Extinguishment

On June 28, 2019, we modified the $5.0 million related party loan and the accounting method used for the changes to the loan resulted in the recognizing a $2.6 million loss on debt extinguishment.

Interest Expense, net

During the three months ended June 30, 2019 and 2018, we incurred net interest expense on our term loans of $119 thousand and $14 thousand, respectively.

Income Taxes

Our results for 2019 and 2018 show no federal or state income tax benefit provisions due to 100% allowances placed against them for the uncertainty of their future utilization.

Six months Ended June 30, 2019 Compared to Six months Ended June 30, 2018

	June 30
	2019			2018			Increase (decrease)
					$000’s					Percent
Revenues:
Royalty revenue	$	113		$	274		$	(161	)	(59	)%

Expenses:
Research and development		575			1,127			(552	)	(50	)
General and administrative		843			1,789			(946	)	(53	)
Total operating expenses		1,418			2,916			(1,498	)	(51	)
Operating loss		(1,305	)		(2,642	)		(1,337	)	(51	)

Loss on debt extinguishment		(2,600	)		-			2,600		-
Interest expense, net		(224	)		(113	)		111		98
Loss before income taxes		(4,129	)		(2,755	)		1,374		50
Provision for income taxes		-			-			-		-
Net loss	$	(4,129	)	$	(2,755	)	$	1,374		50	%

Revenue

Royalty Revenue

In connection with our agreement with Zyla for Oxaydo tablets, we earn a royalty based on Oxaydo net sales. We recognized $98 thousand and $260 thousand of royalty revenue during the six months ended June 30, 2019 and 2018, respectively. Included in the 2018 results is a one-time benefit of $89 thousand on royalty revenue reported to us by Zyla for the effect of their adoption of ASC 606 on Oxaydo net sales.

In connection with our agreement with MainPointe for the Nexafed products, we earn a royalty of 7.5% on net sales.

We recognized $15 thousand and $14 thousand of royalty revenue during the six months ended June 30, 2019 and 2018, respectively.

Expenses

Research and Development

Research and development expense is primarily associated with our Limitx Technology development activity. Included in each of June 30, 2019 and 2018 reported quarterly expenses are share-based compensation expenses of approximately $12 thousand and $38 thousand, respectively. Excluding the share-based compensation expense, our research and development expenses decreased by $526 thousand between reporting periods primarily in the categories of salaries, company insurance premiums and outside clinical and development expenses.

General and Administrative

Our general and administrative expenses primarily consisted of legal, audit and other professional services, corporate insurance, and payroll. Included in each of the June 30, 2019 and 2018 quarterly results are share-based compensation expenses of approximately $68 thousand and $104 thousand, respectively. Excluding this share-based compensation expense, our general and administrative expenses decreased by $910 thousand between reporting periods, resulting primarily in the categories of salaries, company insurance premiums, patent and general legal activities, director compensation, and investment and accounting consulting fees.

Loss on Debt Extinguishment

On June 28, 2019, we modified the $5.0 million related party loan and the accounting method used for the changes to the loan resulted in the recognizing a $2.6 million loss on debt extinguishment.

Interest Expense, net

During the six months ended June 30, 2019 and 2018, we incurred net interest expense on our term loans of $224 thousand and $113 thousand, respectively. The term loan from Oxford having a maturity date of December 1, 2018, was negotiated and settled in October 2018 using loan proceeds from Mr. Schutte.

Income Taxes

Our results for 2019 and 2018 show no federal or state income tax benefit provisions due to 100% allowances placed against them for the uncertainty of their future utilization.

Liquidity and Capital Resources

At June 30, 2019 we had cash of $15 thousand and December 31, 2018 we had cash of $0.1 million. As of February 10, 2020 our cash balance was approximately $800 thousand. Additionally, the License, Development and Commercialization Agreement dated June 28, 2019 (the “Agreement”) requires AD Pharma to pay us monthly license payments of $350 thousand from July 2019 through November 2020 and pay all outside development costs for LTX-03.

However, the Agreement allows AD Pharma to terminate the Agreement “for convenience”. Should AD Pharma exercise their right to terminate the Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma’s right to terminate the Agreement “upon convenience”, our independent auditors have included in their report relating to our 2018 financial statements a “going concern” explanatory paragraph as to substantial doubt of our ability to continue as a going concern.

Critical Accounting Policies

Note 1 of the Notes to Consolidated Financial Statements, in the Company’s 2018 Annual Report on Form 10-K, includes a summary of the Company's significant accounting policies and methods used in the preparation of the financial statements. The application of these accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates. The Company's critical accounting policies described in the 2018 Annual Report are also applicable to 2019.

Item 4. Controls and Procedures

(a) Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined on Rules 13a – 13(e) and 15(d) – 15(e) under the Exchange Act) as of the end of the period covered by this Report. The Company’s disclosure controls and procedures are designed to provide reasonable assurance that information is recorded, processed, summarized and reported accurately and on a timely basis in the Company’s periodic reports filed with the SEC. Based upon such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures are effective to provide reasonable assurance. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute assurance that it will detect or uncover failures within the Company to disclose material information otherwise require to be set forth in the Company’s periodic reports.

(b) Changes in Internal Controls over Financial Reporting. There were no changes in our internal controls over financial reporting during the second fiscal quarter of 2019 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

The information required by this Item is incorporated by reference to Note 15, “Commitments and Contingencies,” in Part I, Item 1, “Financial Statements.”

Item 1A. Risk Factors

Investors in our common stock should consider the following risk factors, in addition to those risk factors set forth in our 2018 Annual Report on Form 10-K:

We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to us; if we fail to raise additional funding we will cease operations and/or seek protection under applicable bankruptcy laws.

Our operations to date have consumed substantial amounts of cash. Negative cash flows from our operations are expected to continue over at least the next several years. Our cash utilization amount is highly dependent on the progress of our product development programs, particularly, the results of our preclinical and clinical studies of our Limitx product candidates and the cost, timing and outcomes of regulatory approval for our Limitx product candidates. In addition, the further development of our ongoing clinical trials will depend on upcoming analysis and results of those studies and our financial resources at that time. As of February 10, 2020 our cash balance was approximately $800 thousand. Additionally, the Agreement with AD Pharma calls for monthly license payments of $350 thousand from July 2019 through November 2020 and as well as their payment of all outside development costs for LTX-03. We expect these amounts will fund operations through 2020. The monthly payments by AD Pharma cease in November 2020 at which time the Company will need to have additional capital to fund operations until such time as LTX-03 is approved and royalty payments commence. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding.

We will require future additional capital infusions including public or private financing, strategic partnerships or other arrangements with organizations that have capabilities and/or products that are complementary to our own capabilities and/or products, in order to continue the development of our product candidates. However, there can be no assurances that we will complete any financings, strategic alliances or collaborative development agreements, and the terms of such arrangements may not be advantageous to us. Any additional equity financing will be dilutive to our current stockholders and debt financing, if available, may involve restrictive covenants. If we raise funds through collaborative or licensing arrangements, we may be required to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize. Our failure to raise capital when needed could materially harm our business, financial condition and results of operations. In the absence of the receipt of additional financing or payments under third-party license or collaborative agreements, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value of the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidate to sustain and grow our operations.

Our ongoing capital requirements will depend on numerous factors, including: the progress and results of preclinical testing and clinical trials of our Limitx product candidates under development; the costs of complying with the FDA and other domestic regulatory agency requirements, the progress of our research and development programs and those of our partners; the time and costs expended and required to obtain any necessary or desired regulatory approvals; our ability to enter into licensing arrangements, including any unanticipated licensing arrangements that may be necessary to enable us to continue our development and clinical trial programs; the costs and expenses of filing, prosecuting and, if necessary, enforcing our patent claims, or defending against possible claims of infringement by third-party patent or other technology rights; the cost of commercialization activities and arrangements that we undertake; and the demand for our products, which demand depends in turn on circumstances and uncertainties that cannot be fully known, understood or quantified unless and until the time of approval, including the FDA approved label for any product.

Item 6. Exhibits

The exhibits required by this Item are listed below.

31.1	Certification of Periodic Report by Chief Executive Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

31.2	Certification of Periodic Report by Chief Financial Officer pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

32.1	Certification of Periodic Report by the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

10.47

Promissory Note Dated May 1, 2019

10.48

Promissory Note Dated June 12, 2019

101.INS	XBRL Instance Document

101.SCH	XBRL Taxonomy Extension Schema Document

101.CAL	XBRL Taxonomy Extension Calculation Linkbase

101.LAB	XBRL Taxonomy Extension Label Linkbase

101.PRE	XBRL Taxonomy Extension Presentation Linkbase

101.DEF	XBRL Taxonomy Extension Definition Linkbase

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

February 10, 2020	ACURA PHARMACEUTICALS, INC.


	/s/ Robert B. Jones
	Robert B. Jones
	Chief Executive Officer


	/s/ Peter A. Clemens
	Peter A. Clemens
	Senior VP & Chief Financial Officer

EX-10.47 2 tm1928371d1_ex10-47.htm EXHIBIT 10.47

Exhibit 10.47

PROMISSORY NOTE

FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his assigns (the “Noteholder”), the principal amount of ONE HUNDRED THOUSAND DOLLARS ($100,000) together with all accrued interest thereon, as provided in this Promissory Note (this "Note").

1. Definitions. Unless defined elsewhere in this Note, capitalized terms used herein shall have the meanings set forth in this Section 1.

"Affiliate" means as to any Person, any other Person that, directly or indirectly through one or more intermediaries, is in control of, is controlled by, or is under common control with, such Person. For purposes of this definition, "control" of a Person means the power, directly or indirectly, either to (a) vote more than 50% of the securities having ordinary voting power for the election of directors (or persons performing similar functions) of such Person or (b) direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.

"Person" means any individual, corporation, limited liability company, trust, joint venture, association, company, limited or general partnership, unincorporated organization, governmental authority or other entity.

"Prime Rate" means the rate of interest per annum equal to the prime rate as reported by the Wall Street Journal.

2. Loan. On the date hereof Noteholder is funding a loan of $100,000 (the “Loan”) to Borrower.

3. Payment Dates; Optional Prepayments;

3.1 Payment Dates. The aggregate unpaid principal amount of the Loan together with all accrued and unpaid interest thereon shall be due and payable on January 2, 2020 (the “Maturity Date”).

3.2 Optional Prepayments. The Borrower may prepay the Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment.

3.3 Payment Mechanics. All payments of interest and principal shall be made in lawful money of the United States of America on the date on which such payment is due by wire transfer of immediately available funds to the Noteholder's account at a bank specified by the Noteholder in writing.

4. Interest. The outstanding principal amount of the Loan shall bear interest at a rate equal to the Prime Rate plus 2% per anum and shall accrue and be payable at the Maturity Date. All computations of interest shall be made on the basis of a 360 day year consisting of 12 months of 30 days.

5. Events of Default. The occurrence and continuance of any of the following shall constitute an “Event of Default” hereunder:

5.1 Failure to Pay. The Borrower fails to pay any amount of principal of, or interest on, the Loan when due and such failure continues for 5 days after written notice to the Borrower.

5.2 Bankruptcy. (A) The Borrower commences any case, proceeding or other action (i) under any existing or future law relating to bankruptcy, insolvency, reorganization, or other relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it as bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts or (ii) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or the Borrower makes a general assignment for the benefit of its creditors; or (B) there is commenced against the Borrower any case, proceeding or other action of a nature referred to in Section 5.2(A) above which (i) results in the entry of an order for relief or any such adjudication or appointment or (ii) remains undismissed, undischarged or unbonded for a period of 60 days.

6. Remedies. Upon the occurrence of any Event of Default and at any time thereafter during the continuance of such Event of Default, the Noteholder may at its option, by written notice to the Borrower declare the entire principal amount of this Note, together with all accrued interest thereon, immediately due and payable, provided, however that, if an Event of Default described in Section 5.2 shall occur, the principal of and accrued interest on the Loan shall become immediately due and payable without any notice, declaration or other act on the part of the Noteholder.

7. Miscellaneous.

7.1 Governing Law. This Note, and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Note and the transactions contemplated hereby and thereby shall be governed by the laws of the State of New York, without giving effect to conflict of law provisions.

7.2 Successors and Assigns. This Note is non-negotiable but may be assigned or transferred by the Noteholder.

7.3 Waiver of Notice. The Borrower hereby waives demand for payment, presentment for payment, protest, notice of payment, notice of dishonor, notice of nonpayment, notice of acceleration of maturity and diligence in taking any action to collect sums owing hereunder.

7.4 Amendments and Waivers. No term of this Note may be waived, modified or amended except by an instrument in writing signed the Noteholder and Borrower. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.

7.5 No Waiver; Cumulative Remedies. No failure to exercise and no delay in exercising on the part of the Noteholder, of any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.

7.6 Security. This Note is secured. Borrower shall grant a security interest to Noteholder, execute all documents reasonably required by Noteholder and take all action reasonably necessary to secure and perfect Noteholder’s security interest in all of Borrower’s property including, but not limited to, accounts, inventory, equipment, general intangibles, intellectual property, chattel paper, investment property, instruments, documents, letter of credit rights, insurance proceeds and real estate, excluding agreements that by their terms may not be collaterally assigned and other property that may not be collaterally assigned (such as intent to use trademark applications), in each case without causing a default, termination or right of termination.

IN WITNESS WHEREOF, the Borrower has executed this Note as of May 1, 2019.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Name: Peter A. Clemens

Title: Senior Vice President & CFO

EX-10.48 3 tm1928371d1_ex10-48.htm EXHIBIT 10.48

Exhibit 10.48

PROMISSORY NOTE

FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, ACURA PHARMACEUTICALS, INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Borrower”), hereby unconditionally promises to pay to the order of John Schutte c/o MainPointe Pharmaceuticals, LLC, 333 E. Main Street, Louisville, KY 40202 or his assigns (the “Noteholder”), the principal amount of ONE HUNDRED FIFTY THOUSAND DOLLARS ($150,000) together with all accrued interest thereon, as provided in this Promissory Note (this "Note").

1. Definitions. Unless defined elsewhere in this Note, capitalized terms used herein shall have the meanings set forth in this Section 1.

"Prime Rate" means the rate of interest per annum equal to the prime rate as reported by the Wall Street Journal.

2. Loan. On the date hereof Noteholder is funding a loan of $150,000 (the “Loan”) to Borrower.

3. Payment Dates; Optional Prepayments;

3.1 Payment Dates. The aggregate unpaid principal amount of the Loan together with all accrued and unpaid interest thereon shall be due and payable on January 2, 2020 (the “Maturity Date”).

5. Events of Default. The occurrence and continuance of any of the following shall constitute an “Event of Default” hereunder:

5.1 Failure to Pay. The Borrower fails to pay any amount of principal of, or interest on, the Loan when due and such failure continues for 5 days after written notice to the Borrower.

7. Miscellaneous.

7.2 Successors and Assigns. This Note is non-negotiable but may be assigned or transferred by the Noteholder.

IN WITNESS WHEREOF, the Borrower has executed this Note as of June 12, 2019.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens

Name: Peter A. Clemens

Title: Senior Vice President & CFO

EX-31.1 4 tm1928371d1_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION OF PERIODIC REPORT PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert B. Jones, the President & Chief Executive Officer of Acura Pharmaceuticals, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Acura Pharmaceuticals, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls.

February 10, 2020	/s/ Robert B. Jones
	Robert B. Jones
	President & Chief Executive Officer

EX-31.2 5 tm1928371d1_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION OF PERIODIC REPORT PURSUANT TO RULES 13a-14 AND 15d-14

OF THE SECURITIES EXCHANGE ACT OF 1934

I, Peter A. Clemens, the Chief Financial Officer of Acura Pharmaceuticals, Inc., certify that:

I have reviewed this quarterly report on Form 10-Q of Acura Pharmaceuticals, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls.

February 10, 2020	/s/ Peter A. Clemens
	Peter A. Clemens
	Chief Financial Officer

EX-32.1 6 tm1928371d1_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATIONS OF THE CHIEF EXEUTIVE OFFICER AND THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Acura Pharmaceuticals, Inc. (the "Company") on Form 10-Q for the period ending June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert B. Jones, the Chief Executive Officer of the Company, and Peter A. Clemens, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

February 10, 2020	/s/ Robert B. Jones
	Robert B. Jones
	Chief Executive Officer

	/s/ Peter A. Clemens
	Peter A. Clemens
	Chief Financial Officer

EX-101.INS 7 acur-20190630.xml XBRL INSTANCE DOCUMENT 0000786947 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2019-06-30 0000786947 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000786947 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000786947 us-gaap:RetainedEarningsMember 2019-06-30 0000786947 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000786947 us-gaap:RetainedEarningsMember 2019-03-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000786947 2019-03-31 0000786947 us-gaap:RetainedEarningsMember 2018-12-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000786947 us-gaap:RetainedEarningsMember 2018-06-30 0000786947 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000786947 us-gaap:RetainedEarningsMember 2018-03-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000786947 2018-03-31 0000786947 us-gaap:RetainedEarningsMember 2017-12-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000786947 us-gaap:CommonStockMember 2019-06-30 0000786947 us-gaap:CommonStockMember 2019-03-31 0000786947 us-gaap:CommonStockMember 2018-12-31 0000786947 us-gaap:CommonStockMember 2018-06-30 0000786947 us-gaap:CommonStockMember 2018-03-31 0000786947 us-gaap:CommonStockMember 2017-12-31 0000786947 us-gaap:WarrantMember 2019-06-30 0000786947 us-gaap:WarrantMember 2018-12-31 0000786947 acur:StockOptionPlanMember 2018-12-31 0000786947 us-gaap:WarrantMember 2018-06-30 0000786947 us-gaap:WarrantMember 2017-12-31 0000786947 acur:StockOptionPlanMember 2017-12-31 0000786947 acur:FourNonEmployeeDirectorsMember acur:RestrictedStockAwardPlanMember 2019-01-01 2019-01-31 0000786947 acur:StockOptionPlanMember 2019-01-01 2019-06-30 0000786947 acur:StockOptionPlanMember 2018-01-01 2018-06-30 0000786947 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000786947 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000786947 acur:StockOptionPlanMember 2019-06-30 0000786947 acur:StockOptionPlanMember 2018-06-30 0000786947 acur:RestrictedStockAwardPlanMember 2019-06-30 0000786947 acur:RestrictedStockAwardPlanTwoMember 2014-03-31 0000786947 acur:RestrictedStockAwardPlanMember 2017-11-30 0000786947 acur:VestedRestrictedStockUnitsMember 2019-06-30 0000786947 acur:RsusMember 2019-06-30 0000786947 acur:NonVestedStockOptionsMember 2019-06-30 0000786947 acur:VestedRestrictedStockUnitsMember 2018-12-31 0000786947 acur:RsusMember 2018-12-31 0000786947 acur:NonVestedStockOptionsMember 2018-12-31 0000786947 acur:VestedRestrictedStockUnitsMember 2018-06-30 0000786947 acur:RsusMember 2018-06-30 0000786947 acur:VestedRestrictedStockUnitsMember 2017-12-31 0000786947 acur:RsusMember 2017-12-31 0000786947 acur:RestrictedStockAwardPlanMember 2018-12-01 2018-12-31 0000786947 acur:RestrictedStockAwardPlanMember 2017-12-01 2017-12-31 0000786947 acur:NonVestedStockOptionsMember 2019-01-01 2019-06-30 0000786947 acur:RestrictedStockAwardPlanMember 2019-01-01 2019-06-30 0000786947 acur:RestrictedStockAwardPlanMember 2018-01-01 2018-01-31 0000786947 acur:RestrictedStockAwardPlanMember 2017-01-01 2017-01-31 0000786947 us-gaap:RoyaltyMember acur:MainPointeAgreementMember 2019-04-01 2019-06-30 0000786947 acur:MainPointeAgreementMember 2019-04-01 2019-06-30 0000786947 acur:EgaletAgreementMember 2019-04-01 2019-06-30 0000786947 us-gaap:RoyaltyMember acur:MainPointeAgreementMember 2019-01-01 2019-06-30 0000786947 acur:MainPointeAgreementMember 2019-01-01 2019-06-30 0000786947 acur:EgaletAgreementMember 2019-01-01 2019-06-30 0000786947 us-gaap:RoyaltyMember acur:MainPointeAgreementMember 2018-04-01 2018-06-30 0000786947 acur:MainPointeAgreementMember 2018-04-01 2018-06-30 0000786947 acur:EgaletAgreementMember 2018-04-01 2018-06-30 0000786947 us-gaap:RoyaltyMember acur:MainPointeAgreementMember 2018-01-01 2018-06-30 0000786947 acur:MainPointeAgreementMember 2018-01-01 2018-06-30 0000786947 acur:EgaletAgreementMember 2018-01-01 2018-06-30 0000786947 acur:OxfordTermLoanAgreementMember 2018-10-01 2018-10-31 0000786947 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2019-06-30 0000786947 us-gaap:OfficeEquipmentMember 2019-06-30 0000786947 us-gaap:MachineryAndEquipmentMember 2019-06-30 0000786947 us-gaap:LandImprovementsMember 2019-06-30 0000786947 us-gaap:BuildingImprovementsMember 2019-06-30 0000786947 acur:ScientificEquipmentMember 2019-06-30 0000786947 acur:ComputerHardwareAndSoftwareMember 2019-06-30 0000786947 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2018-12-31 0000786947 us-gaap:OfficeEquipmentMember 2018-12-31 0000786947 us-gaap:MachineryAndEquipmentMember 2018-12-31 0000786947 us-gaap:LandImprovementsMember 2018-12-31 0000786947 us-gaap:BuildingImprovementsMember 2018-12-31 0000786947 acur:ScientificEquipmentMember 2018-12-31 0000786947 acur:ComputerHardwareAndSoftwareMember 2018-12-31 0000786947 acur:AbuseDeterrentPharmaMember 2019-07-02 2019-07-02 0000786947 acur:AbuseDeterrentPharmaMember 2019-06-28 2019-06-28 0000786947 currency:KRW acur:MainPointeAgreementMember 2017-03-01 2017-03-31 0000786947 country:JP acur:MainPointeAgreementMember 2017-03-01 2017-03-31 0000786947 country:GB acur:MainPointeAgreementMember 2017-03-01 2017-03-31 0000786947 acur:KempharmAgreementMember 2016-10-01 2016-10-31 0000786947 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2019-01-01 2019-06-30 0000786947 acur:SchutteMember 2019-01-01 2019-06-27 0000786947 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000786947 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000786947 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000786947 acur:LoanAgreementWithOxfordMember 2018-01-01 2018-12-31 0000786947 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000786947 acur:SchutteMember acur:AdPharmaAgreementMember 2019-06-28 0000786947 us-gaap:InterestRateBelowMarketReductionMember 2019-01-01 2019-06-30 0000786947 2019-06-28 2019-06-28 0000786947 2018-10-01 2018-10-31 0000786947 acur:EgaletAgreementMember 2019-06-30 0000786947 us-gaap:InterestRateBelowMarketReductionMember 2019-06-30 0000786947 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0000786947 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000786947 acur:TermLoanMember 2019-01-01 2019-06-30 0000786947 2019-06-27 0000786947 acur:LoanAgreementMember 2013-12-31 0000786947 acur:SchutteNoteMember 2019-06-27 0000786947 acur:OxfordTermLoanAgreementMember 2019-06-27 0000786947 2013-12-31 0000786947 acur:SchutteMember acur:AdPharmaAgreementMember 2019-06-28 0000786947 acur:SchutteMember acur:AdPharmaAgreementMember 2019-06-28 2019-06-28 0000786947 acur:SchutteNoteMember 2019-06-28 2019-06-28 0000786947 acur:SchutteMember 2019-06-28 2019-06-28 0000786947 us-gaap:WarrantMember 2019-06-30 0000786947 acur:SchutteNoteMember 2019-06-28 0000786947 acur:SchutteMember 2019-06-28 0000786947 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2017-07-31 0000786947 us-gaap:InvestorMember 2017-07-31 0000786947 srt:MinimumMember 2015-01-31 0000786947 srt:MaximumMember 2015-01-31 0000786947 2018-06-30 0000786947 2017-12-31 0000786947 us-gaap:WarrantMember 2019-04-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000786947 us-gaap:ConvertibleDebtMember 2019-04-01 2019-06-30 0000786947 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000786947 us-gaap:ConvertibleDebtMember 2019-01-01 2019-06-30 0000786947 us-gaap:WarrantMember 2018-04-01 2018-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000786947 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000786947 acur:EgaletAgreementMember 2018-01-01 2018-12-31 0000786947 acur:EgaletAgreementMember 2017-01-01 2017-12-31 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0000786947 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000786947 2019-01-01 2019-03-31 0000786947 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000786947 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000786947 2018-01-01 2018-03-31 0000786947 acur:MainpointePharmaceuticalsLlcMember acur:AdPharmaAgreementMember 2019-01-01 2019-06-30 0000786947 acur:RestrictedStockAwardPlanMember acur:January42016AwardDistributedMember 2019-01-01 2019-01-31 0000786947 acur:VestedRestrictedStockUnitsMember 2019-01-01 2019-06-30 0000786947 acur:RsusMember 2019-01-01 2019-06-30 0000786947 acur:VestedRestrictedStockUnitsMember 2018-01-01 2018-06-30 0000786947 acur:RsusMember 2018-01-01 2018-06-30 0000786947 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2017-07-01 2017-07-31 0000786947 acur:EgaletAgreementMember 2015-10-01 2015-10-09 0000786947 acur:MainpointePharmaceuticalsLlcMember acur:AdPharmaAgreementMember 2019-06-28 2019-06-28 0000786947 us-gaap:PatentsMember 2014-04-01 2014-04-30 0000786947 acur:EgaletAgreementMember 2014-04-01 2014-04-30 0000786947 2018-01-01 2018-12-31 0000786947 2017-07-31 0000786947 acur:MainPointeAgreementMember 2017-03-01 2017-03-31 0000786947 acur:AbuseDeterrentPharmaMember acur:AdPharmaAgreementMember 2019-06-28 2019-06-28 0000786947 acur:AbuseDeterrentPharmaMember acur:AdPharmaAgreementMember 2019-01-01 2019-06-30 0000786947 acur:MainPointeAgreementMember 2017-03-01 2017-03-17 0000786947 2019-06-28 0000786947 2018-04-01 2018-06-30 0000786947 2017-07-01 2017-07-31 0000786947 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000786947 2020-02-10 0000786947 2019-01-01 2019-06-30 0000786947 2018-01-01 2018-06-30 0000786947 acur:MainPointeAgreementMember 2017-03-31 0000786947 acur:EgaletAgreementMember 2019-01-01 2019-06-30 0000786947 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000786947 2019-04-01 2019-06-30 0000786947 us-gaap:WarrantMember 2015-01-01 2015-01-31 0000786947 srt:MinimumMember acur:KempharmAgreementMember 2016-10-31 0000786947 2019-06-30 0000786947 2018-12-31 iso4217:USD xbrli:shares xbrli:shares xbrli:pure iso4217:USD 237000 300000 63000 44000 1000000 33000 1382000 1382000 Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla's launch of Oxaydo. Termination does not affect a party's rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla's supply of Oxaydo for a transition period. 309000 74000 13000 15000 800000 December 27, 2020 P5Y P5Y The Company's reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2019 or December 31, 2018 was $0. 100000 102000 36000 -106000 100000 23000 -93000 24000 13000 66000 34000 0 0 3000 1000 145000 63000 0 0 110000 274000 4000 2000 In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. P5Y P18M P18M 0.075 0.075 one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. 600000 P20Y 2037 13000 23000 2000000 2000000 P5Y 2000 14000 2500000 137000 44000 85% 223000 223000 <div> <div> Property, plant and equipment at June 30, 2019 and December 31, 2018 are summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Building and improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,273 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,273 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Scientific equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 598 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 598 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Computer hardware and software </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Machinery and equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 275 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 275 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Land and improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 162 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 162 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other personal property </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 70 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 70 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Office equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,512 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,512 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated depreciation </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,940) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,906) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net property, plant and equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 572 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 606 </td> </tr> </table></div>   <div /></div> </div> 262000 262000 267000 267000 83000 500000 500000 166000 330000 696000 false --12-31 Q2 2019 2019-06-30 10-Q 0000786947 21650294 No false Non-accelerated Filer Yes ACURA PHARMACEUTICALS, INC false true Common Stock, $0.01 par value ACUR

<div> <div> NOTE 7 – ACCRUED EXPENSES Accrued expenses at June 30, 2019 and December 31, 2018 are summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cost sharing expenses under license agreement </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 237 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other fees and services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 36 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payroll, payroll taxes and benefits </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Professional services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 249 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 132 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Financed premiums on insurance policies </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 102 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Clinical, non-clinical and regulatory services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 44 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 63 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Property taxes </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Franchise taxes </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 23 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 689 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 596 </td> </tr> </table></div>   <div /></div> </div>

605000

674000

7000

4000

596000

689000

132000

249000

983000

1086000

1906000

1940000

380395000

382992000

62000

60000

29000

1145000

142000

104000

38000

53000

24000

51000

14000

66000

48000

18000

19000

11000

29000

7000

68000

56000

12000

6000

4000

50000

8000

33000

27000

6000

4000

2000

23000

4000

34000

66000

208000

103000

208000

103000

3517000

1349000

326000

1842000

3517000

1349000

326000

1842000

41391000

37500000

1390000

659000

1842000

41391000

37500000

1390000

659000

1842000

2152000

2453000

461000

899000

<div> <div> NOTE 1 – OPERATIONS AND BASIS OF PRESENTATION Principal Operations Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine. <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Our Limitx Technology is in development with immediate-release tablets containing hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate due to its large market size and its known prevalence of oral excessive tablet abuse and overdose. The technology is designed to retard the release of active opioid drug when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. US commercialization rights to LTX-03 are licensed to Abuse Deterrent Pharmaceuticals LLC (See Note 3).</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Our Aversion Technology has been licensed to Zyla Life Sciences or Zyla (formerly known as Egalet Corporation) for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths (See Note 3).</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC (MainPointe),  our Impede Technology in the United States and Canada to commercialize these Nexafed products (See Note 3).</td></tr></table></div>   Basis of Presentation, Liquidity and Substantial Doubt in Going Concern The accompanying unaudited consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America for interim financial information, the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not contain all disclosures required by generally accepted accounting principles. Reference should be made to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018. In the opinion of the Company, all normal recurring adjustments have been made that are necessary to present fairly the results of operations for the interim periods. Operating results for the three and six month periods ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of June 30, 2019, we had cash of $15 thousand, working capital deficit of $696 thousand and an accumulated deficit of $388 million. We had a loss from operations of $1.3 million and a net loss of $4.1 million for the six months ended June 30, 2019. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We had a loss from operations of $3.92 million and a net loss of $3.84 million for the year ended December 31, 2018. We anticipate operating losses to continue for the foreseeable future. As of February 10, 2020 we had cash of approximately $800 thousand. On June 28, 2019, we entered into with Abuse Deterrent Pharma, LLC (AD Pharma), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"). AD Pharma has the right to terminate the AD Pharma Agreement for "convenience". Under the AD Pharma Agreement, the required monthly license payments by AD Pharma will only continue until November 2020 if AD Pharma does not exercise their right to terminate the AD Pharma Agreement. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company's ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. Delay or cessation of the Company's continuing product development efforts will have a material adverse effect on the Company's financial condition and results of operations. Should AD Pharma exercise their right to terminate the AD Pharma Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma's right to terminate the Agreement "upon convenience", our auditors included in their report relating to our 2018 financial statements a "going concern" explanatory paragraph as to substantial doubt on our ability to continue as a going concern. In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying consolidated balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. <div /></div> </div>

2220000

568000

91000

15000

-1652000

-76000

7.98

2.52

0.528

0.01

2.52

1782000

10000000

60000

<div> <div> NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement. AD Pharma Agreement covering LTX-03 On June 28, 2019 we entered into with Abuse Deterrent Pharma, LLC ("AD Pharma"), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"), for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM. Acura will receive a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019. AD Pharma will pay for and reimburse Acura for all outside development costs on LTX-03. If the NDA filing for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the Limitx intellectual property. AD Pharma does have the right to terminate the AD Pharma Agreement anytime for "convenience". AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones. We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. (See MainPointe Agreement covering Nexafed products). The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). On June 28, 2019 Mr. John Schutte assigned and transferred to AD Pharma his $6.0 million promissory note, the common stock purchase warrant for 10.0 million common shares, and the security agreement granting a security interest in all of the Company's assets. (See Note 8). Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of remaining common stock purchase warrants he holds). Mr. Schutte controls MainPointe and is the principal investor in AD Pharma. Zyla Agreement covering Oxaydo In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded annual amortization expense of $208 thousand for  each of the years 2018 and 2017. Amortization of the patent for the years 2019 through 2021 is expected to approximate $208 thousand each year and $52 thousand be quarter. In January 2015, we and Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, entered into a Collaboration and License Agreement (the “Zyla Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States.  Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Zyla Agreement, we and Zyla formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions although no meetings were held in 2019 or to date in 2020. Zyla is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Zyla will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Zyla will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion.    Zyla paid us a $5.0 million license fee upon signing of the Zyla Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla's royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor. The Zyla Agreement expires upon the expiration of Zyla’s royalty payment obligations in all countries. Either party may terminate the Zyla Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Zyla Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Zyla Agreement with respect to the U.S. and other countries if Zyla materially breaches its commercialization obligations. Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla’s supply of Oxaydo for a transition period. MainPointe Agreement covering Nexafed products In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country. MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. KemPharm Agreement Covering Certain Opioid Prodrugs In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free. The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm. <div /></div> </div>

<div> <div> NOTE 15 – COMMITMENTS AND CONTINGENCIES Reglan®/Metoclopramide Litigation Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L‑3865‑10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC‑10‑004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. None of the plaintiffs in the lawsuits filed to date have confirmed that they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. All of these lawsuits have been effectively dismissed with the exception of less than ten pending Philadelphia cases that we expect will be finally dismissed without the need for any action by us. We expect that the Court will finally dismiss the small number of remaining Pennsylvania-based cases against us with prejudice by the end of the fourth quarter of 2019. Legal fees related to this matter have been covered by our insurance carrier. Based upon the current status and evaluation, we have not accrued for any potential loss related to these matters as of June 30, 2019.   <div /></div> </div>

0.01

100000000

21034000

21300000

21034000

21300000

210000

213000

2916000

1323000

1418000

668000

37500000

10000000

<div> <div> NOTE 8 – DEBT Fully Paid Loan In December 2013, we entered into a Loan and Security Agreement (the “Oxford Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). In October 2018 we borrowed $1.8 million from Mr. Schutte and  used $1.5 million from the loan proceeds to negotiate, settle and pay-off in full the Oxford Loan for $1.5 million. We recognized a net gain of $296 thousand on the debt settlement. All security interests of Oxford with respect to the Oxford Term Loan have been released. The Oxford Term Loan accrued interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan was due and payable in full on December 1, 2018. As security for its obligations under the initial Oxford Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Upon the execution of the Oxford Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020. In January 2015, we and Oxford amended the Oxford Loan Agreement providing for the exercise price of the Warrants to be lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the Warrant modification. The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses, in connection with the Oxford Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred a total $231 thousand in deferred debt issue costs. We have amortized these costs, including debt modification additional costs, into interest expense over the term of the Term Loan using the loan’s effective interest rate of 10.16%. Related Party Convertible Loan  From January 1, 2019 and through June 27, 2019, we borrowed an aggregate of $650 thousand from Mr. Schutte and issued various promissory notes to him with the same terms and conditions from the previous loans. Because we believed the Schutte Notes’ rate of interest is below current market rates for us, we imputed interest on the below market rate element of the loans using the 10.16% interest rate under the Oxford Loan Agreement and this has aggregated to $185 thousand as of June 27, 2019. We recorded these benefits to interest income in the period we received the loan, with a corresponding like amount as debt discount against the principal amount of the loan. The debt discount will be amortized to interest expense over the term on the loans.  All our assets are pledged as collateral under the Schutte Notes, including our intellectual property. On June 27, 2019 the aggregate amount of the loans made to the Company by Mr. Schutte aggregated $5.0 million. On June 28, 2019 we entered into an agreement to borrow an additional $725 thousand from Mr. Schutte, which was received on July 2, 2019, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted principal and interest conversion rights into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the loan is convertible into 37.5 million shares of our common stock. The modifications to the loan and the method of accounting for the loan changes resulted in a $2.6 million loss on debt extinguishment. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. The events of default under the $6.0 million note are limited to bankruptcy defaults, failure to pay interest and principal when due on July 1, 2023 or upon the termination of the AD Pharma agreement covering LTX-03.  The $6.0 million note may be prepaid at any time in whole or in part but only with the consent of the noteholder. Our debt interest expense for the three and six month months ended June 30, 2019 and 2018 consisted of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Interest expense: </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fully paid term loan </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Related party term loans </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 168 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Debt issue costs </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Financed insurance premiums </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 123 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 237 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 187 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest income on related party loan </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (74) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (13) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (74) </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense, net </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 119 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 224 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 113 </td> </tr> </table></div>   <div /></div> </div>

6000000

10000000

185000

5000000

50000

0.1016

0.1335

0.0835

0.1016

0.075

260000

400000

10000

4000

231000

11000

9000

38000

18000

34000

17000

<div> <div> The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.   On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.   Royalty revenues by licensee are summarized below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Egalet </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 70 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 260 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> MainPointe </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Royalty revenues </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 76 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 113 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> NOTE 12 – SHARE-BASED COMPENSATION EXPENSE Share-based Compensation We have four share-based compensation plans covering stock options and RSUs for our employees and directors. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="11" valign="bottom" style="width:36.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development costs: </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Restricted stock units </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 38 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative costs: </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 53 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted stock units </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 23 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 51 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 68 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 142 </td> </tr> </table></div>   Stock Option Award Plans We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2019 and 2018 is shown below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:48.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:48.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:23.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (000’s) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (000’s) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,560 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.38 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,494 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12.33 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited or expired </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (170) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (30.83) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (145) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (46.39) </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jun. 30 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.44 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,349 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.68 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options exercisable </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,158 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.30 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,129 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.26 </td> </tr> </table></div>   The following table summarizes information about nonvested stock options outstanding at June 30, 2019 (in thousands except price data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Not </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercisable </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1, 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 232 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.10 </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jun. 30, 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 232 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.10 </td> </tr> </table></div>   We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. The intrinsic value of the option awards which were vested and outstanding at each of June 30, 2019 and 2018 was $0. The total remaining unrecognized compensation cost on unvested option awards outstanding at June 30, 2019 was $9 thousand, and is expected to be recognized in operating expense in varying amounts over the 8 months remaining in the requisite service period. Restricted Stock Unit Award Plans We have two Restricted Stock Unit Award Plans for our employees and non-employee directors; a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). The 2017 RSU Plan was approved by our shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. The 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan.  As of June 30, 2019 there are approximately 219 thousand shares available for award under the 2017 RSU Plan and there are no remaining shares available for award under the 2014 RSU Plan. Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The RSU awards to our non-employee directors allow for them to receive payment in cash upon the RSU award's distribution, instead of an exchange into our common stock, for up to 40% of each RSU award. The portion of the RSU award subject to cash settlement is recorded as a liability in the Company’s balance sheet and to either general and administrative expense or research and development expense while being marked-to-market each reporting period until the award is distributed. The  liability was $9 thousand and $11 thousand at June 30, 2019 and December 31, 2018, respectively. The compensation cost to be incurred by the Company on a granted RSU award without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized over the vesting period of the RSU award to either general and administrative expense or research and development expense and recorded as additional paid-in capital. A summary of the grants under the RSU Plans as of June 30, 2019 and 2018, and for the six month period then ended consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:42.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended June 30,  </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:42.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Vested </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 951 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 459 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 462 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 262 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 333 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 267 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Distributed </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (267) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (267) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (262) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (262) </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 133 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited or expired </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (8) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding, Jun. 30 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 358 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 459 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 133 </td> </tr> </table></div>   Information about the award activity under the RSU Plans is as follows: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> In December 2017, we awarded 200 thousand RSUs to employees and such RSU awards were fully vested on December 31, 2018. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2020, 2021 and 2022. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> In January 2017, we awarded approximately 60 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2017. In January 2018, these awards were distributed and they were exchanged into 214 thousand shares of our common stock while 24 thousand RSUs were settled in cash. There were also 24 thousand RSUs exchanged into common stock from prior year awards.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> In January 2018, we awarded approximately 67 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2018. In January 2019, these awards were distributed and they were exchanged into 267 shares of our common stock.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> In December 2018, we awarded 492 thousand RSUs to employees and such RSU awards will vested in full on December 31, 2019. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2021, 2022 and 2023. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> In January 2019, we awarded approximately 83 thousand RSUs to each of our non-employee directors. Such awards vest 25% at the end of each calendar quarter during 2019. These awards will be distributed and exchanged into common stock will occur in one third amounts on each of January 2020 and up to 40% of the award can be settled in cash.</td></tr></table></div><div /></div> </div>

725000

650000

5000000

650000

-0.13

-0.06

-0.19

-0.15

-0.13

-0.06

-0.19

-0.15

-0.13

-0.06

-0.19

-0.15

<div> <div> NOTE 14 – NET LOSS PER SHARE Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to both vested Restricted Stock Units (“RSUs”) which settle in shares (See Note 12) and a stock warrant exercisable for 10.0 million shares having an exercise price of $0.01 per share (See Note 8). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2019 or 2018 as the Company reported a net loss for the three and six month periods, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common share outstanding diluted computation is not impacted during any period where the exercise price of a stock option or common stock warrant is greater than the average market price of our common stock. A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> EPS – basic and diluted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Numerator: net loss </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,341) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,261) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,129) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,755) </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator (weighted): </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,034 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,034 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> RSUs – vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 242 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 67 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 218 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock purchase warrant </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 330 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted weighted average shares outstanding </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,872 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,101 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,684 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,068 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> EPS – basic and diluted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.15) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.06) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.19) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.13) </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Excluded securities (non-weighted): </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares issuable: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> RSUs – vested and nonvested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 659 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 326 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 659 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 326 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options – vested and nonvested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,349 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,349 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase warrants </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible loan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,500 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,500 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total excluded potentially dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,391 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,391 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,517 </td> </tr> </table></div>   <div /></div> </div>

6000

7000

9000

P8M

<div> <div> NOTE 11 – FAIR VALUE MEASUREMENTS The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than our debt, are representative of their respective fair values due to their relatively short maturities. On June 28, 2019, we modified the $5.0 million related party loan and reported the debt using fair value for the changes to the loan resulting in the recognizing a $2.6 million loss on debt extinguishment. <div /></div> </div>

52000

208000

1017000

914000

P9Y8M12D

296000

-2600000

-2755000

-1261000

-4129000

-3341000

<div> <div> NOTE 13 – INCOME TAXES We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $171.8 million gross Federal NOLs at December 31, 2018 (of which approximately $167.7 million were generated prior to 2018). Because we believe the ability for us to use these NOLs generated prior to January 1, 2018 to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382, we had estimated and recorded an amount for the likely limitation to our deferred tax asset in the fourth quarter of 2017, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million at December 31, 2017. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 to offset taxable income is less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely. Future common stock transactions, such as the exercise of common stock purchase warrants or the conversion of debt into common stock, may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both June 30, 2019 and December 31, 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. <div /></div> </div>

67000

68000

659000

69000

-144000

94000

725000

75000

10000

-2000

-121000

-118000

113000

14000

224000

119000

187000

88000

237000

123000

8000

168000

88000

<div> <div> Our debt interest expense for the three and six month months ended June 30, 2019 and 2018 consisted of the following:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Interest expense: </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Fully paid term loan </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 63 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 145 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Related party term loans </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 168 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  8 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Debt discount </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 13 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Debt issue costs </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Financed insurance premiums </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  1 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 123 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 237 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 187 </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest income on related party loan </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (4) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (74) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (13) </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (74) </td> </tr> <tr> <td valign="bottom" style="width:62.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total interest expense, net </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 119 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 224 </td> <td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 113 </td> </tr> </table></div>   <div /></div> </div>

13000

78000

5769000

7599000

2152000

2453000

1435000

1595000

4224000

6000000

0.475

282000

1664000

-1934000

-1740000

-1494000

-2755000

-3840000

-1261000

-788000

-4129000

-3341000

<div> <div> NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS New accounting standards which have been adopted on or before June 30, 2019 Leases In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which establishes a comprehensive new lease accounting model.  The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. The classification of the lease will affect the pattern of expense recognition in the income statement such that operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842)-Targeted Improvements" (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840). The Company adopted ASC 842 using the modified retrospective transition approach during Q1 2019, which allows the Company to not adjust the comparative periods presented. The Company has elected to adopt the package of transition practical expedients and, therefore, has not reassessed whether existing or expired contracts contain a lease or the lease classification for existing or expired. The Company did not elect the practical expedient to use hindsight for leases existing at the adoption date. Upon adoption, operating leases was to be reported on the balance sheet as a gross-up of assets and liabilities, however the Company has elected, as an accounting policy, to not recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The adoption of ASC 842 did not have an impact on the Company’s financial statements as the Company has no leases with term of more than 12 months. <div /></div> </div>

-2642000

-3920000

-1247000

-1305000

-622000

167700000

171800000

36000

26000

11000

9000

74000

13000

4000

166000

48000

1500000

1800000

650000

725000

4000000

3500000

2500000

1000000

500000

250000

350000

1500000

1650000

725000

<div> <div> NOTE 6 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at June 30, 2019 and December 31, 2018 are summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Building and improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,273 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,273 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Scientific equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 598 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 598 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Computer hardware and software </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 107 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Machinery and equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 275 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 275 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Land and improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 162 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 162 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other personal property </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 70 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 70 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Office equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,512 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,512 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated depreciation </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,940) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,906) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net property, plant and equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 572 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 606 </td> </tr> </table></div>   We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts. Depreciation expense was $34 thousand and $38 thousand for the six month periods ended June 30, 2019 and 2018, respectively and was $17 thousand and $18 thousand for the three month periods ended June 30, 2019 and 2018. The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately $2 thousand per month. <div /></div> </div>

2512000

107000

598000

1273000

162000

275000

27000

70000

2512000

107000

598000

1273000

162000

275000

27000

70000

606000

572000

<div> <div> NOTE 9 – RELATED PARTY TRANSACTIONS Private Placement with Mr. John Schutte In July 2017, we completed a $4.0 million private placement with Mr. John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units”) of the Company, at a price of $0.4488 per Unit (the “Transaction”). Each Unit consists of one share of common stock and a warrant to purchase one fifth (0.2) of a share of common stock. The issue price of the Units was equal to 85% of the average last sale price of our common stock for the five trading days prior to completion of the Transaction. The warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s common stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933. MainPointe Pharmaceuticals LLC Investor is a principal of MainPointe Pharmaceuticals LLC, a Kentucky limited liability company ("MainPointe"). In March 2017, we granted MainPointe an exclusive license to our Impede Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company is receiving a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported royalty revenue for the three months ended 2019 and 2018 is $3 thousand and $6 thousand, respectively and for the six months ended 2019 and 2018 is $15 thousand and $14 thousand, respectively of royalty revenue from MainPointe (See Note 3). As part of the closing of the Transaction, the Company and Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our common stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Investor has not designated a director as of the date of filing of this Report. Galen had not designated a director and lost that right in December 2017 when it disposed of its shares of common stock in the Company. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. An independent director has not been named to fill the seat forfeited by Galen. Loans with Mr. John Schutte During the period January 1, 2019 through June 27, 2019 we borrowed an aggregate of $650 thousand from Mr. John Schutte. On June 28, 2019 we borrowed an additional $725 thousand from Mr. Schutte, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted conversion rights of principal and interest into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the note is convertible into 37.5 million shares of our common stock. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. AD Pharma Agreement covering LTX-03 On June 28, 2019, we entered into a License, Development and Commercialization Agreement (the "AD Pharma Agreement") with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The AD Pharma Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03.  Financial arrangements include: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Monthly license payments to Acura by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (“NDA”) for LTX-03;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Reimbursement by AP Pharma of Acura’s LTX-03 outside development expenses;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Acura authorizes MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength).</td></tr></table></div> AD Pharma may terminate the AD Pharma Agreement at any time.  Additionally, if the NDA for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the intellectual property. On July 2, 2019 we received the first monthly license payment of $350 thousand. As of February 10, 2020 we have received the required monthly license payments through January 2020. <div /></div> </div>

1220000

1500000

1127000

477000

575000

262000

<div> <div> NOTE 5 – RESEARCH AND DEVELOPMENT ACTIVITIES Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at June 30, 2019 or December 31, 2018. <div /></div> </div>

-384222000

-388351000

5000000

274000

260000

14000

76000

70000

6000

113000

98000

15000

46000

43000

3000

<div> <div> NOTE 4 – REVENUE FROM CONTRACTS WITH CUSTOMER Adoption of ASC Topic 606, Revenue from Contracts with Customers The Company adopted ASC Topic 606 on January 1, 2018 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. While the timing of future revenues under ASC Topic 606 may differ from the Company’s historical accounting practices under ASC Topic 605, the cumulative effect recorded through the Consolidated Statement of Stockholders’ Deficit was zero because there was no change in timing or measurement of revenues for open contracts at January 1, 2018. Under ASC 606, revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at June 30, 2019. The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract. Sales-based Milestones and Royalty Revenues The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Zyla and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter. License and Collaboration Agreement Revenues The achievement of milestones under the Company’s license and collaboration agreements will be recorded during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled, which may result in later recognition as compared to the previous accounting standards. Disaggregation of Total Revenues The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.   On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.   Royalty revenues by licensee are summarized below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Egalet </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 70 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 98 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 260 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> MainPointe </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14 </td> </tr> <tr> <td valign="bottom" style="width:62.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Royalty revenues </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 46 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 76 </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 113 </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 274 </td> </tr> </table></div>   Contract Balance and Performance Obligations The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2019 or December 31, 2018 was $0. Contract assets may be reported in future periods under prepaid expenses or other current assets on the balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the balance sheet. <div /></div> </div>

274000

76000

113000

46000

4000000

8912655

0.4488

<div> <div> Accrued expenses at June 30, 2019 and December 31, 2018 are summarized as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cost sharing expenses under license agreement </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 237 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other fees and services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 26 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 36 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Payroll, payroll taxes and benefits </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Professional services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 249 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 132 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Financed premiums on insurance policies </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 36 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 102 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Clinical, non-clinical and regulatory services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 44 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 63 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Property taxes </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Franchise taxes </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 23 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 689 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 596 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:21.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> EPS – basic and diluted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Numerator: net loss </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,341) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (1,261) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (4,129) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (2,755) </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Denominator (weighted): </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,034 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 21,034 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> RSUs – vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 242 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 67 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 218 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 34 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common stock purchase warrant </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 330 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Basic and diluted weighted average shares outstanding </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,872 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,101 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,684 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 21,068 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> EPS – basic and diluted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.15) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.06) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.19) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (0.13) </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Excluded securities (non-weighted): </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Common shares issuable: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> RSUs – vested and nonvested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 659 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 326 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 659 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 326 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options – vested and nonvested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,349 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,349 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock purchase warrants </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Convertible loan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,500 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 37,500 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:52.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total excluded potentially dilutive shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,391 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,391 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3,517 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three months Ended </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six months Ended </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="11" valign="bottom" style="width:36.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development costs: </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  2 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  4 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 24 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Restricted stock units </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 12 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 38 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative costs: </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  4 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  6 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 53 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted stock units </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 23 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 29 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 51 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Subtotal </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 27 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 56 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 104 </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:61.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 66 </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 68 </td> <td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 142 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table summarizes information about nonvested stock options outstanding at June 30, 2019 (in thousands except price data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options Not </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercisable </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fair Value </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1, 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 232 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.10 </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:74.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jun. 30, 2019 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 232 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.10 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> A summary of the grants under the RSU Plans as of June 30, 2019 and 2018, and for the six month period then ended consisted of the following (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:42.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended June 30,  </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:18.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:21.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:42.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (in thousands) </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Vested </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> RSUs </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 951 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 459 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 462 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 262 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 333 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 267 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Distributed </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (267) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (267) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (262) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (262) </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 133 </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Forfeited or expired </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (8) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:55.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding, Jun. 30 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,017 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 358 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 459 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 133 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2019 and 2018 is shown below:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:48.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:48.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:22.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:23.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> of </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (000’s) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (000’s) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,560 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.38 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,494 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12.33 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited or expired </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (170) </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (30.83) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (145) </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (46.39) </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jun. 30 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,390 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.44 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,349 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.68 </td> </tr> <tr> <td valign="bottom" style="width:49.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options exercisable </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,158 </td> <td valign="bottom" style="width:02.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.30 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,129 </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.26 </td> </tr> </table></div>   <div /></div> </div>

10000000

1789000

846000

843000

406000

122000

58000

0.25

stock, for up to 40%

8000

0.00

200000

67000

267000

492000

333000

462000

262000

459000

133000

232000

951000

459000

232000

1017000

358000

0.10

133000

166000

0.00

1500000

400000

219000

1129000

1158000

10.26

5.30

145000

170000

60000

25000

10000000

1494000

1842000

1349000

1842000

1560000

1842000

1390000

11842000

12.33

0.59

8.68

0.59

7.38

0.59

4.44

0.10

46.39

30.83

0.01

0.16

20796000

21034000

21300000

1000000

-27000

380145000

208000

-380380000

-1425000

380239000

210000

-381874000

-2626000

380299000

210000

-383135000

-3617000

380395000

210000

-384222000

-4361000

380436000

213000

-385010000

-5146000

382992000

213000

-388351000

<div> <div> NOTE 10 – COMMON STOCK WARRANTS Our warrant activity for the six months ended June 30, 2019 and 2018 consisted of the following (in thousands except price data):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:35.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="9" valign="bottom" style="width:35.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2018 </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> WAvg </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> WAvg </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, Jan. 1 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.59 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.59 </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Issued </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10,000 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.01 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expired </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Modification </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:62.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding, Jun. 30 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11,842 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.10 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,842 </td> <td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.59 </td> </tr> </table></div>   In connection with the issuance of the $10.0 million secured promissory notes to Oxford in December 2013, we issued a common stock purchase warrant (“warrant”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. These warrants contain a cashless exercise feature (See Note 8). As part of our July 2017 private placement transaction with Mr. Schutte, we issued a warrant to purchase approx. 1.782 million shares of our common stock. The warrant is immediately exercisable at a price of $0.528 per share and expire five years after issuance (See Note 9). On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance (see Note 8). The warrant was assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. <div /></div> </div>

238000

266000

34000

32000

2000

15000

12000

3000

150000

P5Y

495000

21068000

21101000

21684000

21872000

21068000

21101000

21684000

21872000

21034000

21300000

21068000

21101000

21684000

21872000

34000

67000

218000

242000

70000

EX-101.SCH 8 acur-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - DEBT - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - OPERATIONS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - DEBT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - COMMON STOCK WARRANTS - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - COMMON STOCK WARRANTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Non-Cash Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - NET LOSS PER SHARE - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - COMMON STOCK WARRANTS link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - SHARE-BASED COMPENSATION EXPENSE link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - COMMON STOCK WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - SHARE-BASED COMPENSATION EXPENSE (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - FAIR VALUE MEASUREMENTS (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 acur-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 acur-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 acur-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Document Information [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Title of 12(b) Security Trading Symbol Entity Common Stock, Shares Outstanding CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Assets [Abstract] Assets: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash at end of period Cash at beginning of period Cash Amount due from clients within one year with respect of use of copyrights, patents, trade names and technology. Royalty Receivable Royalty receivable Due from Related Parties, Current Receivable from related party Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Income Taxes Receivable, Current Income tax receivable Assets, Current, Total Total current assets Income Taxes Receivable, Noncurrent Income tax receivable Property, Plant and Equipment, Net, Total Property, plant and equipment, net (Note 6) Total property, plant and equipment, net Finite-Lived Intangible Assets, Net, Total Intangible asset, net of accumulated amortization of $1,086 and $983 (Note 3) Assets, Total Total assets Liabilities and Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities [Abstract] Liabilities: Accounts Payable Current Accounts payable Accrued Liabilities Current Total Accrued expenses (Note 7) Other Liabilities, Current Other current liabilities Sales returns liability current. Sales Returns Liability Current Sales returns liability Liabilities, Current, Total Total current liabilities Long-term Debt, Excluding Current Maturities, Total Convertible debt to related party, net of discounts (Note 8) Amount of interest payable. Interest Payable Noncurrent Related Party Accrued interest due on the related party loan rolled into principal under modifications Accrued interest to related party (Note 8) Liabilities, Total Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 15) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' deficit: Common Stock Value Common stock - $0.01 par value per share; 100,000 shares authorized, 21,300 and 21,034 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively Additional Paid In Capital Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders Equity Attributable to Parent, Total Balance Balance Total stockholders' deficit Liabilities and Equity, Total Total liabilities and stockholders' deficit Accumulated Amortization, Debt Issuance Costs Accumulated amortization, deferred finance costs Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Revenues [Abstract] Revenues: Revenues, Total Royalty revenue Costs and Expenses [Abstract] Expenses: Research and Development Expense, Total Research and development Selling, General and Administrative Expense, Total General and administrative Costs and Expenses, Total Total expenses Operating Income (Loss), Total Operating loss Gain (Loss) on Extinguishment of Debt Loss on debt extinguishment Loss on debt extinguishment Interest Expense, Total Interest expense, net (Note 10) Total interest expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Provision for income taxes Numerator: net loss Net loss Net Income (Loss) Attributable to Parent, Total Net loss Net (loss) income Net loss NET LOSS PER SHARE Net loss per share: Earnings Per Share, Basic, Total Basic Earnings Per Share, Diluted, Total Diluted Weighted Average Number Of Shares Outstanding Diluted Disclosure Items [Abstract] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Basic, Total Basic Weighted Average Number of Shares Outstanding, Diluted Diluted CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid In Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Accumulated Deficit Shares, Outstanding, Beginning Balance Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Total Non-cash share-based compensation Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total Net distribution of common stock pursuant to restricted stock unit award plan Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total Net distribution of common stock pursuant to restricted stock unit award plan (in shares) Amount of increase (decrease) in additional paid in capital (APIC) resulting from debt premium from debt modification. Adjustments to Additional Paid in Capital, Debt Premium From Debt Modification Debt premium from debt modification Excess fair value premium on the newly issued convertible debt Adjustments to Additional Paid in Capital, Warrant Issued Issuance of warrant Common stock purchase warrant issued to the related party lender CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash Flows from Operating Activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation Share-based Compensation, Total Non-cash share-based compensation Amount of capitalized debt discount. Capitalized Debt Discount Capitalized debt discount Amortization of Financing Costs and Discounts, Total Amortization of debt discount and deferred debt issuance costs Amortization of Intangible Assets Amortization of intangible asset Increase Decrease In Operating Capital [Abstract] Changes in assets and liabilities: Amount of increase (decrease) in royalty receivable. Increase Decrease In Royalty Receivable Royalty receivable Increase (Decrease) in Due from Related Parties Receivable from related party Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable, Total Accounts payable The increase (decrease) during the reporting period of refundable deposits . Increase Decrease In Refundable Deposits Refundable retainer deposits Increase (Decrease) in Accrued Liabilities, Total Accrued expenses Increase (Decrease) in Interest Payable, Net Accrued interest on loan The increase (decrease) during the reporting period in interest payable to related party, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity. Increase (Decrease) in Interest Payable To Related Party Accrued interest on related party loans Increase (Decrease) in Other Current Liabilities Other current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash Flows from Financing Activities: The cash inflow from the distribution of restricted stock units. Proceeds from Distribution of Restricted Stock Units Proceeds from distribution of restricted stock units Proceeds from Related Party Debt Proceeds from related party loans Proceeds from related party loan receivable Repayments of Debt Principal payments on loan Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash interest payments on debt Due to Related Parties Related party loan Related party loans made to Company Interest Income, Related Party Imputed interest on the below market rate recorded as benefit to interest income Write-off on debt extinguishment Write-off of unamortized debt discount Proceeds from Issuance of Long-term Debt Payments of Debt Issuance Costs Less: imputed interest income on related party loan OPERATIONS AND BASIS OF PRESENTATION Business Description and Accounting Policies [Text Block] OPERATIONS AND BASIS OF PRESENTATION RECENT ACCOUNTING PRONOUNCEMENTS New Accounting Pronouncements, Policy [Policy Text Block] RECENT ACCOUNTING PRONOUNCEMENTS LICENSE AND COLLABORATION AGREEMENTS Collaborative Arrangement Disclosure [Text Block] LICENSE AND COLLABORATION AGREEMENTS REVENUE FROM CONTRACTS WITH CUSTOMER Revenue from Contract with Customer [Text Block] REVENUE FROM CONTRACTS WITH CUSTOMER RESEARCH AND DEVELOPMENT ACTIVITIES Research, Development, and Computer Software Disclosure [Text Block] RESEARCH AND DEVELOPMENT ACTIVITIES PROPERTY, PLANT AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] PROPERTY, PLANT AND EQUIPMENT ACCRUED EXPENSES Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES DEBT Debt Disclosure [Text Block] DEBT RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS COMMON STOCK WARRANTS Stockholders Equity Note Disclosure [Text Block] COMMON STOCK WARRANTS FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS SHARE-BASED COMPENSATION EXPENSE Disclosure of Compensation Related Costs, Share-based Payments [Text Block] SHARE-BASED COMPENSATION EXPENSE INCOME TAXES Income Tax Disclosure Text Block INCOME TAXES Earnings Per Share [Text Block] NET LOSS PER SHARE COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure Text Block COMMITMENTS AND CONTINGENCIES Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of revenue Tabular disclosure of gross value of each categories of plant property and equipment of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software, less accumulated depreciation and amortization and net value of long live property plant and equipment. Schedule Of Property Plant And Equipment Net Carrying Value [Table Text Block] Schedule of Property, Plant and equipment Schedule Of Accrued Liabilities Table [Text Block] Schedule of Accrued expenses Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Interest expense Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule Of Common Stock Warrant Activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity Schedule of Nonvested Share Activity [Table Text Block] Schedule of Nonvested Share Activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of reconciliation of basic and diluted Amount of currency on hand as well as demand deposits with banks or financial institutions and refundable deposits. Cash, Cash Equivalents, and Refundable Deposits The amount represents excess balance of current assets over current liabilities. Working Capital Working Capital Deficit License Development and Commercialization Agreement [Table] License Development and Commercialization Agreement [Line Items] License Development and Commercialization Agreement [Line Items] Represents the amount of one-time termination payment under the agreement. Payment for Termination Description of milestone payment to be made when worldwide net sales reached minimum level in a calendar year. Minimum Net Sales Reaching Description Description of notice period of termination when the party breaches a payment obligation, or otherwise materially breaches the agreement. Agreement Termination Notice Description Revenue from Contract with Customer, Including Assessed Tax Royalty revenues Amount of milestone payment on agreement. Proceeds from Milestone Payment On Agreement Proceeds from License Fees Received Monthly license payment receivable Monthly license payment receivable The cash inflow receivable as additional upfront payment. Additional Upfront Payment Receivable Represents the royalty percentage at which royalty on net sales of licensed products calculated. Licensing Agreement, Royalty Percentage Represents the terms and condition of license agreement. License Agreement Option Products Description Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Amortization Expense, Year Two license Receivable, Term license Receivable, Term Period until which monthly license payment is receivable Period until which monthly license payment is receivable Represents the waiver of exercise price if exercise of option occurs by certain date. Waiver of Exercise Price if Exercise of Option Occurs by Certain Date Waiver of exercise price if exercise of option occurs by certain date Represents the period from effective date for exercise of option. Period From Effective Date for Exercise of Option Period from effective date for exercise of option Long-term Debt, Gross Aggregate principal of promissory notes and accrued interest Debt Conversion, Converted Instrument, Warrants or Options Issued Debt Conversion, Converted Instrument, Warrants or Options Issued Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Percentage of common stock held Disclosure of Revenue From Contracts With Customer [Abstract] The description of contract balance and performance obligations. Contract Balance And Performance Obligations description Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross Property, plant and equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation The amount of lease revenue per month. Lease Revenue Per Month Represents the accrued cost sharing expenses under license agreement. Accrued Cost Sharing Expenses Cost sharing expenses under license agreements Other Accrued Liabilities Current Other fees and services Employee Related Liabilities Current Payroll, payroll taxes and benefits Accrued Professional Fees Current Professional services The amount of accrued expenses for Financed insurance premiums. Financed Insurance Premiums Financed premiums on insurance policies Accrued Other Professional Fees, Current Accrued Other Professional Fees Current Clinical, non-clinical and regulatory services EX-101.PRE 12 acur-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R29.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2019

NET LOSS PER SHARE

Schedule of reconciliation of basic and diluted

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):


	Three months Ended				Six months Ended
	June 30,				June 30,
	2019		2018		2019		2018
EPS – basic and diluted
Numerator: net loss	$	(3,341)	$	(1,261)	$	(4,129)	$	(2,755)
Denominator (weighted):
Common shares		21,300		21,034		21,300		21,034
RSUs – vested		242		67		218		34
Common stock purchase warrant		330		—		166		—
Basic and diluted weighted average shares outstanding		21,872		21,101		21,684		21,068
EPS – basic and diluted	$	(0.15)	$	(0.06)	$	(0.19)	$	(0.13)
Excluded securities (non-weighted):
Common shares issuable:
RSUs – vested and nonvested		659		326		659		326
Stock options – vested and nonvested		1,390		1,349		1,390		1,349
Common stock purchase warrants		1,842		1,842		1,842		1,842
Convertible loan		37,500		—		37,500		—
Total excluded potentially dilutive shares		41,391		3,517		41,391		3,517

XML 14 R21.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2019

NET LOSS PER SHARE

NET LOSS PER SHARE

NOTE 14 – NET LOSS PER SHARE

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):


	Three months Ended				Six months Ended
	June 30,				June 30,
	2019		2018		2019		2018
EPS – basic and diluted
Numerator: net loss	$	(3,341)	$	(1,261)	$	(4,129)	$	(2,755)
Denominator (weighted):
Common shares		21,300		21,034		21,300		21,034
RSUs – vested		242		67		218		34
Common stock purchase warrant		330		—		166		—
Basic and diluted weighted average shares outstanding		21,872		21,101		21,684		21,068
EPS – basic and diluted	$	(0.15)	$	(0.06)	$	(0.19)	$	(0.13)
Excluded securities (non-weighted):
Common shares issuable:
RSUs – vested and nonvested		659		326		659		326
Stock options – vested and nonvested		1,390		1,349		1,390		1,349
Common stock purchase warrants		1,842		1,842		1,842		1,842
Convertible loan		37,500		—		37,500		—
Total excluded potentially dilutive shares		41,391		3,517		41,391		3,517

XML 15 R25.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES (Tables)

6 Months Ended

Jun. 30, 2019

ACCRUED EXPENSES

Schedule of Accrued expenses

Accrued expenses at June 30, 2019 and December 31, 2018 are summarized as follows:


	June 30,		December 31,
	2019		2018
	(in thousands)
Cost sharing expenses under license agreement	$	300	$	237
Other fees and services		26		36
Payroll, payroll taxes and benefits		7		6
Professional services		249		132
Financed premiums on insurance policies		36		102
Clinical, non-clinical and regulatory services		44		63
Property taxes		4		7
Franchise taxes		23		13
Total	$	689	$	596

XML 16 R44.htm IDEA: XBRL DOCUMENT

SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Details) - Stock Option Plan [Member] - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,560	1,494
Number of Options, Forfeited or expired	(170)	(145)
Number of Options Outstanding, ending	1,390	1,349
Number of Options exercisable	1,158	1,129
Weighted Average Exercise Price, beginning	$ 7.38	$ 12.33
Weighted Average Exercise Price, Forfeited or expired	(30.83)	(46.39)
Weighted Average Exercise Price, ending	4.44	8.68
Weighted Average Exercise Price, Options exercisable	$ 5.30	$ 10.26

XML 17 R40.htm IDEA: XBRL DOCUMENT

COMMON STOCK WARRANTS - Warrant Activity (Details) - Common stock purchase warrants - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Number of Options
Number of Options Outstanding, beginning	1,842	1,842
Number of Options, Issued	10,000	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	0
Number of Options, Modification	0	0
Number of Options Outstanding, ending	11,842	1,842
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 0.59	$ 0.59
Weighted Average Exercise Price, Issued	0.01	0
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Expired	0	0
Weighted Average Exercise Price, Modification	0	0
Weighted Average Exercise Price, ending	$ 0.10	$ 0.59

XML 18 R48.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jun. 30, 2019
INCOME TAXES
Federal NOLs	$ 167,700	$ 171,800
State income tax benefits	$ 1,000
Operating Loss Carryforwards, Expiration Term	20 years
Operating Loss Carry Forwards Expiration Year	2037
Tax Credit Carryforward, Amount	$ 150

XML 19 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets:
Cash	$ 15	$ 91
Royalty receivable	44	137
Receivable from related party	725	0
Prepaid expenses and other current assets	48	166
Income tax receivable	67	67
Total current assets	899	461
Income tax receivable	68	68
Property, plant and equipment, net (Note 6)	572	606
Intangible asset, net of accumulated amortization of $1,086 and $983 (Note 3)	914	1,017
Total assets	2,453	2,152
Liabilities:
Accounts payable	674	605
Accrued expenses (Note 7)	689	596
Other current liabilities	9	11
Sales returns liability	223	223
Total current liabilities	1,595	1,435
Convertible debt to related party, net of discounts (Note 8)	6,000	4,224
Accrued interest to related party (Note 8)	4	110
Total liabilities	7,599	5,769
Commitments and contingencies (Note 15)
Stockholders' deficit:
Common stock - $0.01 par value per share; 100,000 shares authorized, 21,300 and 21,034 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	213	210
Additional paid-in capital	382,992	380,395
Accumulated deficit	(388,351)	(384,222)
Total stockholders' deficit	(5,146)	(3,617)
Total liabilities and stockholders' deficit	$ 2,453	$ 2,152

XML 20 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (4,129)	$ (2,755)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	34	38
Non-cash share-based compensation	58	122
Capitalized debt discount	(13)	(74)
Amortization of debt discount and deferred debt issuance costs	66	34
Amortization of intangible asset	103	103
Loss on debt extinguishment	2,600
Changes in assets and liabilities:
Royalty receivable	93	(23)
Receivable from related party	(725)
Prepaid expenses and other current assets	118	121
Accounts payable	69	659
Refundable retainer deposits		(100)
Accrued expenses	94	(144)
Accrued interest on loan		75
Accrued interest on related party loans	(106)
Other current liabilities	(2)	10
Net cash used in operating activities	(1,740)	(1,934)
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	14	2
Proceeds from related party loans	1,650	1,500
Principal payments on loan		(1,220)
Net cash provided by financing activities	1,664	282
Net decrease in cash	(76)	(1,652)
Cash at beginning of period	91	2,220
Cash at end of period	$ 15	568
Supplemental disclosure of cash flow information:
Cash interest payments on debt		$ 78

XML 21 R34.htm IDEA: XBRL DOCUMENT

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 2,512	$ 2,512
Less: accumulated depreciation	(1,940)	(1,906)
Total property, plant and equipment, net	572	606
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	1,273	1,273
Scientific Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	598	598
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	107	107
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	275	275
Land and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	162	162
Other Personal Property [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	70	70
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$ 27	$ 27

XML 22 R30.htm IDEA: XBRL DOCUMENT

OPERATIONS AND BASIS OF PRESENTATION (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Feb. 10, 2020
Cash, Cash Equivalents, and Refundable Deposits	$ 15				$ 15			$ 800
Working Capital Deficit	696				696
Retained Earnings (Accumulated Deficit), Total	(388,351)				(388,351)		$ (384,222)
Operating Income (Loss), Total	(622)		$ (1,247)		(1,305)	$ (2,642)	(3,920)
Net (loss) income	$ (3,341)	$ (788)	$ (1,261)	$ (1,494)	$ (4,129)	$ (2,755)
Loan Agreement With Oxford [Member]
Net (loss) income							$ (3,840)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 23 R38.htm IDEA: XBRL DOCUMENT

DEBT - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
DEBT - Interest Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
DEBT
Fully paid term loan	$ 0	$ 63	$ 0	$ 145
Related party term loans	88	8	168	8
Debt discount	34	13	66	24
Debt issue costs	0	4	0	10
Financed insurance premiums	1	0	3	0
Total interest expense	123	88	237	187
Less: imputed interest income on related party loan	(4)	(74)	(13)	(74)
Total interest expense, net	$ 119	$ 14	$ 224	$ 113

ZIP 24 0001104659-20-013529-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-013529-xbrl.zip M4$L#!!0 ( "2$2E"LUZ8?NO\ &B4%0 1 86-U[3O,ZW[:B8(]$MB,[?R_S__QIU__[][>/[_O ' ^)9WRGGS'6M+YPY76I9)[6#6K.V;^WMJ2&^D !>\3U+C-6L M-9)?SM5POG=J-3\VMRU &8O^+33"\/!Z8$!+/ICORR5.7>3\G/(X_MP&L^/&7D>>?6^+IQLG) MR0?Q:_(H#.2PY%E]W,,/\L?X46)'/'D0/Y!!C_!^S?;[\'CCI'[8JL?/LL#? M;S:.)BU1/A&_$/ P>;A#@K9X$+X4(^_5&WNM1OPH$+5+R&#T M#Q];]4<4\T"'W^G?;; ME"=?WT?M@#F,\.$]<>E-YS[T[9^9%V\Y>X(A;UUB4Q1X.8#$!X +W[!PJ#[! M9^;@-QU&N27P1#-$C3%\?O7WG<]U^+^CX\.3_:-?/Z2OI4,%M(L3)E_ 5U*8 M3NG+P&4V4[!8#H/GI.Y24)_.CJ&=S_$[613]^J%PLH6@&8OE=/)B-$\#XMA[ H!/#R7Q' =>[W![X''X,,C\'7?=\36-D,]IJX MK)2H(^M:-CV!KS7:*Z/ED;_E)RRL?-GA'2]0KI$/][(:)ED=(E^O)'1-M+ MUAH"EB23MW".Q%!PPW,AAH ;'B@; I8DBEK8/S44+*T?>NZ2(+CI_$XXAT%O M^!WK]L(,\=1/FT&XL)=DSX51,)JXT>A M,FX&&,_BCYM!*7T9.Y]Q':>%ZR@[A48=22-2I78<"_P.0[%2^QD%%#-*L"04 M*CP3T$CR6P$/'Q]8B <@KCR'/3$G(FY*M*]^Q*]][[(_,4SOT>9 [ ML7+V3+CS,!QHY+ZC0F:&L.LX@+),PHZ16./ ;8D$&T)O MND2/2QT:W5RJ5*$QGB5/8XQ*4&6BI/+$**LJ_-A?A&@/SW[UZ)8L:H6DVU_* M=F5#"=R1$;BW2DPU5J$E87Z'N5'(GN@]A16RD-'@\L5V(X MZ$TGKOF\I?R^1SC],BP>(&6!?P#"J)-#VP^/A1M2%+M"!"F6FH:ALFOQ-3#5 M71 9]HDU4H*+#62449-Q[7M2(#0W=%-H76 O)BRG[.0JV&PWUF+MXKY&:[&J M$@YC+JIF+E;&*<9>E)=>HSDR8R[6+NYK-1Z8P]TG&7'7I'[M:49BMQ'&7*;_9"W M(O?1;.0^6A:Y)Y9N9B'VT)&+O%ZIQ/']SRWTGLL,;?D_Y$[-IMG&7/R1N.,P=N!E_18S@ MD^^$>;<^ RC.NIQNP!4Q>.ZF" U:CR\=#V]T#XS@T+&X7+79V7]#LU/,G#&W MH=,ZPSKDK$+#!G!:3O7!-AN0SD/RR"W(25HCHSI&<.< MY0EOC>DQ)#>F9W-)O5]X6M"8'F-ZBICS>#:_:%EGEHN9TY@>0W)C>C:?U,4' MU8WI,:9G#'.NH5V&,3V&Y,;T5(_4=7T;MSZRCWM!V^&5%X0\RE+ZYJ7C<^>! M\OXWGW@;1O'112ER3US5JNNOZK/57]57< DWV%<8(!SB?F9XYCG877J 2_DR M3+9UISY[$_8HQ\LL]H$_D8\YZH_X/Z3,&=5U,_%2ZPV6;]$#-;F=2M.VO'+ MK"9Y94,TFTF4VU74R+)7VK@E5IBL\DP/Y7\CW'DFG,*S]WXGQ#^K1MZI2RT[ MF8LNS#!QT@;$22N[+L4$2FL,E,I 51,I59W")E2J)EU-K%1-^II@J<)T-='2 MFT1+KZ1SLI=X]-A,BF63OY-B%>J2D#JW!-#QP(D7$%N<@OXRU']):7_6C@)Z M00$E'!9RVR.\3S:#Z+.O5-%^_%)775][M%=OSE!?*Q][Y4[SX6/S6*NECC\8 M_B@Q?QSN-8]GJK_&QU[)'RWMB'$K.6*,17#)I<=_I7Z7DT&/V>KF-\ .H,0> M/O[][O=*%\"-1<'.YQ@'IX"#ZA>_'6$#_IF.0K>6<11Z(:;T(R_DP\??;K>6 M)24&3G^[-0Q9(H;\ZY=M9\B_?C$,N62&C L(#S,%A(?I-6OP$O.ZL #X"]!% MY7OY4._OM#] QV9#^"UF@:FK4ZPP9GDK983#V4H*#U]74CCC4IF=65A@F:1RON/I(X'9C:"X>8QO,]S+IG3VK1$'P!ZL1= M7#>#!R:N33M^5;BXJG8E:247TAL66#,+S*@%EN+F3CZ-:UA@'2RPQE.Z!;M: MWV#U-YUS3AT6?B4V-=H,%ABW-&7Z)ZZM'(?EEMK&^%BW M T8)K%T)S'A>\C5V("[\C7>M,.%V\^Q1'O388(R+/\N!V3-';N=L2-H#TVR9 M92_B_,_#=Y/.YH[!W:K+BG&KZ[67'4P,*5"=BF:SD1U&',3HN^]@X8=X-Y;F1+K,FV]>KYCE@67Q.]:-XS)'U>YIVSO;&2;AFF[+6_2JF'U1XF,]B^9]E\=R=&)?& A M,O.5Y[ GYD1JQQ9_N6"^VE4,7I+V-W]CW*S 'J3A>O?^8P_91&P M3*\RU]X_C5XF(+'L;*5E) Q?&;Y:9EWOM'#%ZX)>[F-3G>R>?MQ'I]SM7BE2HX0RK>'>+N>X-'U8)E6_+ 7RRI,D54_: MOTU)SSR05#.KO^0#3H8MMY MUYE7G\*_QB^K.H5-0>O:"EK?@ O&[A7-5+;R M.T&UN"$F9<9JEZT?]4"D3?##:G^/=-&'$L M=@P3+I,)SWV(M'C(VB[%-)YAP(0!"S%3)>:;7"!J?+_*^W[K:\IC?+\R,M]: M?;_M8D;C^Y72]]LN)C2^7ZE\O[=DOLF-D8SO5VW?[XU;,*V?V8SO5U[?;^N8 MT?A^Y?/]UMB4SIC?FYK?&9N?5839C/DMM?G=+F8TYK>4YG==3%C0$];T MX2J5%5QJ%]BC#,V/#,W?E.9'L]'\:$DTG[*]/G_OI.2I:Q)&'%!Z^3( K(^, M0 FW>V< /'VBKB_N#E5/;@;GK*(ETCSS%Z W \4T_%9IFWX]3/Q7ZE%.7,#Q MF=-G'H/Q"/H-AHV7Q<8S87C;&7FL.[KEFGAA-]UHX4UAWBIKX/6SK]&^&0:N MN!8UFFP9C% )C62TPAQ%2"9"WLC0H@0:K425="9"WE V+H4V+CLCFPBYK"&& MT<(F0MY@]C7:UT3(1I.9"'G+M<*4>F$3(6]D:+%NC5:NHG<3(6\H&Z]?&V\ M(YL(N:PAAM'"*V;>*FO@];.OT;X9!JZX%C6:;!F,4 F-9+3"'$=Z3(2\D:%% M"31:B8/9UVA?$R$;368B9*,5DH*" MECIZ/N]5CF>.PW PXMX2YEQYYV3 0N)N!CO,>+7CQ#66I*B@M<1F!%F&6/O] M,NO$R.2,HA&1]8O(&K.*K=$6+88ARL 0,QK19>K,+$.42V>N!R-CZA3GO;_V M.V'>P&P:#K*F2/?WK!6.7/? MASL=6\L,L@L1KB 9@_&2N$M+]Y\;(_YS-BTDN#"7>Q9/W+HDGQBZP-"#M2-! MZN_$H0^^?.*&?V-]IL@.P#6'XU2%(L>,T#)6$ M&3?\(@NIZX/(L%VLM1-<5)#!UM SUFB[\FN[4B7VC;:KGK9[8P8[TAK5'HWT MJ9TCJH]?N?*>0#)]G@M^QG>\C9^XY>P)A@2WWZYH*!^_DT71,J.;"3UXXT>* MT;SJ/KQ',_7AA<>6$:[4)4\?B "^_G@B/TSG1--[>7DT/]AKU&>@N7SLY-4T M/WQL'FMA0?S!9"=-=O(-PI/#O>;Q3.$)/K:2%@""\5/ L"&@+YOI,_?'[NDB"[;W4+T'B;$E[,L4#-YNDK7"DS[,^V M;2D>6][)F#',8"S=6\C_&Y.\^#:1#=V9?-7%"V?!XTTG#5K6C@+FP7*!AW17 M-OYN06*WM.BL->\M(FB6;X59KIB,CUW8JJ.8UFQ1S%*VVY?LT9ZUHX!>T)!R M#FN67I+Q9/.>['@L&0]V:1[L<@M)#&,;QB[)SE'66L._QEIOA+5N'+W.!4VL MJ.NB)ZQ6OKM+GE^ M&TLGU5T3-U6:]69][3R?JKMF?:_>W&O47ZWN"EEY[0LM73U,N3#R-GOFDOM- M&N;-';ML8JVUC,3:%(ME$N>5L5DSWD1ECGBM_XA7&:XF*Y=A6\_]7 ?ZR9<# MX\>_H1]_,)M./'C=R0[IR8 7+TE\^!CP\/$.DW:"E/CI._-8/^KG,JGG, B# MQ[P0_@)S0B7C?!EF#RG]G?8'F.S;$!,)ZSU-5K_S&3]FEK_,%.E4#"IS/ :% M*W2M#K$4:W'7*DZ%E46/YE-AK85C0R4MY=EKUY:6;*'/OK3_N[>'Q?+6/15[ M!GM[\NL(O\/EXH^-_621#GL" -/)\;GKJ(]\ZV=$H$])$''ZF07^?K-Q=/KC M_N+7#_&7*7\6OR^&O:">WV?>N(&1\]EI@.7:P;B11X?X]8.V OE0T8);R8*G M3S=^E.:840;PYZQCC PQ%J'Z&$#5AVC@TCQ9X?M+5RB0_"]R5\:V>42=-)-JBQ-8BFGN:*= !"R<6?PD8;8<:K,^<8-/.WN RF;K"!C\UP]3YE@4 MD%3+3(&CA7*V"!PW88_R6^YW:! (7_@KI<%Y)';/7H69P]8(0)/F>C5D,Z-J M?W]AP)* X<>@PP&"6S)$AKNC-F5/I U,68"Q-W<^)JW_8.=SHY[AE:EK*D! M\.!?T'9X!:J81_CT#X_T?1ZR?U,\(&S[48Y$*W2\IPE&:W2MLX"?6?4?41#B M<_#BF* 1Q[OEM,^B/A[!P8_??0=LG2W678R,XKALRH(:K>.FOJ17P[:VE2XU M);%.K,7R]T"Y,,GP\[4?,IM>T,#F;# >+ZO(SOWOT"56GPRM4(%#+5!OEO@Z M>=CJ^!Q!>J(>HYY-+8"PT:S_YY]?SNH?'3(,K &X5=QZYBP,J6=Y8CV[UG./ MV;UD9%P7S@2_6KX-,*FW0E],"8Z@[SD6\3SV1'D Z[#\C@#DOP++)9$'0\$7 M-R]DZ/@U2T.?Y?A@#W%8TNF -;>(-AO&OJ[5CL* MY0<+O!D8P J0M^ QJ=4"BPE*>-)#L)Y9F%V-CR_#",1+7P$0_;;+NN()1 Q] M8GX4N,,8B)KU%6 @KJL/%5CO$!A< X0P3!+\_6X1+0;<1\!:J[+X<%W$?!+JP3#P3B0SB@H/20(*';0^TY M'$%-Z% <-Q SX%(X[48NNI=#J\-1)%WRL!Q>E 5UL-['^09/8EO$!+.CYGB)NQI3 M7;(33>-,@51;E-(_PAB!TIG)GN;VK*9 =J1Y0&-F>R4\\YJT^> )>OC_:"R M$86=\!P8/?(<]%2.QHD%IB3+-ZV& M^.78>B:!]4L]-BH+8$7#*2HAC,(B%VU=H:K'/",7$%4VS%Z^Q_AMUFF7LRJ/Z0N.%P3!+D=9 V6Q,! MS<^\1#CG9(235P J>42EZ%;D\C7W=?C&SO@:N(KK9^=P_58$UT($/3Q\*WS- M!U?KM714"C75ISX8X-[EP+D0YZT!SH4X<;R O %*YW=CE@,J M.MC??.+=>,NT)HW]@[$0:C.^ JR%./%P/(F7 ]5"?/<6>'H#B)3K=>U[MMS/ M&>L*SNTL-^JC=)LXW1+ 2T_@3#/X1P668O70S;H'MSALW]"ENJ-/U(LH!'+? M 8C>$ME>"X"*9M(!R:7PY$U0M]QW(CN<'F.OZ@S=%03/:D=CUTJ?LWH0%&/, M[4N80A\?BS/UVG-:\I3R$+Y/AB,N9JK%ZG8Q^I8+MFZ3[W"=\ +FA&_O+T54 M'X40_/\[3D-?]0?4H59([9[GNWYWJ!+"'8BF_8[U"ZAG>,Z/ GQU0'D\G_6N MHQ+L\1=!""S2#7O!^YIU']F]/# J_RVW/N*7;!B6.9C8^H9Y!N(PT$]B"V 0 MT,CQZ:!''0Y?UJPKE1>GG#.1 T?TM2GU,)D/PZ0[#Q*!](5RFP5B&2294.)Z M5\<[+O69P4K:%&$4 8(@PR]'!\6++P"&!2D8I!.J;(K:L(AS^CEL9D!",'8! M4-^C>R'KP\--?78=2">B@DJ4 )9UD @\S[@C-V80)*8D&8 "KE&[%F*;@JM, M#WY0^S?(?UZ.:AE^[4=!F*(5 ^ 8=+%)0L)T25S_68V/3P51"K)<3[(E%B>' M9A;B4<%/H[DYTXME.P&>IAL+5[;8RC>CJ\-MX_B[6?N,:P?I3091&0TPB_!+ M2+IC_+P5M77)V?"F;L314:S5CPXR2YL(^C8N5!4>7=,0(0KN4+O#NVLI6$B- M4*-9.[#ZH*AQ_@ !VVL+^PC?82-1+S5RSSVPQ<\^=YUG!F9>[2][-)3O65S8 MJU\:8-;B =&5 1_ I9Y#U);!D!(>FX+I*-'P=QV)JQ0ZYWZ_[WMBG=>4.@_^ MWWS7P?*B@'71SIP%%XQ3.Y35%CEW.=WRR=&YI=/YZOHKQ(AZRG;^R37(;P:B MG,SK?O.#X)QP/@13B3<[!.F>VE2#-M*4Z[99CXW(K!-,A.GKR"O_ Z2:#Z9F MO74T%J;B"728<,M)U0<^D)?E%$7JZGC,IJ%]F MC[XII8S-3"EC(:BK6,KK>T\N=UUB'QB+U"Y%L13 A9OB\/REB=O.,YO.K23!I,V%&>9=J%B^4F3:EB_ M"H*(WO)9RE_+WY/_^. O:O735IA#!OB/8<2]X%M<_[(,]Z&I&^])LRP.S.Q^ MQ"*PV#WJ1(A'D"9PR2 X<0EH?<_!:C%1X0KNM_#/P%?[!W$C^B##T9?PBPN8 MGZM( M"^[S*5:(L\Y0?J4^G(H4UQX$''Z7DT'O8P? V>L0B#"&IP\0P@36-7VV[OP^ M\7;%Y]T C%1'/A>P?]-3JX'S[,2 "$CPUQ@8AP4#E^!,+O.H?#!&UJXU0'2) MQ"J-$8;U4=G"*/PYJ8PB_<%'KQT,TNHH+(P.HCZL&HLL+8*Y,M?UGX-3A.4# M J.CZ<-@,Y&6KGR&90%KQ&-!.!GV3AOU^E_4./!S*-4H==T!)L.][J>=^H[X M' R('7\6*/BT@\$V&ACC M?Q?9U8*?>U3^ &L!2BDLG6:I-I:#+/'_M?K!()R9.;(3^D^4=X"'3WO,<:BG ML4X>A&F\D[[9B-\K+7V#>%F(ER6#*_&?*.V?VPPOP[, MG]2:AN?7@GFC;8RVV3;,&VVS?,S+SWRS?=8VL7]VN1]Y#GKG/C^U_DRBT'\- MB>0X?Y;IVT4"G>.%W=7DS4J[JRN@F1:^RM#M]51L+$&I 1 07 (AFCN3:=*H MUXZ:AB8KD:Q9IWB6*K?MNTX1I%D!Q6R-EI>I[QJ)73MW&(DM'TW*([&%V=0% MI=:X3L9UJ@K-*BWT&C-,_FL15EFKK0A\ESF66GHY^&:C.05WW8S", K#* RC M,&95&,?&:31.H[$!)8S>#Z8HV&:K=G18?05;(>66G!W8J:"M+1LZ*6<2287=EPK+21.JZ#>!VF[F#D_GV.XS: M,VJO9-@U:L^HO56KO4KX]B: QSM2(NS*V2/<><;S]KC;$/B=$#]4T!!N#,DK M9B(W!N_&>)JDV1*39O4CHT2-$MTVO!LE:I3H^I1H)6*3;9'H[Z)W,>7#;*^P M"EK-DE&T8K:Q9-@U%M#DX.:U<\VC Z/VC-K;9.P:M6?4WJK57B7<>Q/*?T-_ MWYQM* ^E*V89-P;OQF::9-D2DV6'3:-$C1+=-KP;)6J4Z/J4:"5"DFV1:'&5 M'%Y;',0718LK2RIH-4M&T8K9QI)AUUA DWJ;U\X=U8W6,UIOD[%KM)[1>BO6 M>I5P[DT@?]/I,)M6NL)H8XA;5H)>*1Q27:.MPTJ7[P0^)6T%"63"N7WQQN,G:-S3.)MKD-V^Y! MHXK52"433:/XC.(SBJ]$E%U \57"J3VH'[DDI([ET &G-B,A M\[T*FL*-(7GYC:1)EE7;?I: OAMN5M\U=D_VZ^^-&C5JM-1BME%29=3H-JK1 M^N%\:K02\FP9&SE*W1IR="[,M'9D%N-5DN\:B7D M#H[,/H31=T;?&7VW'?KNL'[X&O=>?B1MER8O.^Q)_[4 A4M RA2,3(I7$[ ' M,<@ L?4A#[^E?_CU [$C?GIO]Z@3N?2F<#X&C M_D'H%(_)]Q3KRN:''T M99@^\FP&.$%PP^(6UHY Z5]XMX-'' MB^ ]Y-,[VOFTEY#!XYD7,H>Y4 MZ#T%B%G(:'#Y8KN10YVOW._+*R'$6#>=2\(]6', $TJPA\4#G+VPX!$1\'@7 M1,%WVF]3OF-%'I/ _8 _&JT=RZ$VZQ,W^+2SU]KYW#QL L?&1'A#Q!EZI?3Z M!PT Q#N*T-KPUWT(#(WT,E1<@(HG.A5/2BIU1X9>ZZ;7$J1N Z@X,JGX(H!E M4_X$>/3YURB,.$VF@=>GDZOQV&KDR(5K>1@.J"806=2*)]"J2_0F;^HS!]^) M0Q]\^<0-_\;Z+$3(>>A1_F6H/YJ=ZS?B180/]P&F0S&1AK89R7G^4&ZS@-X"GNA5\O&F(XE_8\/#P9?A.3A$A'D7)*2+B-(=%740 MB,;A RPA(+9 ]I>A_DN*S.\PU\!G,,\MK*I/; KPVX"H;ZZ=(QY2X::C(28= MY:QA._Y@L"T'H1BK4><,AB)= M>AT)4>Y(^?B=(.QA, <73Y7;QN&AMH199E\.M/L+0=MJU5\!K<]_@I$[)P,6 M$C<#UEGP>-,9#T<>C,,3'6F98>5\#F6G9\!'#O+25Y=TYR'9YPY,1'_],#)( M.O9YQ#E^R0)@]?^AA%]ZSISZ;>?SWEZCN==JR(G&C9C.>>';PL3*1Z0M_0K? MS<6.G_^[*><;.]JX"1&F^:?#_RV:,!EM=#H)RR((Q?_=JQ_NM>K9*3,CCDZ( M>FFN>1KUO?_.SH!#I -?@N\6@H+Q0D[<*\^A+W^GP[EF0"D[.CX\V3^2\Q2. M.#*AW^_[GO!6I S>1&$0$@^S6 72UGQLX'3-^D2IO[K^"HAM'![4FR?[&6 F MS#8"F63N.SKP>0B_WX/?.R86NK^E?O/80]](>+-1P=- M$TP8,C_O5^92?@Z\UO7Y?/-=^]X>L6T*[XO:3S&2/G]FZ/R\5S 11WO]1('3 MB4+27 #\#PWTZ8I'S,][1[OH*(*ZOR;]^43I[/S'W9EU^[>SN^]GYY<_'J[. MS[[=[UI7U^M7^JU>L,:$(XY]GCR_/CIS.#GH=3>#_MMWYV; M?'+TS!AR:.7WG9[9MA^!*P"Q!B8]SSP'O@&<.-\8:3-7!+80:=BN'T#,D>1$ MYP)$I6N3!.WT9+/8;&DTY\TZ/PNGYQ06Z;PR#7U]\W"9IJ*/M*PT_O7G%UA8 MZZ-U=GY^]^/RPKK\Y^WE]?WE_824]:3,NK8;\4<4A*PSE%^I#Z?HP/,]YE"_ MR\F@]T:9>,4'%GW!*!4F(:'U6^11JU7?M9"PHN#D@MHB&D@QU&J(GX\MO&\X MB/JP4 #!L4A@=7S7]9^#TTKA::8=B_@3[EIDMM(:]?I?U#BX\88R:(&)<=4& MUZ<=\ #P;;,VI'3,;<$P& 3V-__@H)[*.0>_$L4>[JS,D9W0AW"J SQ\VF..0SV-=1;:_Q-O-N(W5UJKN>YJA@TB M7/DK'0SF-^*8Y/9BWF@;HVVV#?-&VRP?\Y4XF%!P2H5$H;_6"L3CA=W5Y,U* MNZLKH)D6OLK0K1QEN@ $!)= B.;.9)HTZK6CIJ')2B1KD0Q7 :19 <5LC9:7 MJ>\:B5T[=QB)+1]-RB.QA=G4!:76N$[&=:H*S2HM]+G-I?%_+<(J:[45KS[, MOWR^V6A.P5TWHS",PC *PRB,617&L7$:C=-H;$ )H_>#*0JVV:H='59?P5;( M,+]C7LH/8<^/ N(YP1:V8C)]U\[] $;M$8[UW4D)'2"$3DYH&+;[QN#]Y5)WH;T.UD35:O5"*55K^(5UQLCPT9W&MUI=.>&ZLYFRUQ, M5UE!%JT^K [%8SN>8V'K" @Z@@H:RY)1M&(FL63879F\;%J;])42L6)V;KY> MB4;K&:U7,NP:K6>TWMR9D5=UB-U,Y][$[[=DR'W7W;4&\@\K)"\J!&A3CW98 M6,408&/H7C$SN3%X-P;4),Z69UKUOC!&F1IENF5X-\K4*--5*-,M#%BV1;)O MN=^A0R]BOXKGMTHFF$;M&;5GU%Z)*&LU6O/= MSUD)Y]X$]%^91SR;.M: TSZ+^H'E>Q;S@HCCU]; =YG-*AD(; SM*V8K-P;O MQHJ:)-K:-ON-#C4ZM )X-SK4Z- EQBCU+8Q1MD6BSV$ O/AP%]>_9ZM/HBZ* MTV[DDA O@S([$\9D5@&[QC":%-V\YF]_WV@]H_4V&;M&ZQFM-Z_6.VQMG\]O MXOM;[@\H#X?R=$0%[=[&D+AB%G%C\&YLI4F=K:*&MXI!Q,8(M5&F1ID:95H= M96K:,U56LK]B!52/!;2R(4C)*%E^VSA?9^Z2H=>8P#>A8K4L77.^Y)O1>T;O ME0V]1N\9O;? :8CM<^Q7$F-$6*C/8WV--IS8[7GP\MJ86#M9\R!>+RS7^I!? MO*5_^/5#%.QU"1F""!;;K!Q&G M#X"2+ZYO__S\'W^RK%_'#'(><4YA939 ""_-OK MCA5Y3/[T _YH[%@.M5F?N,&GG;W6SN?#^@%PQ%@XU10+@G'XV*HC%"=3H3C: M7P0*'A'WJ\\?<,]$W'#QT"/>E6?[?2J^6P:"CO* S3CI$H&=&8TC2%PT0^%I1S7)P/M"@U=A[N2XE8=QUGF7"?#,.&W4 MCT>$\M4 7] !AUG4BP.7XA]H?+4!X_+?6Y=X(?QV^:^(#?JO9MR3^MCEO JJ M-UOK[)0[0<.S^J6"LQX*V;HES+GRSLF A<0]]_M]W[L/P5MZ%<%:Q_762'8F_!Z_:=.VK[74^,\@_B1C2SO(N(BU$/>W$*<[VLXGSUL,G@RO)F?[7?".?C] M5T$ $?02F:W1V,][\W,"\W9K>4N&6#I>7->W,=03;/,ESS:7+_CG#![OS-Y7 M8S_GILX$P(J!3FAS3<*(TYN.&B)#M[]2CW+B8OCK])G'@A"'?*+JV1GI5]_? MT.7?T8 2;O=@_1?TB;J^"/+G6CP$Z>5=^]DSX<[#<)!=]65_X/I#2D4X?C/ M<>1:WXYE#EI;AK4E<%JSS%)6C#-8=2Y$-&;/VTAKB,C-, M2>UP*0+BN5!6$C-\4-]"S"V!X4H18(><2L']8P0K #N.6%Q.LR/'06!'0*M$<(;5(S?936)43M M@#F,\.$]<8'7!#\*3B-VQ!\ON_!M>-;E5!0OS*K)CB I[$2:;+%]N-'.I\Y7X?55@4JL$N"?= MR();RH62@ZFBW &)^7BJ-:*=#AHY3WD9$*YWT:DI>]W$7X;% \SFA4U%?:.5 M/[IE4#\7ZB?Z)-,YOWEHL/\*[*LZO%F9_3A?*K=1Z)ZI(J%JRG7*IIE1KE5& M_38KU_5C?ZN4ZTQ>^,BB]QNMDT;55OVF3';N>T\40A>(52YH>U9F:QV)322# M][58M1.#^O59M<.#3?8IUH_]K;)J,VW:5LZJ3=E;,%:MLGC?6JNV?M1OLU5; M/_9+:-5&MSSF;4'4;!SDP"S:S1@WSQS=R_(' L=.LXP6;ON'C8+9BGNC39ET MYB4>GYS,.N>7*& >#8(+&MB<"14JNW,BB8'HM[[+;&".I"?G//'T9]4G-.D, M.KU%JF@>W&@.POEZGSY3T?ZV[;O.A(ZR4[JAB@>O;QXNTQZH#:T=*O[UYQ=8 M6.NC=7-[>7?V<'5S?6^=75]87\[NK^ZMFZ_6[=WE_>7U@_AI0O_4MT #GR* MI]>9_4J4W'+FV6Q 7.MF0"7!@]>8X$9M()DF]IZ%_:HE7+.^4=4K,0;IE]= M?-S-/"! &/_S[W3\;S\"_3?+YYE?;R*N__S>8@% ;#'/\Y]$/9'E\*@+FL2% MOP%T6T)J4:]+NA16YEFX&*YJ:G;AR:2D1BP=7NA3;C.@JMR9MOR.%5*[Y_FN MWP4=(IX:<-^);, 24M@#IQ2''S &0T1]4#Y8-"V^+F<3T:ABK M'[DA&[@T ;)F =:L;ZS/PI<8>8UF\Z/U$(\Y1#3J2\$*K3[PGT06"W[*90-# M4(MV.A273H+ QZZ \,8S"WL6KLCQ8=GM(> 7H,>^W K;+B42'\1.B00_ PH8 M-JV %5&@C \S([5$2VJ<@E-XPX99O= =(B\,(F#5@'8B%S[# .# 44[P0(FD(73-X'!8&PCZQPP'P&-&M'[ MU'7Q7WU90I@X>";$D\SB)VM#BHG:'PZ,F8X9>%@4@9-+-GM"E+?!4V*P.@%Y M.OL?0 =8L%S^%4#MT+&+=QBGZ.A:)(RI&Y,'-!8G8B0E 9["I,!*0"/'IX,> M=0 G- %?K 6Q!Q/V@-HP)JW-H$^QX7:FN3PX%G_9B3MPB]%'?_^X8]F 7=7K M_=-.77X.!L16GY,!>/*7DQOG.&D.KJMU[<=4Z];U1]-FX:J3>JYE?N@/=BSU M-[:_SS7/MQI'M?JH$D\ 6-0F%-DCK>U\WE!,L\WWPSZ87;V7.DZB7V#[YY[&JC<44_5S",/"Q>D.'^[;OX,4*;=!('"MPJ1!Y_PP*(;"^/?QSK]YZCW^BMH#Q$_N')LAA#@[C1!2U$WH.+B")@B+G/RF@ M JU([%/(,0>< H6H9PN+ .K3!15D8]/EIQAPI>7PO=BLU*P'F#W,*C4: *&E M1I@+H\[IN@A4Q.K$\'V@%6%/S2.S\ MN"_P7<2=%L)L2"J*98(OC06^ FMG L\7-*0R7LMYC=:W;^?6NWMP2JY]('+K M?5;%CY7(#ZD>GGR_A#$'QAP8$(7< MVPSU;(#:3'S[#H,)RD&?)?I=%AQ;YVD0^-Z"IT0$ \;FYH4,'5_W*Y7&?.>_ M#)4Y^=NYNVN=7UV]5^&CM!0=Q@/0Y /T8C'T&C%2Z0"Q/5'A&>:#X W122]0 M6D\H*B=15"YI4W2W:PI G-26N2%87#(I*&L<\.O%F5B3-$K22R^8";X\Z$O7 M^ZB&?P4A#-@->T&J!-,XVFC##="&LRE!H_N6@^)EJSP9U.8\8)'P %&]IB^D M0YTBU=2J@_#F0U?04N^%;(^^>,\\<,9N,240@8?T_UFWX#3KPWUH-0^*AQQU MH-^GF1Y=*W^'(6]]3$*,Y.:DFY4^\%[+UJ5_^<4(*5)D"-,Y\8A#<&;=+Q0I M'="D"@=I)FN57MZZ;A&;/W]QO[5\0<%@X% ML^"A)$Q2 8]8%W[4%J;XKSY:RG,?/ CN53-7CC$EA'TR2XRKC3P2.4*4('06 MEQ2*_%]'GML#[ 1Q>U^!4Q0]E0V7$B^<,8AP!T2D=T&?].,\6_S<,W-=$9B# MTJ$RS.L*3-L2T]*'\@1\S#]R?2"0&10CY%7[6-I7J4G\>-^LG M'_];P'S&09^Y5'\&I[VC7;Q(!CW7^[U_UJPSL2X,;(=BHB%$L!#3AG&R BR8 M*W*C\B*] .)Y8%4NO;E9D5"#:2$X%EF&H.='KH.Y\CYQ1)I"(T>ZG7#R,;#. M/"\"7-Q1\(5#"R">L.B_"T3"4.GO0TH@OA=)Y@MJBXUMS5]L[%JXV5JSKB2! M_ 'SXAV&%*!=L7X/:>'"TM&I%?G@M,6SQFER03T2BLC>HYA&P7T#6.- BKO5 M(0S]?;7M$;F21<(2 ]$5'+<-Y#,P>?QB_*C:(R)>#JQL#X9(NGHRT FL,O[@:;OI2:B"J7/-*>$0.@2A@"NSR.7=&!I@C(BUR<] MB$*5B/1ELG4Z$XE#_,%-;ZM+=N68 M8GZEW92 X :*3/6U51$ *!BQ_ SC[2(H/0(CD:"'O_[2.(!A_"B X>%'G_\4 M.)2MTB'.[#";A>+!PY/#Y$GI[ G5'-^.E7FV=7QL <%=L2OSNYR16*#'0'2X MW]>E3L!0:\6/RY%!+D+Y./Z\7VLD/\>2!_)F"3$KE*_4\PQ$;A!^3S4(CDM' M <&)Q2LHEU*]XK(&?L"$3 J,=5S_>>3569;8JITT)ZVQ53O>SR]R;GWZ.^HB ML#UL@.SI)VI+K5BXP(K38SS"O\#$5'!E)\+N"[5T9,E 7VF;1ZA,&P*[S7J> MAT26X86!S:2@QGXYKM<31JFHMKGQ)+\UCS6QH@B*",D T<)3*SD3+PL2-A)!DI_V8'8*_VZI[8L1!9!JZ/&S36$\'*B"%*7ZRK M$;AXP]P7ZPHY\0*2.J[Q-KJ^@$CX"S5 N3"-7+C9JJ*B"VK/RUK*-FI4&WV6 M3N0*<]F.]]70I8??>EFDP".!*$I$-;085GQ/^;C2= )]@UUD"G3V7'=7S-*1 MLU!G5\(["LALD\,28RPE/)OUDX5%P2HZ3[";8*28?9V,45#>+6D'\1[?*%1B MI7NXTN$L$ HQXSHMTG#5$>$JO!6%.KS_!99-^!##C/X?$VZ-Q&=M3:KA_< F M+M9AV#\%](FL9>WH!_@-C,I/Q&4HBS- LE%]@*F 90I"MHGWDT>#T(:5DV? MUP5PO]AO%"YQ.!H1_%<0PR]C')DKUW>!:0<45TQ(8$. MLE5V[-21@UFDA B<%$8+->M>1E.IAEE8(PD%\RQ&\ZC:Q5VCIC'*8(.4P=JD M];7%B9$&>GF4^>];I0P#[*KJ\Y'J ?Q@ETXC3M1 .80O>: M=F5XAYDTGV/()HOR5>R&2D(F6/+BB.[\F,#2VLEH[1WA%!" QL_]C9QPH-,3@W$5JP&+A%@;Z(CB]S9&WFWP(W>QOH5T M)870$\:U22HHY9!'$7UA0:Q\@%<7QV&Q9A6DY!5D#!!$M%@7% MTV,@!FO] PMVL'8R%4)\D#LR#8LU1:K6)NCASC>;($&9C' F#]PF+I$I12JJ M(!'M U0&@.18"D:TX$B"3];O(@01(&ATD%E0W@< 1%&5$*^-&Y26N4$&!YGM/K#=-VC$5"E=Y46$#8R MS69F=$ X2EZ1_G&!@JRC*JD1G6-(6_RPGDV2*46AT=IZPE3EB'7+@K757IRV MTE-E G.HYR;IB7@__T-^4\S2/Z3'6^8^PY(] G-.@A[^/UXZ**KKPB ]W88_ MP +[0G)YT-.IIZ%*G9S)Y"?!4HJUW5S#T##W*7,91X3;.?XLH=D#9K6@OO M3>^3>&"6]#9+DO??7GDVQWJT"RK_E4=(0>7"'SWB=>D=6+)+Z7/M[AE.+@-'[Z3EY8/^H7'YK>U['3W/E\5#LYUE"S"'AFA2M8(9Z_ MFG6%S=I!LY0K/!KI,'U'Q8[H+29R'K0<_)>A_DNF!\"5]P3"Z/,9< '"7@=< ME)/<*T#&# VCXR< T"<8\M8E]H2FT9N#SZF$C$'D/);0GZBK$&U:QZ(U>=[R)S'^> T,<*AYA8 M\3UTM&;O [,>:S"V^J7=1"'FQAV5_GT+/A_M+C7#HC4XMV)5Z8;@$SW#5^3V MQD52*[RE#7Y:8QK\?+LZO[R^OQ3=?0>K&^#:E*M3HAE1WAP'*NP1/& 5)+<=U4KDKX "U#Q MQ&Q9TH]EI[*?F]C#X+3CBCXLN&6!>U2 8@66OHDARZ8#67EK4RSH%#L8,I.A MRB&Q:TLR59L(A"",0<_GX1[Z+9:-1]FQRCR1NNJ5.,YP%$K/M&IS9R7UG[M)A6^^LU-26=*)FR&\&],20QXXSASIF]!B M(PJ9Z@0ANE[]5V!A%;*'N\7?KKY?/;R,'*:;QH*"/@?(!?[@=&\?_I#%V+YW M*C=+G^A'?'JO)WDU.27\\'V>N<0K-0FU+#J)-0095\@J2[8/TCKG;&$KHKYQ M'->G%]2TRIUC>3 \/_0S"6( L*H=)F_&1>VYTEEX0TPEBUI8ORV. ,AUB.^Q MO!:<""Q@TKG QCO74+-)^M>L*[DO?XVGPYEHWH2O*^Y@LMXV.6:D'257)0W) M4G(,5B$$C5!4ZIP^CMU4I%$:TU)$U/K+.H8"!@I".L"&9HE%1*P'Q(W; MI_DH(*)*0'S'912$YP PZ/' @E93@>)!!6RNTT5W%ZL7(A DKBHZYCD@+#J! M!=C]1G1Q2>@FCY4E)5\9UB".LRL*=#Q+MAFV;N.69[+R8O1EA5Y?@!-C%[1]+:N$1-YH],2YW;ZF099*D2F&5T?+1)%_!UT,)RL"/2#/+X>U>G*J2'K3 =8)@D*GN\IC M[O=1)V$N'1L]@3\,]'N6@:@T9'5MC/AQ[!P<[":R):MZL4HIX34AVJ*8*OU5 M(!0TFZ4.MXZ4=\N#<#7M$/XQL"8B(%X['NG#@W%X1 X&$H#TP$>E7!V?P_9^ MV+;J&8M;,P>3]H]J!W\159\1SZ[[G2S!Z[(G!%B5EBIEH/,TIWU5WSP1;6"/ M0+X!J" 'O IM ETZM48Q@Z0U*U-9+T140M%7\WMICN*+%CP%:DGUV*FD6%\! M)8' ;IJB .'>%Z7_B:\BSU0F>!'^]VT'9N2I%:.B5A*8,Y)GV>-F2#=)$Z&" MWD8W+\#1)#4DLO\'BF#R?FR!E%^3#XX)%J[N"8\I?G#S51/R%:<,SR8 M-FY**AF9K% N+H%576[C*U+CLD^>@D'") K(\0W,OX-#JX^>77<<)B;OG>"I=C_J M]M!(-Q"OR9%S=)Y2E9J##8'(5S;#U[\<-+4HB5K_BB"\I+RBQAND_#?BB=.R M6/0@Q!L7+C3>C_M="YM.I]]\"YW:KL D5D=!I'<$THU/ M[&;S#OA&)C$'$ZG,0CYMH'>3SNKC;&/ID;XYBVHB4E( D&S MS+6H-<1]YQ(:PZ*2,$2R+,A%)KTOH7!)>8= MI#&3#2/@DR2;Z#=#0EK .8'(^26=W?.90ZTQ. (JX]M 'B%S4;^#O?#D:0R\ M702 XV#IJ"OLN; J:&=\:2+%5Y@%BP4$C]E@ZEYT(8@[$U %BK*&P<@)"<4[ MF+;2FM&/P)?(Q&Y\G$\=_1&S)YDTDCD*) [2J&,UQ=#H?3WB3%S6V,#1C"?(IX'@F.;XS#WCOM$&JB&MYKBB9>=U;V->2VA2N0AGLZ*'F-QF6/ M)(Q1I>HE;FXJS)0E69((4Z2(M5UM^<+=ZXA&Q;@'+$QGGX@V*VG:*W_83+1^FJKM M-5A3T';5 2/5!PH/-(UH\D2!)YE,A3C,VL87*&A(E_T$Q!$<'FL(-!<%K+$; M'Y?"3C80K6 T4&0(TK^L:FIQ@<\!80Y&:@3\8"WJB6T_R+D\Z88)'7$*N,@S MD2T=P.&R0S_3^>5D5WF9VC1-]'[4-$D>&6EB^YZG3O&/J/(8^_)K=-T]F1K [=\4\=$,1CVP8GSW^@)_](X M2#'%Q!XQEJ4[A&?#"]GOAE.5;1<:%[.(TOW*Y=Y!GX3IZ^!9V=@2"H);+EP- MW,U-!N@S9T\U''=8EZE+*OP(5,F>^B+9'!Y9@R.5BUA),=S6.QI7TF?6CJ>2 M$QA&I%2=BGXOCI+CCO:8P14'I1$H8%"&K^E ):^Y(_98DUQ>$E?H21(>;5!,ZORK$#1Q_-^;1?QB MWP%,_6Y\DA4U\'"O/=Q3?\8G6I/SLN+Y3*#ODD H?CF2:(7K)%D/E[!^/@$G M^C1@=X)XCG>RJX+L/2);UV4&"/)OB-RR-Q4H"8J$H;A9HW8N6B@/F%B^)%"# MG1IMV;O*98$DI()+#0?>4K;NY4;4;5A??/^G\M1&3WI++ #7W27;=FEW!7"2 ML"HF69E $"Q*= QCMD738S1BE^D90CK\5_A8<1<)O4E#W(ZQ+2-ZH5YM\?/D M@' D,(_-O]RVQT0BZ( NHJXO#UI@]S*_JIF7AU&S*1D^&,>&^'2N*&J"[*KH M./&!:M8E$UZ1[-#_A"K"B_HW_*C= MU[0&6:E#RSJQ_SN*5A86[?]KO*'YSA,AZH@,7E)H@"J]T:RGAM(APP!==GCL MF6/4COHN!%LRQ.:J>DNM,J#8\ 2C2[QG)= 2BEEVETD8W=U[ MT"9(.JT1N1]&)#?D)$;J(F+;/!+[R4SR!; X:**V;$65&@V1RG=2/5CDEFH@ MJ#9F/>*EK^#^G2:6>(D.WB C&^%RT1SCJPKWM*$@CD5@9..X6 F\WRVBDLH1 M:$U>,2?(8JV1C\K2Z%N+4Q,W5.S3Z!&9JE)\HD.1W-&4?I2$^"(_BN,&R3:- M%A?+"AWUDXJ1L[F1V!"H'8,"R@<12-@P%UD3?:52.51GRW&^>HAJFD@('+[C M;8^9+U^I+3*:)+LS>]P%>6^5BE"=_+4+ MK48D-D<*[L@U!@A7 MTD4&M^X]FQ=](>GME-J(8_)7FN[9G3>9E3>'R84'\16<:L,E M[9-932&X29,MXQE;^S9)K6 X XK=BRLV5897[6@?I%O?#V.&E3R4,2]B5P5# MU4$H^S>)$A4MPDX#T#ANBF_22/E&](+*>:XXN$A!Q%(@ A@5 4X,)=75:UA] MEK])4X56VH94)DH4B4XYA8,NGK+YK@\!%Y=AV\=W\I0,W5HX[8:BD'L1K,K'1 TTVE=[$%B[](=Y)P)P78 M. =,TB1-UL7E;]G\A@4.Q,&M*F'7[ M.MYQJ;%^8:I!BB##+T<'Q8LO $;6U$@PTNY_6HD4?LQA,P,2@K&;R<+K+)4! MTE'-WG5K($ B5MI9-;D7FLN[/=/+53,-4T5[O23[-%(_G>%7T3 [02O&T#'H ML;I.EL3UG_/6)6/ DO"ZHNJNL*_\M")Y4P(_4@)OBME+PM!C?6%UFXU6^@H8 MI7I&59J6I/&O3,'W_'&XL0:P@"H;:2SB;5A MF!P&JKG#;.JI,U-XD$NH22\DZ1(]:B_C?$[BW^74F@1' V07.UN+I>7/[_XK MP@)X:3AXNDF!9P[30!!6A2;*E_T[X\[*"%Z:ZBF6]WDN"$Q6(UI-HQ9"@*N3 M//H[[0N!U?CW/$X=G2N^NI%7:Z.ZX5&WNAFDD2($8,C#)(<48TKOIFW7]!S, MQ:HD9/"U.X6+(S)X+9FBH]P5=2UPODYN M;%FFO"HLD91(.%--_&44'RC@ \E(J=,+NBH! KU9D4T0+JU67JH'1VA]!7P% M["MR;*(\_MG/!PAC9UU^5JJB5D_:E!=J1[HM&27#;OI=09HI<]983S!=I3R3 M>"F![D.+W02:86R=G47(U,>+9,36BHA-GOUL:@EUF$JX)',EI8X1[JF*H$>+ M=-,HHX"?U-BY\#9?K2'\IF0ZO$WKV=(+5*"D2'R54;8R0+J78(XTW)P.XDFJ03!U([)\63)YLE:30CM1\X-4@C U&J'C(D0B[2A10UA M,'2?8!JR*W#R&UXU-E0;ABX#\R)^TC?L\/I-' F&O<)#[*>6XMZ$H_*$_TZ" MP'K 6[]2%MBU;GO,)0YU!SV&AWC!.QGB/UR$?^>RV\0MIM%WXP/&J2I!/T#L M%]0!;%\[;0-:\^3H8Q:PS*SWD?"U>#I5NNQ=ZQMYMBX@4@_$LV>A*RX75M#M M DH"FIVO>7R"R=$ =[0N0+O3,/O[V<.WO6_:S?&MX\,#[6.C+M..$M \WG"Z MH ADG33WL,"O>&\AF!H_@?2WR&$BY,(O;(;_*FY0.P1X'$+4@>G0[A_BS")4^O\M_,,V-J'>AU?*XAST:_"WH+ *+) &R);$$$B6=O%VZC$)O^S+RZ" M!X=&%'V+'UBG([RO:]KF)/B)&Z[8Y%#>^AW&U:':LT^^"RN7U\J#<&+;%RD; MH[='8Q<*=3TA"[13@/&]4ZFP6*2+E0UA*IJ#3'NFY.4T!X3WL:E;S>59"U$= MG%9#"@=_5X<\/@SP1R2\\W@GA7&9T9#.NN)D0(8G6E;VLYR"W\;E^-F?*IIO MNL9#5G%;APS'R(C_.8C$!69,'=\2FU&B7 ?, MXH,SA>C4*2TV<")9H(U'__SX_C?MF2PO* ]]W-!)?JI95]MJI.M#3)@<) VT MI8G%R/W]>,LMP_K)B;?DC*:X$ W,D,J!42\Q!1E5+&U+?.VI[(21[*V+4YTC M\\07\(J[7&5_OJ$E.UUK.%)#Q6A7ZD6,G!M6UC'U,4;R1'?G;"LBW6RIDW<2 MZ%A<(U7\!Y;W#U2$-"XFHE)Z1'(*9^_ESM>?U*QOM(N7SU*M.9T(J%F@[EO4 M,*^5*LEN!ND-LAR$F=>L+P*Z)*L!PB\:8Z*%CM1)Z2?B1B31FF)PU7U0A*PQ M.M/.>7BW?18V&J270+&*GME57;10+3Z,N,Q"<)P :#9Y\3UQL<4OX#1<5 M2\X_ "?TEO+[GFS6.WL0F.D:?W7]=:1K_O3YE@'@V.AQE?")7X,S632![8#F M0=QH8_GZ:/_U\7.]!JBQR%HM3%?B9M'7(:G9J+?V)\,CIUD4EMEQTVRTIJ%F M)E F-XM?+FXF-'R?"ZJE8FD6H(1 ONKZPF9C+!AB\+FGGOGB-(F"V6<.A%J_ MC'M8+.\BO.9)(W>%6VZN12#97P221JN9Q\GK(5GH5KO&?N-X53B9#Y+#_$6H M$P'!ZVW.,;DO]M'D7V"XKL =XQ&Z!KH&:A2#F5Z>(^!-M(X.<;'0NA>?7LPB2Q9+S!:CE] LO+IU(FF9S&)04E64O$J4DE$0F3<= M;4,P?>',D67 R4YF&?"[]9MTQV/VZ"XNOSQ482M.//A55-C<8H7--Y]X%6W! M=34FX=W:';FQA4@\B*-=<;OR"16G-R\=GROXNC1)G$_36[H7M0?M MBY5E)A1[!*KX5[87?L:3V9S[SX##7QJUX[00$)/V>M]SP&I1TBT*Y)L'V3=% MSAI7-) ;,Z)>W:-=/\1[9W:M@(:A*W/) S+<\SL=7"S6C(E7==(@CO0)1.95 MW47U;]$!"P_8=M6Y@%^:)X?I@1 _+NYMAVI*60F(">B1CO:JRZ28N:C\2/V4 MH%9+FZK3,:_OM5!.&7PH6GV8M/KH5[0S;@R\ITIMGV!=$/B5RHSNN*MT:>W,V(<)MVI5PCS)F:*DVJ M\4!)'IO8B_)?$7&+UAF ^7#3HZK-0^T,5!!U.LQFJD \;J0N8$II%W<'QV_[ M))1R$!]O&E6W$D7'4FXB3Q1U%H,OSIO*!Y*5%,E2"@K2%L\W*E4@*@AC5> 7 MZ?X4F""5X;BB7R]42XN!&=Y:)SK"%6A\ZUWF%.F#.%!Y!K\XXE!7EIQQF;[4 MYN/NQ=":T&*5G-SM$H67<8<)@3,\-:HSJVH9YJ@K-':UAAOJ_>)F8O&-&S_2 M4M-83T10!?>SH&ZP/\AWI8EIP"UQ<+W MHZ8P=IMSEO!WK7__+_N9X]V!-!AB!Q3-+>#7MYG8G$KV(./+RZP.8:(Q0I3L MWL832B+CCJD40E&B$LHNA8I7DDL"XEL.A"L05WDCM60Y>?PQ6PJ:GDQ,!N3B M -I#!@IL0A??^.8.8R*0^/B'38*>.GZ'AC2AD>B-K'6<*/#"CG9E#^AJ6KWT M'H",XYE>"*"DBO3%$=GQ@J:*6^,[V3('4Y.3K!G.D2T%7?]9.+?"HY(R@L*" MUT;KPH)O@B?"\?@LAGUQTV!:*(GPQS4)'/*O!)9&772K@M=&*I:!Y$G'*_WT M*XG58ZK(1F_>F4U>50ON]"Z-].!)5@K%$9I6*J:< GP!E1<4B?WO<9)H]7V' M=53#_XHR:]Y=4H90JG8\[R/O:,4^M+&+>Q<7"@L-5Q&FWFZLBV\_18OJ<@T=WR M;>TMB\I\@^[0!9K$2B',"6<:M13[$I),+)#GAV-*R/8UC>.#C!L;ETW%E,QZ MO5)5J>:O0<8O!<7E]Y.ST?(LE[+2\D[;>#EQIV(@$I?GBH6Z<]E/&B>K1MUI M5=,V+K45CRW]V.R[<=6>IG"GZTPOQ7YAX9@H1P1G1<91PF$>N-3IBDA,7I,> MBE+=E#89OM(5_=@[@*JG:[/=;A2+2?T 52F6QVISNG26!IE%F[$ZF-GPMW1 MA(]8CS #S=9NDN+()GB2L>QDBRJ]9A @FA+[:QU[4.FEX6HL,E M,RA%[8"P]% ?7)21QZT59KW$-.M%Q/-#9/4HL+4H#<9KJ"(9)<41GWA27@P97^ @CQ:( MNT<.TRM.L"X7#Z:B#@9= V-$+.A)-QWA>.W=M#&T!7?/BL,61/3='W-3;DYG M9!IG^3D]4:OH[A@2031\5SRJYL+TM[LZFUL_4Z8 MBZ7^*G1,,_R>KA9$DU%,W<8J4:D03"8E]>$%_9A2*J743LYEJ^OLB\ST",.) M]:@F5. 0REX#XE)XV;U W)KB8X,&T1P?#U.+ ])B4R#Q-E'/:DX:#BHO(ZY6 MFP*\S%4&L'EO*>F1+L[['$;H/\7VP8@ YCI@0_OIGT6""0B<,FR4$$ M%SQAH.9II3 X5U2(IPW46,_,"7NGC7K]+VH<^%G>GC0$>YP<6^//%"?YGQ3^ZM!.._U6. M/OYWX444_-R347P#U@*D4F@ZS9)MLMX&-!S,4;"1G1 54@?8^+3''(=Z&N_D M09@I)R'>;,1OCF&E+!LIM@J=^0A7;]1.#@WA9B)>/R<7@O0)?[D>=@ZM'GI]:?213ZKR&1'.?/\B3<(EGYJ5?3\7&$I0: !$,"!#B8&.C7>6C,AN@LB6U7%:._=4B%>N77[^^ M@C.LPV6DN@IRUL^8+D\JK92W5G/6E8Q]V:1VLKY5Z)KS?Z6;/J64ZR-.C7JM/1GNHPZ+5:G MARVC.HWJW#:\&]5I5*?Q1"LGUD:=&G5:^O.^1IT6J]/&_L'V97T$P M$%<0)*GPH((6LV3ZN6)VL63879G K/1,R[KSV]MM[(ZK6&]6,KDT6L]HO;+E M4K9;ZZ6D->K/J+^-QJY1?T;]S9WA.#1JSZB]C<;NIJJ]]:9\MUOM+>KU52+! M:TJ@<88+_4[+"MK C=FIJYAUW!B\;ZK=-#70):2YU=HW.M3HT&W#^\;J4%.] M5SZ:6PU3^&QTZ-;AW>A0HT.7>'CDT.A0HT.W#>^;JD--V7,):6XUYXOE*Y$4 MW[K4-PN"B%JV'X2FVMG8Q8W&[J9:/U/M7(8=X(J?E"R9K!I-:#1AV7(I1A-* MTE9Q"Z]D FK4GU%_1OV5B++&$32:L(+8W51-:(JBUUA^4-^^M*^IA<89OC*/ M>#9U+.8%$<<_K0&G?1;UJY@;WIA=O?*;R%?WY"\GXC?5>BX]H;PN^E;+L*94 M;QAU:M1I^<3-J-.W2U$DGV5Z32&\U-$_4'/R2NQ?!^4!J$%GT94"^@%32G)=/=Y3>:FXS= ME8E+%>])W&ZKUVA6,7@HF3P:;6>TG2D?7#]!3==\H^PV'+M&V1EE-^O!\-:1 MT79&VVTR=C=,VYEZZ#4&LL?S:;M*Y&I74A#=W-\T:?Y&@^#48OU!%(JR:)7- M99[M]ZGE>Q;/W!R(EP96T#)NS,9=^6VFV3$MU8YI92JE-?INN+E]M__>J%"C M0DLM8ALE4::&;^M4Z)'1H4:';A_>C0HM#7DW78,V6D:#&@VZ=7C?5 U:E0;2 M%=*@\_J@E4B;FQ)GNFMYM(H7*99,4Y??0LX7QY<,O1NV/[SF//:6;Q W3HR^ M,_K.Z+L-KOXS^FX.?6<:1!MU9]2=47?;H>Z:<]Z#9?2=T7=E0^^&Z;LU-[+8 M;GW7F//^Z5SB5GXD;9%49!GWF$/]+B># MWD)(S.!P%@2*]Y+7QFQA)&L>Q.N%Y5H?\HNW] ^_?HB"O2XA@U.\@^^"!;;K M!Q&G#[#D+ZYO__S\'W^RK%_UAZZ\(.11GWKA.>%\".QYUO/S7KCY%$-\'@GJY1OL4CY@1,O(';(?"_X,M1_.7MAP2.Q M(_YX;_>B,*3?:;]-^8X5>4R._P/^:.Q8#K59G[C!IYV]@YW/AY)[LFL:!ZY9 MV&P+^^9[7>#X/@[T,!S0D25<^V89F\%FR2B(@)O.&8E8?#2:CZT&(J0U#9Y&?3) Z30+ P/$.;!; M6#R;"06< XTKM+]Z! MG%UV.A0D[XG>4F[#;Z1+YP&NJ4.WO_.Y7FO4&X?CH)LR\:PPWX="04P">+R M%4#<:AW, G%^VI6 .U4&9Y"\T276C]>^Q$0ZE\=";P'M,G1)9H4M08^C$I!C ME8[?FRP9GF*^P^Q;,L2/F55>1)P@^(^-QX9,#"UT(W](Q!,7PEPO&P3GT>2[< M.WLF$'[$I$T-%R@Q9L,"[T/?_HD(">[N?\P8E>1I_9HEKQA]* M !;!Q!A+M":MXQS$Z2R;-O]"MJBQ]/7/IYA:>6.XN?,OI)@;1[/.SP+2A3"O M*WZ[Z=S1)^I%] %W 9*<]CR(^:SRZ$GFO"1;"/5Y]A!DD72/6JABB#>T>B2P MPF??90ZR%^<6B%OO4='KCU$1T6\1SKYH4,'3__ MYMD3Y0&R4_;=_QVZI&:=N:[E=\1S:FUI9_.3CX'%_2%QP2IPR0>!13BU*.$> M@-KA?A_?#&@6%PA*_%O\+[%I+4>@:N$.&TZ*WC P]8),X66<]@@:VS"TMFQH6L(+$=X"G7 M'XA'D&<4JR!??'OXYUZ]9;WK#1WNV[Z#F[IM%A(>@K*A M6ZS?IPZH-+K'J4L),B4J+>"M* 1#_V\4AS,04?)?@36 QSR4SV]7WZ\>7D8V M26?:3A1'>_S!Z1[V0AKX 4,M>"K:"+$G^A&?WNM1N3%=K_]%ZI#O\\PE=W%[ MY EA)U8?GNR!=HGQ-%#Y!\#7+ZV#.N#4CP)$9'N8PW;C6+X,N/ &=:U_R3\ M+*!=LUZS4+-U& _"D:&?0<^!I:"P( M6!N;4>/H]5'8"!^G#Q MJJE9F2,[(6@TWD$6[C''H9[&.@M5W,Q4,+*<(BD@W%KK!S>(<$NO+5QOOX;M MQ?QAK6EX?DT\?](TF%\/YIMK/=&^O9@WVL9HF^W#O-$V1MML%^9!VZRU.=0V M8]YHF[5I&\/S2\9\[AS49N;C"EJ9D2CTUWJ>\7CA5%SR9J53<96AV:Q3/$MA M;ONN4P3I6-)/_FL1QH#9@P$!SCC8F<]>%A%'XY65R<(;KVR[-&S5;%RE M->REYU#',LY.-46Q:@;,B*)Q=(RC8QR=38V M6"RG"%?LW-O&X-VH3J,Z7ZTZC^I&=1K5N6UX-ZK3J,Y7J\Z3%6U1E"U-6DX1 M-JK3J,[2=W(PJG/,K>&'\[F=E4AS;XL@IQWT*YC0+AD1RY^V-C?#%\G(2LL[ M5Q PF"OB9S=N6FEV!7,K)9/0\H1KE679:6XW&BK;X*U*U:+2GT9YET)ZEZSECM"=6 1^]*OLM/Y*V2Y.7'?:D M_UJ PB4@90I&)I6W)& /8I !8NM#'GY+__#KARC8ZQ(R.+U@ >EV.>V2D/G> M3>=.IHX?$ 4/P I?7-_^^?D__F19OVJOV*X?1)S>=,[]_H!Z@7CYCKHDI,ZY M'X3!?8]P^H4$U+DEPS[UPB 9S+(!FZYN'RY14C:9&-OSKSR^PLM9'Z_YO M9W>7>U_.[B\OK/.;[[>7U_=G#UR,A_9U:/?)$K8X? M<2O0EFYK2[?@-2^ KYY@1J\+XZ%<^ /\+;"(YUAW]S\"&(-;. SM#UQ_2*G\ MR6&AIA5Y+,3Y\5D'P,:G )M>N&L]4RL*8=Y_4_'K M%Q=,^MZ]W?-=G$F\OC?@S,:I^KY#W9IU(P?%^21"Q/](8#D4.*8/I'2LMMB&9/09I\"'>PR>@[>)"_AL@UZ) MAT1C@@^)H8/WL$IXFM@V.#<"S2@&8R4)?Q3"PC1BSP1O,5$ ]S!6& !&*+=9 M0 7/+2AJ)96PFTFJ"3G!@V6#DO&['DSA *L(3*'R)MXPM6(G'Y'S@L@-A63X M RJ-.6@N[O?18=VS2= 36@O_V!OX''\70\:"%BA)0W&>H.P$D)PAN$+L?-?U M!6N]$]#Y40"/!^]/*T6HF3R^^!-Z?9D@I8$E&3NQ'RB<6LNFKJL"A$\[]1WQ M.1@0._ZL@A[9]RX)>E0L OZV2P8!/8W_^"@GLH[KM62NQ6M(&LOOXSE7BF*# MKLB>(7X2;S;B-U=]W8:Y57XMM\HW:JVU5N-L+^8/:\<&\VO!?+/66.L^X/9B MWFB;]6D;8V'7Q?/&*5V;MEEK2?GV8OY@S94VVXOY1NW8:)LU87Z]O;JV%_-& MVRP?\[E=[I]3JPP^] MP+KT'.JL1% KIUPW7E!+V!2YA#0ICZ#>LY?%Q=2X2,9%J@K--E[SKL!%*N$U M@A52O;]%'M5Z4M9W5RRRE5.S&R^R93P_5D*B5$]DC>-D'*>JT*SL6GCJ_G=%=Y^ONPS*2&.1-+9*=RK42./K;D,W$[C:V(;M:YYU1P-*N"T/\3OTB;K^0/3'P+8(P>EVV)8MH_F* M78?U'B+<&/)6[,"R:5@W3=96*74EW"THI]09I5II\E;L7+91JNM4JB8Z*1&A M5Z)4RY:L*"=Y*W8@U"C5]2K5TNW=E5/J-E6I_O_LO6USXS;2+OQ]J_8_H+S9 M.C/UR(HHR;8\LTF5Q_;L/3DS8Q_;LSGW\\4%D9#%A"(5@K2M^]>?;H!ODF5; MKQ8)=J622!8)-/KEZD:C >QVGWUEQ$N@2J!:ES1[G>YHO2Z>]6U@^MQL&-UU MHJ5DW-V:E6SGSI;=9L!K[>A8;HEM _/;);-+0CU"O9*DJ.N->I9E8-ZY9.9H MV+FC)>-NIH-=;HG+W<%7C<1PR>S2L/-/2\9=0CU"O45O'%WKPM%J M)FRWL8I2O53NE9!1Z*IK\_25P9FQDN&S*8E;$K& MWDJM"N\\N5UOKY;;XJ&!*>R2&2;A'N%>:;+0]<8](X]7+YD]FI9(+AE[*P5W M.T]KU!SNMK&;;=^[3G[6E>^$,W3*<)WX3H&G,?E(XGL%]A'7E>^[3O?5E^]T%BWA MC E\-R+/5C+F;RV)^F_ABY![ZD8U[HQ7E'[ MUBRK(GOO=R15HQPJG2M;#ELF#"4,+7TBFC#TF1VOQP9FI"MCPH;EJBO#]TI! MYZZS-@2=NS@3:M?I[,K8LF&)[LKPG3"4,'1M##WHU"\%7J=$=VTN52L9.)<_ M)T.'[)A0$TVG[2QQM>AROJX:6>J2&2;A'N$>G2%;*M&RMHDIYI(99OD3R81[ M)I3[$>XMD=MH&9@6+IEAEC_Y2[A'N%R7U0*; Y5K;S;'!E&%^IV)# LYRRALZ6V\=K1.:X4I:\_;6; M7:=Y2R8.T[(=9K-WYRE;L]F[ZQRIV=PE;-@R-E2L"+5:[*4PSNA$G]GLW?F, MU&SV[CI_9CIWJ6:2L*%\[#4B.[25NL)VMVIIX!LJ*JR(U55DKED9QE=J967G M^2]:69F_LM(Q<>MY96R8P)/ LP()0@+/^>!YN)V:'O,F%A4!3RI9- \\=YXE M(?!\!CRW4^]-!9&U3/56AO$$G@2>&RB([+;7*8C47WG?$]G+CGM?_'4."XL\ M^R.6D3N8Z#\E7V!<$8C2=41P%_+Q< -,7*/H,!OF^)5A*8-7&^J7HO=!*)7M M!YZ3# ;_N!&P"![S2'I2\ NU"5@[.2!APZ[]/C,?6 +#["D@F5'TQ\&M^M%LQX]E((4'C ;.%Y";;^LM?:4]_EF-OI]\1?V *5)O,7 M"8P#5'E\+,6'],-'W1'K ?2F?:V\YM8];EH[O0!HJ&W>@K& I-8(+!95CND. M@WL1#E GAZ[C"+^@.BNY'O6FE;ZYU=KM=O-PIZMI%1+= M)\[OA/,6H?*PY&'-X?Q, M1\%.ES]Z*Z-3DML06:%7*].T95C]1"(D&,.@CC>>\6.>N;9T19DLI)E MK;*T,8?2:0.]=A_9-TRO2W;N.\)99UF*D)>0M[(R(^3=PF)_"852'NC%!:%4&G>Q7H2LL1;6V%%E*V2- MY;;&Y2K)*=RA<,<4F1D]ORDHP\N?-J\JNRZ;(E593E6^QZ.^"+>#&:0(%5*$ MK6)&%C>V7XD;K5;SB-2F0FKSNWIXR=4+BCI,5(6=1AV[+26KAJJ\Q7'29+)D MLN3T#5>;E9P^98\H>V2*S"KIG"DU4RV4#0:4EJFP,5+X8ZIAGMR+D-\)/XK0=B6E#ZILGI0^,,DDM^HPR2+)8590)N6QSI4< M)B4-*&E@BLQ*BKAOGC0HX09 @V#V'?Q=*<$_'G&?[D?YGA((%;;.G<9#9*G; MM-3+T+4I?5!EXWSS] $9I FNDZR37&<5A5(>2UW>=9J:2*C9)7\7<20CKNZO M:K#?N-]D5CTPNF9RKMKA%G2KXT9N=6P<'+;JD:XHISV7_YH$NA5W.9O:QJVX M6[B#@?!S$_AYU.QLXU)Q"H=V+=FJG;I!YKR9<*A[W"5[IG"H?(9652"E<*A. M^-EN=CKURQ*N;LOLL&KV_.^0^V8>6U<71*Y:IF^K0C0+?V>.(%.KJMTM%0M6 M2LRU#UNKS-W*(F&EA$A(2%%+B25:M80KM-[,>0Q5A.9WUE'KO8&9P9+99?GCV#]CL'"\'?$;DQ"@E/GWV7>PW M66=+AV49DAROJJ#-SJ'1XL=SI[UTCNGP.PIU2VAH5052.NVE1OC9;7;IL"P3 MK=CL#!Z9\[/A4/>8[)G"H?(96E6!E,*A&N%G#^RM?EG"NIAR =-(]XK6:[<-U\F#ZJTJPI"\[[GWQUSE,+'+M MCUA&[F"B_Y1\@9%%(#+7$<%=R,?##;#Q%1Z^Y-JS88ZK.:R;H6"#P/."!]!S MIF3%9#P"NJ%%R5Q_$(0CC@DSQOM!K SD7DC<]RS.WT>X*B^K+J#$43< /3]OA8B@_IAX^Z(]8# MJ$K[6CEM?=1M'G5W&;\,]>77%HP%)+6&NUU4.:8[#.Y%. #S^3!T'4?X!=59 M":K5FU;ZYE;G$^VFU2;!+22XS0:EX%>/B/.[X#SI_,XX;S4[Q/F=<+[7/-YI M@L%$SF]BP7_GD=.<\@\>1\%.4Q:]E8.F7BV"IBW(K#")TA.('4EQT2X>M'GW M \^91^FSRO#RIXVKRLZC/%*5Y53E>SSJBS!7B6! ^%%[I=@J?D#O#[T%$ MYEEA\Z2 R%13/;D7(;];;J,%Q4,4#YDBLY("[IO'0VMO4"RA(,J#LN=;WM)& M9EF#.(A,=)LF^IF[A1SS?[@74U!4P_,$I@\DY'Z36;I6LAZX73-I5VV=D8Z1 MV$3]?+O3)FO>G367OX"-#N'9_1ZC+53'$7IN CU;36NYK=!&1,9UNK[NWR'W MEUTCKX:/K L@5RVNW:H0S8+?F2*G;=[33+9:J:BURMRM)!+N? <'(6$);E;> M>6BZC?EG]8+6_ZC-[P;Z04HO&!W-4IJAYG%N9>S;L BX,GRO)*[N/#8F7*6H MF1*Z26U+$ Z$:V9X3&!=SB"8#O2C6+?LQEK^B);.-#4A<"4LI/B4IJ>;N!N< M:G&-%;?9 2ZE(Z@6MX36;%H$7!G&;\VBJ!:W1NBY;BVN_DH7 606;[5+.[[? M!1/0_XA'@D5#D1SPGT^2CC]*-N!NB+8LK!QX,!N\.:7A9+=9L _/V3 M!R:U?VT/ P_HU6WMX\G_^, H<(37G'DFCEQ/W3W I8Q'R>T"H? XWCD0!4P\ MCH6M/HMPU& #G7..0Q@^NP_@,7@]FC14[Z$K_]P?A$(PQ4L8%PNA'?TC:"#P MUG?8Q!6>P]X]#%U[R-RD8]U97[#_$6'0@+^Q!\&&_%X 9$1LS %5N#]A-I?# MK"7Y'O[F,#$:>\$$.DUN&!70#+SI!F&3G:?49Z2Z^9@=YOISN*;8Q'@([7 ) M#R4L'[HR"H"3W"N,&V40Q"&S@]$(GM-W-*B;%IKLYGF.X+ !&-U[:'X0!B/5 MP8_F-;P4"B[C<))PR8[#>WR7B<$ !H)7/>"CH"^Y^'5/F9P\=Z!^P^?4[_)) M;X6A9#SC=@1LC29-,\T,600]AZXO73NUI4'!XAA_X*$#:J?4\@%DQ9*+-U#' M9J[;$!R>@=>GK]W !^%#CSV ^O[4TG*)@@C8'(H1=WU\._9#80=WOM(_4)NQ M\*6^\,,.0#O@_W%ZX\^*%Z/,XN_6@H6EQ9L%YE7(6N0:>"L0!EQ/;P M,5\J1;OGX41U,0*_#+J#YSDK-O5R) 95CX:R,*C$CD+Q5^Q*%_0;1':/UXU M#V[@K*U32^E(<7^X5AIL^(,+E MF=;S>X+%T4/ 7F4!^@@%BBDP2Z6-$/KM9U#MN*"*@$'R(^.HP4>O-LO>H8;E M?O'THW[M^H?Z.?_A[*-V"ZK=[FKM=N>WJRUZJE]E>7P\#@-$U_Y$#5P.P7N M,P'0Q3M]V'?X$0^[U:\B<6 7(Q>L*P-I1)-XC&9J-0\8B--#TU<-R?E.)@YE MC"_"*PE"0!R=V.H4B1G5W>>IGJ7X&Y_H-UXAM@M1?@HZZU";D]:<=]SKB7R* MMO F8#2Z:3601Q5">4"V=?R$)'[/74]=[8.ZJ0AXCEMJQ'G;?E" N45;*X[& M2#S JEQD" @%.(:#%7[D1A@]J5!)*1+*&JQ<0-P!QJAX-U\\D(J$.M5M%C/$X"NJSM_R6G MNF_ H^!_N9,,3SS:0^[?J?@A>$*^"HDS:_@GOJ.B@ZQU/9!Q$*JA)3%']BN3 M%!'P45,LE<.&*;2# 3&'T([W==B9.-Q3B!\@+)Z>+?0Y*![X M7CD4(M+J#&&\BSK-[H0//M_3 .F,0*UAW! #W(LL!H#1@)(+'L(@\#%'W LO M&"N*TF<@2/(PS%:S"A[^*9S]*-A7GY+@*!1JQ/"[#@' 0"!B5D3K<;L%I@O- MI'F6GP]Y)L11M/UD684_S 9%^,Q]&F3J M8-#U8781:OPO*).VQSN]6;2@J \N)G&J*U/5?F[VVF#9I ^?3/1% M7TSW##(\F>PV&* ,^*A(YG,7')0VLZ=CQ0GF"%41@]XLF+U/ "Q1SB=6N7&+ MP;]/&;/CN$@DM(R3VWV%3F.,45?4Q)(JX$ERO>%D9DJ:^\O456(BX/DYE9[1 M)/C.I/O(U"0D%2#\$8#:=]2<"J9X>OZD>\SO6YRZ%Y%N09Q:2:O4+8@'!W2E M6U5O06QM^E9U4P6WX46\([H1;F>W()+.[X;SQ\T#XCSI?*TX3SI/.E\WSH/. MTYVK);QS=>?S-+H.HGHP5HTCSC=Z[OS1*^?.=]O-=NDJ,$LHE/*<.W_M/K)O MNDSB7*4E,:U96(1H-5:T88)E@F539%9V6.Z\=AU(KWF\:9F4$)8K#<1;VUA& MUE@R:VQ;M0B2JFZ-/0IW*-PA@"TAP-(LU+19Z#O7S_4AKWPA!"8$)@0VS=CG ME<_._;1Y5=EU;4DU5&7[&_7)9,ED*U(F0*JRG*I\CZ>W,00#D% &E"$R1624Q=@LI JJHVR;( M0L23J<#5]0])MFFL;6YAR1[)'LD>ZQJ?H#LL53V:&IZH&9W MATW?N(D7 ECU@.6:R;EJ6SSHLKA-7!9W?$#63-9LP%R*K!FLN7M0D]-*RFG- M-4A9D)FAF1UNYWYJ,C.SG6;I$AYDS7C;_)+6;$1>8W639H=5,^M_Z]NH#(1L M N9RYB:V*D2ST+?3Z9!ADF&6L;Z[WH8YLZU87K>1&5%GO1A4.N_-N2Q;6 M&I$&H'(&[.%S$ Z$&PF'!2$3CV,W-#)=0-G=JB42:,,:16%DX&4Q<-I?7DZA MDX&7SL#+G\78E>49M'+:HQ((\J&[SW&0#RV)#S4B(U(7*Y\^IC+VFZS3,A#. MZR).LS,;]89FJ]&R:%LLV68YIT;UMLW.08\LD[()9#)U/W2U9"9366>VV^Q MO2USS1((_97W/9&][+CWQ5_GL+#(LS]B&;F#B?Y3\@7&%8' 7$<$=R$?#S? MQ%\'<<2BH6#\@8<.XW;DWKO1 MA,4^V(KZX>KZ![OTN"^9*QF7;!!X7O @/RS '%"!:2NW6JU_[J4:HM3EZ>\? M]Y@M/"\QQU_V6OJ['',[^9XU$&:?G)EV\LL]BS(J_)BSL%5\5--?4/89[ )@ MVF/)9\2A&11CUE&S]50B&0%OI1#SE'%OVIB+6C+O\6+7UY-1/_!64V=%E2*J MF&W\Q^.GHZ?F-4>%IL4P+<>79 R_Y9^6%/:4?(N2+[-0-^0;$H1@9\(6> 4Y M:[>LHP9[2 !"./"'%N!"$$ON.P@.DD4!$Z.Q%TP$-(M_E;$]5+BAWI'P=BC8 M(/:\";M7&[)84.BA8S6PEUZ396?+(#0% X0?*=)&L&'$(_%H#[E_)QCP-6!V M,!K!PS(*[#_9@^MY++#M.(0?&7KW:.@BJHV"V(\D]BHXD 9-_\;]F(<3IOIN MM]1_+=4'?&@WV0WVE UJR.^%ZCP8*]J@XS&?J+^,>8@Z$HN$X&F*%#=$%'GX MX"0$Z 0BH^$P\!#<6,0?H76@50YY")^@B:G7H;T)>PAB#S@&G\,'%_C1%RP$ MW@%.0POP5NQ%^ E:X8..VGX,@<%] H"D+99->(^PE< M)T#?/OAG'D]S'6H*:!9:4BW:W(.O@*%_ 6' 4>;$(:(94MADTR3W&M,>0;D5 M)S^/+'41$_U+ZB@<[2G:5C;A&NV M'$KW9E'Z>#V4AL$\#\Z$C82-A(V$C3,)BFEP[!ZWETY08.(@@4"([3!5,2]% M<;S#%(7^;SM-470H14&XOCBNKV_2B\'S/%2N"YW-!)(K MA)''"L\*42/B9/]IX/C2?'H%;,7 ;[Z M&")R?R]F)P:[5O.]8M.ML]%ONN_ND'?+#VF"-L4"%/_K*WW]G[M54@ M^(4^UJ+F\+;30F*.7R/FJ'W0:JU*T4TP][D3W_D>^/8+Q+6/%'&W25NW7P/_ M#O1]=";ZT77G+H87;:WL81Y'X'D3BFXHU7AO0(8YG>D"+D+G!L?46 M8OR!+B\H.:$'92!T054N#:$%M>: /0#0L1TI)/\6..[ M14H*1U/G_R"4PQX M\@JZ_22\X.$;#_\4T+H#K\+#;ZC[YSST@51Y*<(4*UU[:KAG<:A&<&O=:L2[ MO0FRT3^!OVZ1RO;>K_NMIM7):9S;WDJ'6X+8H2'AT7*7JBRO-X=+QE M'BU/T<'Z%('>G;F>BE;>5J/RCC= Y=:T;*-4;DWSML'+S6OCHE2^N3ZN3]4V M]&]CO-JHOFV,5QO5KX6HRJ85RW#KUV3*DTUR7J\2G9_Q?76&_2!4G6\_\)PU MZR6_7]R=MG.1_;]_(9]O;B^9I?G5^SZOTZNSI\D-I[F-2I8/JH] M[_GE-=:#POQ[K'2S/X&I^KVK4H:8X7-]^$G@H5HP897X,TZJM5!P*G\O0GZ7 M9R*3W&*^,35-#7 V!IH#IX$M>K'Z*7DZ:RS4$2!.X/M!-$P3N2HR=6W\>*WR M V@*DKW+I7;Z$;,<^?>SC^]Q^=\>I@G1/.WY[EH(AK,T$,U[E3'@:=:!AWAI M.A./(K1=J7*+ QBW!7C$0!:>FP]PR%5&E/OITP+7_VV5F/T)GK=PM$EV-.^Q M]Q[SSAH#$K[W<8*/"0WD:A0*+N-PDA T$M$PT-F27#S%YR4'R?BQRFQ#QPEM ML=0)#GRBKV2LZ;"Y9\=>4B[L.XDG2Y .88%I^2.K)U.FN8V"]T<@>&%*FR=ZY'G%([4K/5O,F7 MUZ47AOJ2(OP)+M[ [-GU7%Y8YT+( '9@RE?IDB/\ *Q._P$>T:"A?BDJ"BB( MJVM^=2MZ_P#*[YW2*YUO5I52 CQ?#H .C_C[1;895(>S2VTMF;N(]7%F%>N5 M%:MT$<,6.-YLT2C9"F6#*/A8B@_IAV2QA/7 %Z5]K7Z>1WO'A]H.=0AHZ96Q M-7;I+:HK&>8IM"&WJQGE" M&XIMS.%\H9RTNOFX.>65_B:GXK8@LT)J7J>ERW%P M(! AQQP$<;#WLDS:5O.P2S+9BF6M4MTQA])I [U1JZ)J-52R<]^IRPU?)50* M,M3RR:0\AGJ=%BVL8J84(E&(9(K,"'FW<-=+"852'NC]+?9%KA"=5H-,=N?: M029;0J&89[(4.%'@9(K,C#;XF8TGSW]:154R1]%^Q5&TCIM'I;O';_-Z4VE- MP?T#!!@$&&4!C-ZFRP\(,#8.&"9>9D6 45' H BCY)I"$08!1ID @R*,DFO* MTA&&J6FI%:^$=Z](=[M-O2O,=Y9C?8AX1WA'>$=Q7=U MP+MNPVH?$]X1WA'>47Q7 [QK-XX.#I;#.R,2MI591MF:[,_RBY38N_2FK)F; MC\QP?961=?F=HIE\K^92]*[/5]^*>-_$GQIVW'IE[(SPC?!MI]."W8N7\*TD M@J@ WPG?3,J2QZHT=ROKEW8:[-R'IQ&-RDC7D>V7=)U6&E$_FK-UM$X@2B-:-[Y4%44,J0:ZS9'(MOX.L].E.IMU84G,_U*$JE:J9#"'2MA&I6B?"F85(,UN@ M51E!U\1-T&9;$8$4A4WF@I1U>$B(5#&3(42BL,E<1-I V&1$DI'6$SYQZ=J, M^PYS7"^.A,/2 W89OQM+[XB*= E)2VAIA*1EG+(0DCZ+I%;+(B0E)"V?I1&24DQ:&:$CDA[V M3#R"IS(&34A*2$HQJ1%(VCI<;N>#$0GUNECU^>7U],$5_=D\NH%>M&3"-X([LK&WJK!7;7*9XR"N]8AP1W!'<$= M17>U@#OKF.".X([@CJ*[>L!=9SFX,R)O2^LTYX^V%SO"85+8<>A&+KS\#IBT MG]9#O_]@H!>LC-S+[Q_-Y'MEUT7I-+A2RYPNK"Z!<1.H$JCN=%I"H$J@:IIQ M$Z@2J%*D2J!*H$J@6GF^5Q94*5(MM$B8GTDN&V8?ZR9-RMK%>D2[Y+(%F3)Q0E,U2"08+!LDT." 8)!@D&#>)N M96&0HL$22)9@D�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end XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

PROPERTY, PLANT AND EQUIPMENT
6 Months Ended

Jun. 30, 2019

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at June 30, 2019 and December 31, 2018 are summarized as follows:

June 30,

December 31,



2019



2018

(in thousands)

Building and improvements

$

1,273

$

1,273

Scientific equipment

598

598

Computer hardware and software

107

107

Machinery and equipment

275

275

Land and improvements

162

162

Other personal property

70

70

Office equipment

27

27

Total

2,512

2,512

Less: accumulated depreciation

(1,940)

(1,906)

Net property, plant and equipment

$

572

$

606

We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

Depreciation expense was $34 thousand and $38 thousand for the six month periods ended June 30, 2019 and 2018, respectively and was $17 thousand and $18 thousand for the three month periods ended June 30, 2019 and 2018. The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately $2 thousand per month.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

COMMON STOCK WARRANTS
6 Months Ended

Jun. 30, 2019

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS

NOTE 10 – COMMON STOCK WARRANTS

Our warrant activity for the six months ended June 30, 2019 and 2018 consisted of the following (in thousands except price data):

Six Months Ended

June 30,

2019

2018





WAvg





WAvg

Exercise

Exercise

Number

Price

Number

Price

Outstanding, Jan. 1

1,842

$

0.59

1,842

$

0.59

Issued

10,000

0.01

—

—

Exercised

—

—

—

—

Expired

—

—

—

—

Modification

—

—

—

—

Outstanding, Jun. 30

11,842

$

0.10

1,842

$

0.59

In connection with the issuance of the $10.0 million secured promissory notes to Oxford in December 2013, we issued a common stock purchase warrant (“warrant”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. These warrants contain a cashless exercise feature (See Note 8).

As part of our July 2017 private placement transaction with Mr. Schutte, we issued a warrant to purchase approx. 1.782 million shares of our common stock. The warrant is immediately exercisable at a price of $0.528 per share and expire five years after issuance (See Note 9).

On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance (see Note 8). The warrant was assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 28 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands

Jun. 30, 2019

Dec. 31, 2018

CONSOLIDATED BALANCE SHEETS

Accumulated amortization, deferred finance costs $ 1,086 $ 983

Common stock, par value $ 0.01 $ 0.01

Common stock, shares authorized 100,000 100,000

Common stock, shares issued 21,300 21,034

Common stock, shares outstanding 21,300 21,034

X

- Definition
Amount of accumulated amortization of debt issuance costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedAmortizationDeferredFinanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)
$ in Thousands
6 Months Ended

Jun. 28, 2019

USD ($)

Jun. 30, 2019

USD ($)

Related party loans made to Company $ 5,000 $ 5,000

Loss on debt extinguishment (2,600) (2,600)

Write-off of unamortized debt discount 70

Accrued interest due on the related party loan rolled into principal under modifications 274 4

Proceeds from related party loan receivable $ 725 1,650

Payments of Debt Issuance Costs 13

Interest Rate Below Market Reduction [Member]

Related party loans made to Company 650

Imputed interest on the below market rate recorded as benefit to interest income $ 13

X

- Definition
Amount of interest payable.
+ References
No definition available.
+ Details

Name: acur_InterestPayableNoncurrentRelatedParty

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of interest income earned from interest-bearing assets owed to the entity by related party.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_LoanRestructuringModificationAxis=us-gaap_InterestRateBelowMarketReductionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

NET LOSS PER SHARE - Additional Information (Details)
shares in Millions

Jun. 28, 2019

$ / shares

shares

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Schutte Note [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Debt Conversion, Converted Instrument, Warrants or Options Issued | shares 10.0

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=acur_SchutteNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Jul. 02, 2019

Jun. 28, 2019

Oct. 31, 2018

Jul. 31, 2017

Mar. 31, 2017

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 27, 2019

Jun. 30, 2018

Dec. 31, 2013

Related Party Transaction [Line Items]

Fixed interest rate 10.16% 13.35%

Number Of Common Stock Need To Hold To Designate As Director 600,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Proceeds from Issuance of Long-term Debt $ 1,800 $ 1,500

Class Of Warrants Or Rights, Expiry Period 5 years

Royalty revenues $ 46 $ 76 $ 113 274

MainPointe

Related Party Transaction [Line Items]

Proceeds from License Fees Received $ 2,500

Asset Transferred, License Agreement $ 309

Licensing Agreement, Royalty Percentage 7.50%

MainPointe | Royalty [Member]

Related Party Transaction [Line Items]

Royalty revenues 3 $ 6 15 $ 14

Investor [Member]

Related Party Transaction [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.528

Investor [Member] | Private Placement [Member]

Related Party Transaction [Line Items]

Sale of Stock, Consideration Received on Transaction $ 4,000

Sale of Stock, Number of Shares Issued in Transaction 8,912,655

Sale of Stock, Price Per Share $ 0.4488

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.528

Sale Of Stock, Issue Price Description 85%

Warrants Not Settleable in Cash, Fair Value Disclosure $ 495 495

Proceeds from Issuance of Warrants $ 4,000

Schutte

Related Party Transaction [Line Items]

Aggregate principal of promissory notes and accrued interest $ 6,000

Fixed interest rate 7.50%

Share Price $ 0.16

Debt Conversion, Converted Instrument, Warrants or Options Issued 10,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Debt Conversion, Converted Instrument, Shares Issued 37,500,000

Proceeds from Issuance of Long-term Debt $ 725 $ 650

Abuse Deterrent Pharma, LLC

Related Party Transaction [Line Items]

Proceeds from License Fees Received $ 350 $ 350

X

- Definition
The value od asset transferred during licensing agreement.
+ References
No definition available.
+ Details

Name: acur_AssetTransferredLicenseAgreement

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The expiry period of warrants.
+ References
No definition available.
+ Details

Name: acur_ClassOfWarrantsOrRightsExpiryPeriod

Namespace Prefix: acur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the royalty percentage at which royalty on net sales of licensed products calculated.
+ References
No definition available.
+ Details

Name: acur_LicensingAgreementRoyaltyPercentage

Namespace Prefix: acur_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common stock need to hold to designate as director.
+ References
No definition available.
+ Details

Name: acur_NumberOfCommonStockNeedToHoldToDesignateAsDirector

Namespace Prefix: acur_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The detailed description of issue price of the units.
+ References
No definition available.
+ Details

Name: acur_SaleOfStockIssuePriceDescription

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value portion of warrants not settleable in cash classified as equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=acur_MainPointeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_SchutteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_AbuseDeterrentPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 32 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 33 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

PROPERTY, PLANT AND EQUIPMENT

Depreciation $ 17 $ 18 $ 34 $ 38

Lease Revenue Per Month $ 2

X

- Definition
The amount of lease revenue per month.
+ References
No definition available.
+ Details

Name: acur_LeaseRevenuePerMonth

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

LICENSE AND COLLABORATION AGREEMENTS (Details) - USD ($)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Jul. 02, 2019

Jun. 28, 2019

Oct. 09, 2015

Mar. 31, 2017

Mar. 17, 2017

Oct. 31, 2016

Apr. 30, 2014

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

License Development and Commercialization Agreement [Line Items]

Revenue from Contract with Customer, Including Assessed Tax $ 46 $ 76 $ 113 $ 274

Amortization of Intangible Assets 103 $ 103

Finite-Lived Intangible Assets, Amortization Expense, Year Two 52 $ 52

Patents [Member]

License Development and Commercialization Agreement [Line Items]

Payment for Termination $ 2,000

Schutte | AD Pharma Agreement

License Development and Commercialization Agreement [Line Items]

Percentage of common stock held 47.50%

Abuse Deterrent Pharma, LLC

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 350 $ 350

Abuse Deterrent Pharma, LLC | AD Pharma Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 350

Period until which monthly license payment is receivable 18 months 5 years

MainPointe Pharmaceuticals, LLC | AD Pharma Agreement

License Development and Commercialization Agreement [Line Items]

Waiver of exercise price if exercise of option occurs by certain date $ 500 $ 500

Period from effective date for exercise of option 5 years

Schutte

License Development and Commercialization Agreement [Line Items]

Aggregate principal of promissory notes and accrued interest $ 6,000

Debt Conversion, Converted Instrument, Warrants or Options Issued 10.0

Schutte | AD Pharma Agreement

License Development and Commercialization Agreement [Line Items]

Aggregate principal of promissory notes and accrued interest $ 6,000

Debt Conversion, Converted Instrument, Warrants or Options Issued 10.0

Zyla

License Development and Commercialization Agreement [Line Items]

Payment for Termination $ 2,000

Minimum Net Sales Reaching Description one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.

Agreement Termination Notice Description Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla's launch of Oxaydo. Termination does not affect a party's rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla's supply of Oxaydo for a transition period.

Revenue from Contract with Customer, Including Assessed Tax $ 5,000

Proceeds from Milestone Payment On Agreement $ 2,500

Amortization of Intangible Assets $ 208 $ 208

Finite-Lived Intangible Asset, Useful Life 9 years 8 months 12 days

Finite-Lived Intangible Assets, Amortization Expense, Year Two $ 208 $ 208

MainPointe

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 2,500

Licensing Agreement, Royalty Percentage 7.50%

License Agreement Option Products Description In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

MainPointe | UNITED KINGDOM

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 1,000

MainPointe | JAPAN

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable 500

MainPointe | South Korea [Member]

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 250

Kempharm Agreement [Member]

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable $ 3,500

Kempharm Agreement [Member] | Minimum

License Development and Commercialization Agreement [Line Items]

Additional Upfront Payment Receivable $ 1,000

X

- Definition
The cash inflow receivable as additional upfront payment.
+ References
No definition available.
+ Details

Name: acur_AdditionalUpfrontPaymentReceivable

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Description of notice period of termination when the party breaches a payment obligation, or otherwise materially breaches the agreement.
+ References
No definition available.
+ Details

Name: acur_AgreementTerminationNoticeDescription

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the terms and condition of license agreement.
+ References
No definition available.
+ Details

Name: acur_LicenseAgreementOptionProductsDescription

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: acur_LicenseDevelopmentAndCommercializationAgreementLineItems

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
license Receivable, Term
+ References
No definition available.
+ Details

Name: acur_LicenseReceivableTerm

Namespace Prefix: acur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the royalty percentage at which royalty on net sales of licensed products calculated.
+ References
No definition available.
+ Details

Name: acur_LicensingAgreementRoyaltyPercentage

Namespace Prefix: acur_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of milestone payment to be made when worldwide net sales reached minimum level in a calendar year.
+ References
No definition available.
+ Details

Name: acur_MinimumNetSalesReachingDescription

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount of one-time termination payment under the agreement.
+ References
No definition available.
+ Details

Name: acur_PaymentForTermination

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the period from effective date for exercise of option.
+ References
No definition available.
+ Details

Name: acur_PeriodFromEffectiveDateForExerciseOfOption

Namespace Prefix: acur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of milestone payment on agreement.
+ References
No definition available.
+ Details

Name: acur_ProceedsFromMilestonePaymentOnAgreement

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the waiver of exercise price if exercise of option occurs by certain date.
+ References
No definition available.
+ Details

Name: acur_WaiverOfExercisePriceIfExerciseOfOptionOccursByCertainDate

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=acur_SchutteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=acur_AdPharmaAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_AbuseDeterrentPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_MainpointePharmaceuticalsLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_SchutteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=acur_EgaletAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=acur_MainPointeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_GB

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_JP

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=currency_KRW

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContingentConsiderationByTypeAxis=acur_KempharmAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 199 305 1 false 54 0 false 4 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://acurapharm.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://acurapharm.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://acurapharm.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://acurapharm.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT Sheet http://acurapharm.com/role/StatementConsolidatedStatementOfChangesInAccumulatedStockholdersDeficit CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://acurapharm.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00405 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://acurapharm.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 10101 - Disclosure - OPERATIONS AND BASIS OF PRESENTATION Sheet http://acurapharm.com/role/DisclosureOperationsAndBasisOfPresentation OPERATIONS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 10201 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://acurapharm.com/role/DisclosureRecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 9 false false R10.htm 10301 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS Sheet http://acurapharm.com/role/DisclosureLicenseAndCollaborationAgreements LICENSE AND COLLABORATION AGREEMENTS Notes 10 false false R11.htm 10401 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER Sheet http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomer REVENUE FROM CONTRACTS WITH CUSTOMER Notes 11 false false R12.htm 10501 - Disclosure - RESEARCH AND DEVELOPMENT ACTIVITIES Sheet http://acurapharm.com/role/DisclosureResearchAndDevelopmentActivities RESEARCH AND DEVELOPMENT ACTIVITIES Notes 12 false false R13.htm 10601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT Sheet http://acurapharm.com/role/DisclosurePropertyPlantAndEquipment PROPERTY, PLANT AND EQUIPMENT Notes 13 false false R14.htm 10701 - Disclosure - ACCRUED EXPENSES Sheet http://acurapharm.com/role/DisclosureAccruedExpenses ACCRUED EXPENSES Notes 14 false false R15.htm 10801 - Disclosure - DEBT Sheet http://acurapharm.com/role/DisclosureDebt DEBT Notes 15 false false R16.htm 10901 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://acurapharm.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 11001 - Disclosure - COMMON STOCK WARRANTS Sheet http://acurapharm.com/role/DisclosureCommonStockWarrants COMMON STOCK WARRANTS Notes 17 false false R18.htm 11101 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://acurapharm.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 18 false false R19.htm 11201 - Disclosure - SHARE-BASED COMPENSATION EXPENSE Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpense SHARE-BASED COMPENSATION EXPENSE Notes 19 false false R20.htm 11301 - Disclosure - INCOME TAXES Sheet http://acurapharm.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 20 false false R21.htm 11401 - Disclosure - NET LOSS PER SHARE Sheet http://acurapharm.com/role/DisclosureNetLossPerShare NET LOSS PER SHARE Notes 21 false false R22.htm 11501 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://acurapharm.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 30403 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER (Tables) Sheet http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomerTables REVENUE FROM CONTRACTS WITH CUSTOMER (Tables) Tables http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomer 23 false false R24.htm 30603 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables) Sheet http://acurapharm.com/role/DisclosurePropertyPlantAndEquipmentTables PROPERTY, PLANT AND EQUIPMENT (Tables) Tables http://acurapharm.com/role/DisclosurePropertyPlantAndEquipment 24 false false R25.htm 30703 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://acurapharm.com/role/DisclosureAccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://acurapharm.com/role/DisclosureAccruedExpenses 25 false false R26.htm 30803 - Disclosure - DEBT (Tables) Sheet http://acurapharm.com/role/DisclosureDebtTables DEBT (Tables) Tables http://acurapharm.com/role/DisclosureDebt 26 false false R27.htm 31003 - Disclosure - COMMON STOCK WARRANTS (Tables) Sheet http://acurapharm.com/role/DisclosureCommonStockWarrantsTables COMMON STOCK WARRANTS (Tables) Tables http://acurapharm.com/role/DisclosureCommonStockWarrants 27 false false R28.htm 31203 - Disclosure - SHARE-BASED COMPENSATION EXPENSE (Tables) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseTables SHARE-BASED COMPENSATION EXPENSE (Tables) Tables http://acurapharm.com/role/DisclosureShareBasedCompensationExpense 28 false false R29.htm 31403 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://acurapharm.com/role/DisclosureNetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://acurapharm.com/role/DisclosureNetLossPerShare 29 false false R30.htm 40101 - Disclosure - OPERATIONS AND BASIS OF PRESENTATION (Details) Sheet http://acurapharm.com/role/DisclosureOperationsAndBasisOfPresentationDetails OPERATIONS AND BASIS OF PRESENTATION (Details) Details http://acurapharm.com/role/DisclosureOperationsAndBasisOfPresentation 30 false false R31.htm 40301 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Details) Sheet http://acurapharm.com/role/DisclosureLicenseAndCollaborationAgreementsDetails LICENSE AND COLLABORATION AGREEMENTS (Details) Details http://acurapharm.com/role/DisclosureLicenseAndCollaborationAgreements 31 false false R32.htm 40401 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER (Details) Sheet http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomerDetails REVENUE FROM CONTRACTS WITH CUSTOMER (Details) Details http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomerTables 32 false false R33.htm 40402 - Disclosure - REVENUE FROM CONTRACTS WITH CUSTOMER - Additional Information (Details) Sheet http://acurapharm.com/role/DisclosureRevenueFromContractsWithCustomerAdditionalInformationDetails REVENUE FROM CONTRACTS WITH CUSTOMER - Additional Information (Details) Details 33 false false R34.htm 40601 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details) Sheet http://acurapharm.com/role/DisclosurePropertyPlantAndEquipmentDetails PROPERTY, PLANT AND EQUIPMENT (Details) Details http://acurapharm.com/role/DisclosurePropertyPlantAndEquipmentTables 34 false false R35.htm 40602 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Additional Information (Details) Sheet http://acurapharm.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails PROPERTY, PLANT AND EQUIPMENT - Additional Information (Details) Details 35 false false R36.htm 40701 - Disclosure - ACCRUED EXPENSES (Details) Sheet http://acurapharm.com/role/DisclosureAccruedExpensesDetails ACCRUED EXPENSES (Details) Details http://acurapharm.com/role/DisclosureAccruedExpensesTables 36 false false R37.htm 40801 - Disclosure - DEBT - Additional Information (Details) Sheet http://acurapharm.com/role/DisclosureDebtAdditionalInformationDetails DEBT - Additional Information (Details) Details 37 false false R38.htm 40802 - Disclosure - DEBT - Interest Expense (Details) Sheet http://acurapharm.com/role/DisclosureDebtInterestExpenseDetails DEBT - Interest Expense (Details) Details 38 false false R39.htm 40901 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://acurapharm.com/role/DisclosureRelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://acurapharm.com/role/DisclosureRelatedPartyTransactions 39 false false R40.htm 41001 - Disclosure - COMMON STOCK WARRANTS - Warrant Activity (Details) Sheet http://acurapharm.com/role/DisclosureCommonStockWarrantsWarrantActivityDetails COMMON STOCK WARRANTS - Warrant Activity (Details) Details 40 false false R41.htm 41002 - Disclosure - COMMON STOCK WARRANTS - Additional Information (Details) Sheet http://acurapharm.com/role/DisclosureCommonStockWarrantsAdditionalInformationDetails COMMON STOCK WARRANTS - Additional Information (Details) Details 41 false false R42.htm 41101 - Disclosure - FAIR VALUE MEASUREMENTS (Detail) Sheet http://acurapharm.com/role/DisclosureFairValueMeasurementsDetail FAIR VALUE MEASUREMENTS (Detail) Details http://acurapharm.com/role/DisclosureFairValueMeasurements 42 false false R43.htm 41201 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Non-Cash Share-Based Compensation Expense (Details) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseNonCashShareBasedCompensationExpenseDetails SHARE-BASED COMPENSATION EXPENSE - Non-Cash Share-Based Compensation Expense (Details) Details 43 false false R44.htm 41202 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Details) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseStockOptionAwardActivityDetails SHARE-BASED COMPENSATION EXPENSE - Stock Option Award Activity (Details) Details 44 false false R45.htm 41203 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseSummaryOfInformationAboutNonVestedStockOptionsDetails SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) Details 45 false false R46.htm 41204 - Disclosure - SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseSummaryOfRsuPlanDetails SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) Details 46 false false R47.htm 41205 - Disclosure - SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) Sheet http://acurapharm.com/role/DisclosureShareBasedCompensationExpenseAdditionalInformationDetails SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) Details 47 false false R48.htm 41301 - Disclosure - INCOME TAXES (Details) Sheet http://acurapharm.com/role/DisclosureIncomeTaxesDetails INCOME TAXES (Details) Details http://acurapharm.com/role/DisclosureIncomeTaxes 48 false false R49.htm 41401 - Disclosure - NET LOSS PER SHARE (Details) Sheet http://acurapharm.com/role/DisclosureNetLossPerShareDetails NET LOSS PER SHARE (Details) Details http://acurapharm.com/role/DisclosureNetLossPerShareTables 49 false false R50.htm 41402 - Disclosure - NET LOSS PER SHARE - Additional Information (Details) Sheet http://acurapharm.com/role/DisclosureNetLossPerShareAdditionalInformationDetails NET LOSS PER SHARE - Additional Information (Details) Details 50 false false All Reports Book All Reports acur-20190630.xml acur-20190630.xsd acur-20190630_cal.xml acur-20190630_def.xml acur-20190630_lab.xml acur-20190630_pre.xml http://xbrl.sec.gov/currency/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 36 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

RESEARCH AND DEVELOPMENT ACTIVITIES
6 Months Ended

Jun. 30, 2019

RESEARCH AND DEVELOPMENT ACTIVITIES

RESEARCH AND DEVELOPMENT ACTIVITIES

NOTE 5 – RESEARCH AND DEVELOPMENT ACTIVITIES

Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at June 30, 2019 or December 31, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 730
-URI http://asc.fasb.org/subtopic&trid=2197926
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

RELATED PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2019

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

Private Placement with Mr. John Schutte

In July 2017, we completed a $4.0 million private placement with Mr. John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units”) of the Company, at a price of $0.4488 per Unit (the “Transaction”). Each Unit consists of one share of common stock and a warrant to purchase one fifth (0.2) of a share of common stock. The issue price of the Units was equal to 85% of the average last sale price of our common stock for the five trading days prior to completion of the Transaction. The warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s common stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933.

MainPointe Pharmaceuticals LLC

Investor is a principal of MainPointe Pharmaceuticals LLC, a Kentucky limited liability company ("MainPointe"). In March 2017, we granted MainPointe an exclusive license to our Impede Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company is receiving a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported royalty revenue for the three months ended 2019 and 2018 is $3 thousand and $6 thousand, respectively and for the six months ended 2019 and 2018 is $15 thousand and $14 thousand, respectively of royalty revenue from MainPointe (See Note 3).

As part of the closing of the Transaction, the Company and Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our common stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Investor has not designated a director as of the date of filing of this Report. Galen had not designated a director and lost that right in December 2017 when it disposed of its shares of common stock in the Company. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. An independent director has not been named to fill the seat forfeited by Galen.

Loans with Mr. John Schutte

During the period January 1, 2019 through June 27, 2019 we borrowed an aggregate of $650 thousand from Mr. John Schutte. On June 28, 2019 we borrowed an additional $725 thousand from Mr. Schutte, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted conversion rights of principal and interest into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the note is convertible into 37.5 million shares of our common stock. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

AD Pharma Agreement covering LTX-03

On June 28, 2019, we entered into a License, Development and Commercialization Agreement (the "AD Pharma Agreement") with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The AD Pharma Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03. Financial arrangements include:

·

Monthly license payments to Acura by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (“NDA”) for LTX-03;

·

Reimbursement by AP Pharma of Acura’s LTX-03 outside development expenses;

·

Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones; and

·

Acura authorizes MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength).

AD Pharma may terminate the AD Pharma Agreement at any time. Additionally, if the NDA for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the intellectual property. On July 2, 2019 we received the first monthly license payment of $350 thousand. As of February 10, 2020 we have received the required monthly license payments through January 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

INCOME TAXES
6 Months Ended

Jun. 30, 2019

INCOME TAXES

INCOME TAXES

NOTE 13 – INCOME TAXES

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse.

Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $171.8 million gross Federal NOLs at December 31, 2018 (of which approximately $167.7 million were generated prior to 2018). Because we believe the ability for us to use these NOLs generated prior to January 1, 2018 to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382, we had estimated and recorded an amount for the likely limitation to our deferred tax asset in the fourth quarter of 2017, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million at December 31, 2017. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 to offset taxable income is less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely. Future common stock transactions, such as the exercise of common stock purchase warrants or the conversion of debt into common stock, may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs.

The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both June 30, 2019 and December 31, 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

PROPERTY, PLANT AND EQUIPMENT (Tables)
6 Months Ended

Jun. 30, 2019

PROPERTY, PLANT AND EQUIPMENT

Schedule of Property, Plant and equipment

Property, plant and equipment at June 30, 2019 and December 31, 2018 are summarized as follows:

June 30,

December 31,



2019



2018

(in thousands)

Building and improvements

$

1,273

$

1,273

Scientific equipment

598

598

Computer hardware and software

107

107

Machinery and equipment

275

275

Land and improvements

162

162

Other personal property

70

70

Office equipment

27

27

Total

2,512

2,512

Less: accumulated depreciation

(1,940)

(1,906)

Net property, plant and equipment

$

572

$

606

X

- Definition
Tabular disclosure of gross value of each categories of plant property and equipment of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software, less accumulated depreciation and amortization and net value of long live property plant and equipment.
+ References
No definition available.
+ Details

Name: acur_ScheduleOfPropertyPlantAndEquipmentNetCarryingValueTableTextBlock

Namespace Prefix: acur_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE (Tables)
6 Months Ended

Jun. 30, 2019

SHARE-BASED COMPENSATION EXPENSE

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):

Three months Ended

Six months Ended

June 30,

June 30,

2019

2018

2019

2018



(in thousands)

Research and development costs:









Stock options

$

2

$

11

$

4

$

24

Restricted stock units

4

7

8

14

Subtotal

$

6

$

18

$

12

$

38

General and administrative costs:









Stock options

$

4

$

19

$

6

$

53

Restricted stock units

23

29

50

51

Subtotal

27

$

48

56

$

104

Total

$

33

$

66

$

68

$

142

Schedule of Share-based Compensation, Stock Options, Activity

We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2019 and 2018 is shown below:

Six Months Ended

June 30,

2019

2018



Number



Weighted





Weighted

of

Average

Number of

Average

Options

Exercise

Options

Exercise

(000’s)

Price

(000’s)

Price

Outstanding, Jan. 1

1,560

$

7.38

1,494

$

12.33

Granted

—

—

—

—

Exercised

—

—

—

—

Forfeited or expired

(170)

(30.83)

(145)

(46.39)

Outstanding, Jun. 30

1,390

$

4.44

1,349

$

8.68

Options exercisable

1,158

$

5.30

1,129

$

10.26

Schedule of Nonvested Share Activity

The following table summarizes information about nonvested stock options outstanding at June 30, 2019 (in thousands except price data):



Number of



Weighted

Options Not

Average

Exercisable

Fair Value

Outstanding, Jan. 1, 2019

232

$

0.10

Granted

—

—

Vested

—

—

Forfeited

—

—

Outstanding, Jun. 30, 2019

232

$

0.10

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans as of June 30, 2019 and 2018, and for the six month period then ended consisted of the following (in thousands):

Six Months Ended June 30,

2019

2018

(in thousands)





Number of





Number of

Number

Vested

Number of

Vested

of RSUs

RSUs

RSUs

RSUs

Outstanding, Jan. 1

951

459

462

262

Granted

333

—

267

—

Distributed

(267)

(267)

(262)

(262)

Vested

—

166

—

133

Forfeited or expired

—

—

(8)

—

Outstanding, Jun. 30

1,017

358

459

133

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

NET LOSS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2018

Mar. 31, 2018

Jun. 30, 2019

Jun. 30, 2018

EPS - basic and diluted

Numerator: net loss $ (3,341) $ (788) $ (1,261) $ (1,494) $ (4,129) $ (2,755)

Denominator (weighted):

Common shares 21,300 21,034 21,300 21,034

RSUs - vested 242 67 218 34

Common stock purchase warrants 330 166

Basic and diluted weighted average shares outstanding 21,872 21,101 21,684 21,068

EPS - basic and diluted $ (0.15) $ (0.06) $ (0.19) $ (0.13)

Common stock issuable:

Total excluded potentially dilutive shares 41,391 3,517 41,391 3,517

Restricted stock units

Common stock issuable:

Total excluded potentially dilutive shares 659 326 659 326

Stock options

Common stock issuable:

Total excluded potentially dilutive shares 1,390 1,349 1,390 1,349

Common stock purchase warrants

Common stock issuable:

Total excluded potentially dilutive shares 1,842 1,842 1,842 1,842

Convertible loan

Common stock issuable:

Total excluded potentially dilutive shares 37,500 37,500

X

- References
No definition available.
+ Details

Name: acur_CommonStockIssuableAbstract

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the weighted average total number of warrants issued throughout the period.
+ References
No definition available.
+ Details

Name: acur_WeightedAverageNumberOfSharesWarrants

Namespace Prefix: acur_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesRestrictedStock

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) - Non Vested Stock Options [Member]
shares in Thousands
6 Months Ended

Jun. 30, 2019

$ / shares

shares

Summary Of Information About Non Vested Stock Options Disclosure [Line Items]

Outstanding, beginning | shares 232

Granted | shares 0

Vested | shares 0

Forfeited | shares 0

Outstanding, ending | shares 232

Outstanding beginning, Weighted Average Fair Value | $ / shares $ 0.10

Granted, Weighted Average Fair Value | $ / shares 0

Vested, Weighted Average Fair Value | $ / shares 0.00

Forfeited, Weighted Average Fair Value | $ / shares 0.00

Outstanding ending, Weighted Average Fair Value | $ / shares $ 0.10

X

- References
No definition available.
+ Details

Name: acur_SummaryOfInformationAboutNonVestedStockOptionsDisclosureLineItems

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=acur_NonVestedStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

COMMON STOCK WARRANTS - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
6 Months Ended

Jun. 30, 2019

Jun. 28, 2019

Jul. 31, 2017

Dec. 31, 2013

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock 10,000

Warrants expiration term 5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Secured Debt $ 10.0

Class Of Warrant Or Right Term 5 years

Investor [Member]

Class of Warrant or Right [Line Items]

Warrant to purchase shares of common stock 1,782

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.528

Investor [Member] | Private Placement [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.528

Common stock purchase warrants

Class of Warrant or Right [Line Items]

Common stock warrant exercisable outstanding, shares 60

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.52

X

- Definition
The term of warrants or rights.
+ References
No definition available.
+ Details

Name: acur_ClassOfWarrantOrRightTerm

Namespace Prefix: acur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_SecuredDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

RECENT ACCOUNTING PRONOUNCEMENTS
6 Months Ended

Jun. 30, 2019

RECENT ACCOUNTING PRONOUNCEMENTS

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS

New accounting standards which have been adopted on or before June 30, 2019

Leases

In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. The classification of the lease will affect the pattern of expense recognition in the income statement such that operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842)-Targeted Improvements" (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840).

The Company adopted ASC 842 using the modified retrospective transition approach during Q1 2019, which allows the Company to not adjust the comparative periods presented. The Company has elected to adopt the package of transition practical expedients and, therefore, has not reassessed whether existing or expired contracts contain a lease or the lease classification for existing or expired. The Company did not elect the practical expedient to use hindsight for leases existing at the adoption date. Upon adoption, operating leases was to be reported on the balance sheet as a gross-up of assets and liabilities, however the Company has elected, as an accounting policy, to not recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The adoption of ASC 842 did not have an impact on the Company’s financial statements as the Company has no leases with term of more than 12 months.

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Document And Entity Information - shares
6 Months Ended

Jun. 30, 2019

Feb. 10, 2020

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q2

Entity Registrant Name ACURA PHARMACEUTICALS, INC

Entity Central Index Key 0000786947

Current Fiscal Year End Date --12-31

Entity Current Reporting Status No

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Entity Shell Company false

Title of 12(b) Security Common Stock, $0.01 par value

Trading Symbol ACUR

Entity Common Stock, Shares Outstanding 21,650,294

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 47 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT - USD ($)
shares in Thousands, $ in Thousands

Common Stock

Additional Paid-in Capital

Accumulated Deficit

Total

Balance at Dec. 31, 2017 $ 208 $ 380,145 $ (380,380) $ (27)

Balance (in shares) at Dec. 31, 2017 20,796

Net loss (1,494) (1,494)

Non-cash share-based compensation 62 62

Net distribution of common stock pursuant to restricted stock unit award plan $ 2 32 34

Net distribution of common stock pursuant to restricted stock unit award plan (in shares) 238

Balance at Mar. 31, 2018 $ 210 380,239 (381,874) (1,425)

Balance (in shares) at Mar. 31, 2018 21,034

Balance at Dec. 31, 2017 $ 208 380,145 (380,380) (27)

Balance (in shares) at Dec. 31, 2017 20,796

Net loss (2,755)

Balance at Jun. 30, 2018 $ 210 380,299 (383,135) (2,626)

Balance (in shares) at Jun. 30, 2018 21,034

Balance at Dec. 31, 2017 $ 208 380,145 (380,380) (27)

Balance (in shares) at Dec. 31, 2017 20,796

Balance at Dec. 31, 2018 $ 210 380,395 (384,222) (3,617)

Balance (in shares) at Dec. 31, 2018 21,034

Balance at Mar. 31, 2018 $ 210 380,239 (381,874) (1,425)

Balance (in shares) at Mar. 31, 2018 21,034

Net loss (1,261) (1,261)

Non-cash share-based compensation 60 60

Balance at Jun. 30, 2018 $ 210 380,299 (383,135) (2,626)

Balance (in shares) at Jun. 30, 2018 21,034

Balance at Dec. 31, 2018 $ 210 380,395 (384,222) (3,617)

Balance (in shares) at Dec. 31, 2018 21,034

Net loss (788) (788)

Non-cash share-based compensation 29 29

Net distribution of common stock pursuant to restricted stock unit award plan $ 3 12 15

Net distribution of common stock pursuant to restricted stock unit award plan (in shares) 266

Balance at Mar. 31, 2019 $ 213 380,436 (385,010) (4,361)

Balance (in shares) at Mar. 31, 2019 21,300

Balance at Dec. 31, 2018 $ 210 380,395 (384,222) (3,617)

Balance (in shares) at Dec. 31, 2018 21,034

Net loss (4,129)

Balance at Jun. 30, 2019 $ 213 382,992 (388,351) (5,146)

Balance (in shares) at Jun. 30, 2019 21,300

Balance at Mar. 31, 2019 $ 213 380,436 (385,010) (4,361)

Balance (in shares) at Mar. 31, 2019 21,300

Net loss (3,341) (3,341)

Non-cash share-based compensation 29 29

Debt premium from debt modification 1,382 1,382

Issuance of warrant 1,145 1,145

Balance at Jun. 30, 2019 $ 213 $ 382,992 $ (388,351) $ (5,146)

Balance (in shares) at Jun. 30, 2019 21,300

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from debt premium from debt modification.
+ References
No definition available.
+ Details

Name: acur_AdjustmentsToAdditionalPaidInCapitalDebtPremiumFromDebtModification

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 48 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

FAIR VALUE MEASUREMENTS
6 Months Ended

Jun. 30, 2019

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

NOTE 11 – FAIR VALUE MEASUREMENTS

The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than our debt, are representative of their respective fair values due to their relatively short maturities. On June 28, 2019, we modified the $5.0 million related party loan and reported the debt using fair value for the changes to the loan resulting in the recognizing a $2.6 million loss on debt extinguishment.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

LICENSE AND COLLABORATION AGREEMENTS
6 Months Ended

Jun. 30, 2019

LICENSE AND COLLABORATION AGREEMENTS

LICENSE AND COLLABORATION AGREEMENTS

NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS

The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement.

AD Pharma Agreement covering LTX-03

On June 28, 2019 we entered into with Abuse Deterrent Pharma, LLC ("AD Pharma"), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"), for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM. Acura will receive a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019. AD Pharma will pay for and reimburse Acura for all outside development costs on LTX-03. If the NDA filing for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the Limitx intellectual property. AD Pharma does have the right to terminate the AD Pharma Agreement anytime for "convenience". AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones.

We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. (See MainPointe Agreement covering Nexafed products). The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement).

On June 28, 2019 Mr. John Schutte assigned and transferred to AD Pharma his $6.0 million promissory note, the common stock purchase warrant for 10.0 million common shares, and the security agreement granting a security interest in all of the Company's assets. (See Note 8). Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of remaining common stock purchase warrants he holds). Mr. Schutte controls MainPointe and is the principal investor in AD Pharma.

Zyla Agreement covering Oxaydo

In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded annual amortization expense of $208 thousand for each of the years 2018 and 2017. Amortization of the patent for the years 2019 through 2021 is expected to approximate $208 thousand each year and $52 thousand be quarter.

In January 2015, we and Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, entered into a Collaboration and License Agreement (the “Zyla Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Zyla Agreement, we and Zyla formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions although no meetings were held in 2019 or to date in 2020. Zyla is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Zyla will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Zyla will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion.

Zyla paid us a $5.0 million license fee upon signing of the Zyla Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla's royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Zyla Agreement expires upon the expiration of Zyla’s royalty payment obligations in all countries. Either party may terminate the Zyla Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Zyla Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Zyla Agreement with respect to the U.S. and other countries if Zyla materially breaches its commercialization obligations. Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla’s supply of Oxaydo for a transition period.

MainPointe Agreement covering Nexafed products

In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement.

On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country.

MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement).

The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura.

KemPharm Agreement Covering Certain Opioid Prodrugs

In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities.

Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free.

The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

X

- References
No definition available.
+ Details

Name: acur_LicenseAndCollaborationAgreementsAbstract

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI http://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

ACCRUED EXPENSES
6 Months Ended

Jun. 30, 2019

ACCRUED EXPENSES

ACCRUED EXPENSES

NOTE 7 – ACCRUED EXPENSES

Accrued expenses at June 30, 2019 and December 31, 2018 are summarized as follows:

June 30,

December 31,



2019



2018

(in thousands)

Cost sharing expenses under license agreement

$

300

$

237

Other fees and services

26

36

Payroll, payroll taxes and benefits

7

6

Professional services

249

132

Financed premiums on insurance policies

36

102

Clinical, non-clinical and regulatory services

44

63

Property taxes

4

7

Franchise taxes

23

13

Total

$

689

$

596

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

DEBT - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Jun. 28, 2019

Oct. 31, 2018

Jan. 31, 2015

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Jun. 27, 2019

Dec. 31, 2013

Debt Instrument [Line Items]

Debt instrument principal amount $ 10,000

Proceeds from Issuance of Long-term Debt $ 1,800 $ 1,500

Debt instrument, interest rate, stated percentage 10.16% 13.35%

Debt instrument, fee amount $ 50 $ 50

Gain (Loss) on Extinguishment of Debt $ (2,600) 296 (2,600) (2,600)

Debt consulting placement fee 100

Deferred debt issue costs $ 0 $ 4 0 10

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Repayments of Debt $ 1,220

Debt Instrument, Periodic Payment $ 260

Debt Instrument, Interest Rate, Effective Percentage 10.16% 10.16%

Related party loans made to Company $ 5,000 $ 5,000 $ 5,000

Term Loan [Member]

Debt Instrument [Line Items]

Deferred debt issue costs 231

Schutte Note [Member]

Debt Instrument [Line Items]

Debt instrument principal amount $ 5,000

Proceeds from Issuance of Long-term Debt 725

Aggregate principal of promissory notes and accrued interest 6,000

Debt instrument, interest rate, stated percentage 7.50%

Gain (Loss) on Extinguishment of Debt $ (2,600)

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.01

Debt Conversion, Converted Instrument, Shares Issued 37,500

Debt Conversion, Converted Instrument, Warrants or Options Issued 10,000

Share Price $ 0.16

Related party loans made to Company $ 650

Loan Agreement [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate, stated percentage 8.35%

Oxford Term Loan Agreement [Member]

Debt Instrument [Line Items]

Debt instrument principal amount $ 185

Repayments of Debt $ 1,500

Maximum

Debt Instrument [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 7.98

Minimum

Debt Instrument [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.52

Common stock purchase warrants

Debt Instrument [Line Items]

Debt instrument unamortized discount $ 400 $ 400

Warrants to purchase common stock 60 60

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.52 $ 2.52

Warrants, expiry date December 27, 2020

Additions To Debt Instrument Unamortized Discount $ 33

X

- Definition
It represents the additions made to debt instrument unamortized discount during the period.
+ References
No definition available.
+ Details

Name: acur_AdditionsToDebtInstrumentUnamortizedDiscount

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Class of warrant or right, expiration date.
+ References
No definition available.
+ Details

Name: acur_ClassOfWarrantOrRightExpirationDate

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt consulting placement fee.
+ References
No definition available.
+ Details

Name: acur_DebtConsultingPlacementFee

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the fee that accompanies borrowing money under the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the charge against earnings during the period for commitment fees and debt issuance expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=acur_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=acur_SchutteNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=acur_LoanAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=acur_OxfordTermLoanAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

REVENUE FROM CONTRACTS WITH CUSTOMER - Additional Information (Details) - USD ($)
$ in Thousands
6 Months Ended

Jul. 02, 2019

Jun. 28, 2019

Jun. 30, 2019

Contract Balance And Performance Obligations description The Company's reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2019 or December 31, 2018 was $0.

Abuse Deterrent Pharma, LLC

Monthly license payment receivable $ 350 $ 350

Abuse Deterrent Pharma, LLC | AD Pharma Agreement

Monthly license payment receivable $ 350

Period until which monthly license payment is receivable 18 months 5 years

X

- Definition
The description of contract balance and performance obligations.
+ References
No definition available.
+ Details

Name: acur_ContractBalanceAndPerformanceObligationsDescription

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
license Receivable, Term
+ References
No definition available.
+ Details

Name: acur_LicenseReceivableTerm

Namespace Prefix: acur_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received from licensees for license fees during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromLicenseFeesReceived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acur_AbuseDeterrentPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=acur_AdPharmaAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

COMMITMENTS AND CONTINGENCIES
6 Months Ended

Jun. 30, 2019

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

NOTE 15 – COMMITMENTS AND CONTINGENCIES

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L‑3865‑10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC‑10‑004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

None of the plaintiffs in the lawsuits filed to date have confirmed that they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. All of these lawsuits have been effectively dismissed with the exception of less than ten pending Philadelphia cases that we expect will be finally dismissed without the need for any action by us. We expect that the Court will finally dismiss the small number of remaining Pennsylvania-based cases against us with prejudice by the end of the fourth quarter of 2019. Legal fees related to this matter have been covered by our insurance carrier. Based upon the current status and evaluation, we have not accrued for any potential loss related to these matters as of June 30, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

DEBT (Tables)
6 Months Ended

Jun. 30, 2019

DEBT

Schedule of Interest expense

Our debt interest expense for the three and six month months ended June 30, 2019 and 2018 consisted of the following:

Three months Ended

Six months Ended

June 30,

June 30,

Interest expense:



2019



2018



2019



2018

Fully paid term loan

$

—

$

63

$

—

$

145

Related party term loans

88

8

168

8

Debt discount

34

13

66

24

Debt issue costs

—

4

—

10

Financed insurance premiums

1

—

3

—

Total interest expense

$

123

$

88

$

237

$

187

Less: imputed interest income on related party loan

(4)

(74)

(13)

(74)

Total interest expense, net

$

119

$

14

$

224

$

113

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) - USD ($)
shares in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Jan. 31, 2019

Dec. 31, 2018

Jan. 31, 2018

Dec. 31, 2017

Jan. 31, 2017

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Nov. 30, 2017

Mar. 31, 2014

Employee Benefit Plans Disclosure [Line Items]

Aggregate intrinsic value of the option awards vested $ 0 $ 0 $ 0 $ 0

Unrecognized compensation cost on unvested option awards outstanding 9 9

Allocated Share-based Compensation Expense 33 $ 66 $ 68 $ 142

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 8 months

Restricted stock units | Director [Member]

Employee Benefit Plans Disclosure [Line Items]

Deferred Compensation Arrangement with Individual, Recorded Liability $ 11 $ 9 $ 9

Restricted Stock Award Plan

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 219 219

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 60

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 25.00% 25.00%

Share-based Compensation Arrangement by Share-based Payment Award, Description stock, for up to 40%

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 1,500

Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period 492 67 200

Restricted Stock Award Plan | January 4, 2016 Award Distributed [Member]

Employee Benefit Plans Disclosure [Line Items]

Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution 83

Restricted Stock Award Plan | Four Non Employee Directors [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 25

2014 Restricted Stock Unit Award Plan [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 400

X

- References
No definition available.
+ Details

Name: acur_EmployeeBenefitPlansDisclosureLineItems

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options reserved for future distribution to employees.
+ References
No definition available.
+ Details

Name: acur_ShareBasedCompensationArrangementShareBasedPaymentSharesReservedForFutureDistribution

Namespace Prefix: acur_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 30
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363
+ Details

Name: us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of vesting of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=srt_DirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=acur_RestrictedStockAwardPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis=acur_January42016AwardDistributedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=acur_FourNonEmployeeDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=acur_RestrictedStockAwardPlanTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE - Non-Cash Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Total Stock Compensation

Allocated Share-based Compensation Expense $ 33 $ 66 $ 68 $ 142

Research and development expense

Total Stock Compensation

Allocated Share-based Compensation Expense 6 18 12 38

Research and development expense | Stock options

Total Stock Compensation

Allocated Share-based Compensation Expense 2 11 4 24

Research and development expense | Restricted stock units

Total Stock Compensation

Allocated Share-based Compensation Expense 4 7 8 14

General and administrative expense

Total Stock Compensation

Allocated Share-based Compensation Expense 27 48 56 104

General and administrative expense | Stock options

Total Stock Compensation

Allocated Share-based Compensation Expense 4 19 6 53

General and administrative expense | Restricted stock units

Total Stock Compensation

Allocated Share-based Compensation Expense $ 23 $ 29 $ 50 $ 51

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: acur_AllocatedShareBasedCompensationExpenseAbstract

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NatureOfExpenseAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_NatureOfExpenseAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

REVENUE FROM CONTRACTS WITH CUSTOMER (Tables)
6 Months Ended

Jun. 30, 2019

REVENUE FROM CONTRACTS WITH CUSTOMER

Schedule of disaggregation of revenue

The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.

On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.

Royalty revenues by licensee are summarized below:



Three months

Six months

Ended

Ended

June 30,

June 30,

2019

2018

2019

2018

Egalet

$

43

$

70

$

98

$

260

MainPointe

3

6

15

14

Royalty revenues

$

46

$

76

$

113

$

274

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

COMMON STOCK WARRANTS (Tables)
6 Months Ended

Jun. 30, 2019

COMMON STOCK WARRANTS

Schedule Of Common Stock Warrant Activity

Our warrant activity for the six months ended June 30, 2019 and 2018 consisted of the following (in thousands except price data):

Six Months Ended

June 30,

2019

2018





WAvg





WAvg

Exercise

Exercise

Number

Price

Number

Price

Outstanding, Jan. 1

1,842

$

0.59

1,842

$

0.59

Issued

10,000

0.01

—

—

Exercised

—

—

—

—

Expired

—

—

—

—

Modification

—

—

—

—

Outstanding, Jun. 30

11,842

$

0.10

1,842

$

0.59

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) - shares
shares in Thousands
6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Restricted Stock Units [Member]

Share based Compensation Arrangement by Share-based Payment Award [Line Items]

Outstanding, beginning 951 462

Granted 333 267

Distributed (267) (262)

Forfeited or expired (8)

Outstanding, ending 1,017 459

Vested Restricted Stock Units (RSUs) [Member]

Share based Compensation Arrangement by Share-based Payment Award [Line Items]

Outstanding, beginning 459 262

Distributed (267) (262)

Vested 166 133

Outstanding, ending 358 133

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Distributed In Period
+ References
No definition available.
+ Details

Name: acur_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsDistributedInPeriod

Namespace Prefix: acur_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=acur_RsusMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=acur_VestedRestrictedStockUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

FAIR VALUE MEASUREMENTS (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended

Jun. 28, 2019

Oct. 31, 2018

Jun. 30, 2019

Jun. 30, 2019

FAIR VALUE MEASUREMENTS

Related party loan $ 5,000 $ 5,000 $ 5,000

Loss on debt extinguishment $ (2,600) $ 296 $ (2,600) $ (2,600)

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_EquityFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 62 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Revenues:

Royalty revenue $ 46 $ 76 $ 113 $ 274

Expenses:

Research and development 262 477 575 1,127

General and administrative 406 846 843 1,789

Total expenses 668 1,323 1,418 2,916

Operating loss (622) (1,247) (1,305) (2,642)

Loss on debt extinguishment (2,600) (2,600)

Interest expense, net (Note 10) (119) (14) (224) (113)

Loss before income taxes (3,341) (1,261) (4,129) (2,755)

Provision for income taxes 0 0

Net loss $ (3,341) $ (1,261) $ (4,129) $ (2,755)

Net loss per share:

Basic $ (0.15) $ (0.06) $ (0.19) $ (0.13)

Diluted $ (0.15) $ (0.06) $ (0.19) $ (0.13)

Weighted average number of shares outstanding:

Basic 21,872 21,101 21,684 21,068

Diluted 21,872 21,101 21,684 21,068

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 63 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

OPERATIONS AND BASIS OF PRESENTATION
6 Months Ended

Jun. 30, 2019

OPERATIONS AND BASIS OF PRESENTATION

OPERATIONS AND BASIS OF PRESENTATION

NOTE 1 – OPERATIONS AND BASIS OF PRESENTATION

Principal Operations

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

·

Our Limitx Technology is in development with immediate-release tablets containing hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate due to its large market size and its known prevalence of oral excessive tablet abuse and overdose. The technology is designed to retard the release of active opioid drug when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. US commercialization rights to LTX-03 are licensed to Abuse Deterrent Pharmaceuticals LLC (See Note 3).

·

Our Aversion Technology has been licensed to Zyla Life Sciences or Zyla (formerly known as Egalet Corporation) for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths (See Note 3).

·

Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC (MainPointe), our Impede Technology in the United States and Canada to commercialize these Nexafed products (See Note 3).

Basis of Presentation, Liquidity and Substantial Doubt in Going Concern

The accompanying unaudited consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America for interim financial information, the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not contain all disclosures required by generally accepted accounting principles. Reference should be made to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018. In the opinion of the Company, all normal recurring adjustments have been made that are necessary to present fairly the results of operations for the interim periods. Operating results for the three and six month periods ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of June 30, 2019, we had cash of $15 thousand, working capital deficit of $696 thousand and an accumulated deficit of $388 million. We had a loss from operations of $1.3 million and a net loss of $4.1 million for the six months ended June 30, 2019. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We had a loss from operations of $3.92 million and a net loss of $3.84 million for the year ended December 31, 2018. We anticipate operating losses to continue for the foreseeable future. As of February 10, 2020 we had cash of approximately $800 thousand.

On June 28, 2019, we entered into with Abuse Deterrent Pharma, LLC (AD Pharma), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"). AD Pharma has the right to terminate the AD Pharma Agreement for "convenience". Under the AD Pharma Agreement, the required monthly license payments by AD Pharma will only continue until November 2020 if AD Pharma does not exercise their right to terminate the AD Pharma Agreement. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company's ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. Delay or cessation of the Company's continuing product development efforts will have a material adverse effect on the Company's financial condition and results of operations. Should AD Pharma exercise their right to terminate the AD Pharma Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma's right to terminate the Agreement "upon convenience", our auditors included in their report relating to our 2018 financial statements a "going concern" explanatory paragraph as to substantial doubt on our ability to continue as a going concern.

In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying consolidated balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

X

- References
No definition available.
+ Details

Name: acur_DescriptionOfOperationAndSummaryOfSignificantAccountingPoliciesDisclosureAbstract

Namespace Prefix: acur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

REVENUE FROM CONTRACTS WITH CUSTOMER
6 Months Ended

Jun. 30, 2019

REVENUE FROM CONTRACTS WITH CUSTOMER

REVENUE FROM CONTRACTS WITH CUSTOMER

NOTE 4 – REVENUE FROM CONTRACTS WITH CUSTOMER

Adoption of ASC Topic 606, Revenue from Contracts with Customers

The Company adopted ASC Topic 606 on January 1, 2018 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. While the timing of future revenues under ASC Topic 606 may differ from the Company’s historical accounting practices under ASC Topic 605, the cumulative effect recorded through the Consolidated Statement of Stockholders’ Deficit was zero because there was no change in timing or measurement of revenues for open contracts at January 1, 2018.

Under ASC 606, revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at June 30, 2019.

The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation.

The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract.

Sales-based Milestones and Royalty Revenues

The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Zyla and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter.

License and Collaboration Agreement Revenues

The achievement of milestones under the Company’s license and collaboration agreements will be recorded during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled, which may result in later recognition as compared to the previous accounting standards.

Disaggregation of Total Revenues

The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.

On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.

Royalty revenues by licensee are summarized below:



Three months

Six months

Ended

Ended

June 30,

June 30,

2019

2018

2019

2018

Egalet

$

43

$

70

$

98

$

260

MainPointe

3

6

15

14

Royalty revenues

$

46

$

76

$

113

$

274

Contract Balance and Performance Obligations

The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2019 or December 31, 2018 was $0. Contract assets may be reported in future periods under prepaid expenses or other current assets on the balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the balance sheet.

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

DEBT
6 Months Ended

Jun. 30, 2019

DEBT

DEBT

NOTE 8 – DEBT

Fully Paid Loan

In December 2013, we entered into a Loan and Security Agreement (the “Oxford Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). In October 2018 we borrowed $1.8 million from Mr. Schutte and used $1.5 million from the loan proceeds to negotiate, settle and pay-off in full the Oxford Loan for $1.5 million. We recognized a net gain of $296 thousand on the debt settlement. All security interests of Oxford with respect to the Oxford Term Loan have been released.

The Oxford Term Loan accrued interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan was due and payable in full on December 1, 2018. As security for its obligations under the initial Oxford Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Upon the execution of the Oxford Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

In January 2015, we and Oxford amended the Oxford Loan Agreement providing for the exercise price of the Warrants to be lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the Warrant modification.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses, in connection with the Oxford Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred a total $231 thousand in deferred debt issue costs. We have amortized these costs, including debt modification additional costs, into interest expense over the term of the Term Loan using the loan’s effective interest rate of 10.16%.

Related Party Convertible Loan

From January 1, 2019 and through June 27, 2019, we borrowed an aggregate of $650 thousand from Mr. Schutte and issued various promissory notes to him with the same terms and conditions from the previous loans. Because we believed the Schutte Notes’ rate of interest is below current market rates for us, we imputed interest on the below market rate element of the loans using the 10.16% interest rate under the Oxford Loan Agreement and this has aggregated to $185 thousand as of June 27, 2019. We recorded these benefits to interest income in the period we received the loan, with a corresponding like amount as debt discount against the principal amount of the loan. The debt discount will be amortized to interest expense over the term on the loans. All our assets are pledged as collateral under the Schutte Notes, including our intellectual property.

On June 27, 2019 the aggregate amount of the loans made to the Company by Mr. Schutte aggregated $5.0 million. On June 28, 2019 we entered into an agreement to borrow an additional $725 thousand from Mr. Schutte, which was received on July 2, 2019, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted principal and interest conversion rights into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the loan is convertible into 37.5 million shares of our common stock. The modifications to the loan and the method of accounting for the loan changes resulted in a $2.6 million loss on debt extinguishment. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

The events of default under the $6.0 million note are limited to bankruptcy defaults, failure to pay interest and principal when due on July 1, 2023 or upon the termination of the AD Pharma agreement covering LTX-03. The $6.0 million note may be prepaid at any time in whole or in part but only with the consent of the noteholder.

Our debt interest expense for the three and six month months ended June 30, 2019 and 2018 consisted of the following:

Three months Ended

Six months Ended

June 30,

June 30,

Interest expense:



2019



2018



2019



2018

Fully paid term loan

$

—

$

63

$

—

$

145

Related party term loans

88

8

168

8

Debt discount

34

13

66

24

Debt issue costs

—

4

—

10

Financed insurance premiums

1

—

3

—

Total interest expense

$

123

$

88

$

237

$

187

Less: imputed interest income on related party loan

(4)

(74)

(13)

(74)

Total interest expense, net

$

119

$

14

$

224

$

113

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

SHARE-BASED COMPENSATION EXPENSE
6 Months Ended

Jun. 30, 2019

SHARE-BASED COMPENSATION EXPENSE

SHARE-BASED COMPENSATION EXPENSE

NOTE 12 – SHARE-BASED COMPENSATION EXPENSE

Share-based Compensation

We have four share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):

Three months Ended

Six months Ended

June 30,

June 30,

2019

2018

2019

2018



(in thousands)

Research and development costs:









Stock options

$

2

$

11

$

4

$

24

Restricted stock units

4

7

8

14

Subtotal

$

6

$

18

$

12

$

38

General and administrative costs:









Stock options

$

4

$

19

$

6

$

53

Restricted stock units

23

29

50

51

Subtotal

27

$

48

56

$

104

Total

$

33

$

66

$

68

$

142

Stock Option Award Plans

We maintain various stock option plans. A summary of our stock option plan activity during the six month periods ending June 30, 2019 and 2018 is shown below:

Six Months Ended

June 30,

2019

2018



Number



Weighted





Weighted

of

Average

Number of

Average

Options

Exercise

Options

Exercise

(000’s)

Price

(000’s)

Price

Outstanding, Jan. 1

1,560

$

7.38

1,494

$

12.33

Granted

—

—

—

—

Exercised

—

—

—

—

Forfeited or expired

(170)

(30.83)

(145)

(46.39)

Outstanding, Jun. 30

1,390

$

4.44

1,349

$

8.68

Options exercisable

1,158

$

5.30

1,129

$

10.26

The following table summarizes information about nonvested stock options outstanding at June 30, 2019 (in thousands except price data):



Number of



Weighted

Options Not

Average

Exercisable

Fair Value

Outstanding, Jan. 1, 2019

232

$

0.10

Granted

—

—

Vested

—

—

Forfeited

—

—

Outstanding, Jun. 30, 2019

232

$

0.10

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity.

The intrinsic value of the option awards which were vested and outstanding at each of June 30, 2019 and 2018 was $0. The total remaining unrecognized compensation cost on unvested option awards outstanding at June 30, 2019 was $9 thousand, and is expected to be recognized in operating expense in varying amounts over the 8 months remaining in the requisite service period.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors; a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). The 2017 RSU Plan was approved by our shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. The 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of June 30, 2019 there are approximately 219 thousand shares available for award under the 2017 RSU Plan and there are no remaining shares available for award under the 2014 RSU Plan.

Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The RSU awards to our non-employee directors allow for them to receive payment in cash upon the RSU award's distribution, instead of an exchange into our common stock, for up to 40% of each RSU award. The portion of the RSU award subject to cash settlement is recorded as a liability in the Company’s balance sheet and to either general and administrative expense or research and development expense while being marked-to-market each reporting period until the award is distributed. The liability was $9 thousand and $11 thousand at June 30, 2019 and December 31, 2018, respectively.

The compensation cost to be incurred by the Company on a granted RSU award without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized over the vesting period of the RSU award to either general and administrative expense or research and development expense and recorded as additional paid-in capital.

A summary of the grants under the RSU Plans as of June 30, 2019 and 2018, and for the six month period then ended consisted of the following (in thousands):

Six Months Ended June 30,

2019

2018

(in thousands)





Number of





Number of

Number

Vested

Number of

Vested

of RSUs

RSUs

RSUs

RSUs

Outstanding, Jan. 1

951

459

462

262

Granted

333

—

267

—

Distributed

(267)

(267)

(262)

(262)

Vested

—

166

—

133

Forfeited or expired

—

—

(8)

—

Outstanding, Jun. 30

1,017

358

459

133

Information about the award activity under the RSU Plans is as follows:

·

In December 2017, we awarded 200 thousand RSUs to employees and such RSU awards were fully vested on December 31, 2018. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2020, 2021 and 2022. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

·

In January 2017, we awarded approximately 60 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2017. In January 2018, these awards were distributed and they were exchanged into 214 thousand shares of our common stock while 24 thousand RSUs were settled in cash. There were also 24 thousand RSUs exchanged into common stock from prior year awards.

·

In January 2018, we awarded approximately 67 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2018. In January 2019, these awards were distributed and they were exchanged into 267 shares of our common stock.

·

In December 2018, we awarded 492 thousand RSUs to employees and such RSU awards will vested in full on December 31, 2019. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2021, 2022 and 2023. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

·

In January 2019, we awarded approximately 83 thousand RSUs to each of our non-employee directors. Such awards vest 25% at the end of each calendar quarter during 2019. These awards will be distributed and exchanged into common stock will occur in one third amounts on each of January 2020 and up to 40% of the award can be settled in cash.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 67 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands

Jun. 30, 2019

Dec. 31, 2018

ACCRUED EXPENSES

Cost sharing expenses under license agreements $ 300 $ 237

Other fees and services 26 36

Payroll, payroll taxes and benefits 7 6

Professional services 249 132

Financed premiums on insurance policies 36 102

Clinical, non-clinical and regulatory services 44 63

Property taxes 4 7

Franchise taxes 23 13

Total $ 689 $ 596

X

- Definition
Represents the accrued cost sharing expenses under license agreement.
+ References
No definition available.
+ Details

Name: acur_AccruedCostSharingExpenses

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Other Professional Fees, Current
+ References
No definition available.
+ Details

Name: acur_AccruedOtherProfessionalFeesCurrent

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of accrued expenses for Financed insurance premiums.
+ References
No definition available.
+ Details

Name: acur_FinancedInsurancePremiums

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Other Accrued Taxes Current
+ References
No definition available.
+ Details

Name: acur_OtherAccruedTaxesCurrent

Namespace Prefix: acur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

REVENUE FROM CONTRACTS WITH CUSTOMER (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Royalty revenues $ 46 $ 76 $ 113 $ 274

Zyla

Royalty revenues 43 70 98 260

MainPointe

Royalty revenues $ 3 $ 6 $ 15 $ 14

X

- Definition
Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=acur_EgaletAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=acur_MainPointeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Accumulated amortization, deferred finance costs	$ 1,086	$ 983
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	21,300	21,034
Common stock, shares outstanding	21,300	21,034

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands		6 Months Ended
	Jun. 28, 2019 USD ($)	Jun. 30, 2019 USD ($)
Related party loans made to Company	$ 5,000	$ 5,000
Loss on debt extinguishment	(2,600)	(2,600)
Write-off of unamortized debt discount	70
Accrued interest due on the related party loan rolled into principal under modifications	274	4
Proceeds from related party loan receivable	$ 725	1,650
Payments of Debt Issuance Costs		13
Interest Rate Below Market Reduction [Member]
Related party loans made to Company		650
Imputed interest on the below market rate recorded as benefit to interest income		$ 13

NET LOSS PER SHARE - Additional Information (Details) shares in Millions	Jun. 28, 2019 $ / shares shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Schutte Note [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued \| shares	10.0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended		6 Months Ended
	Jul. 02, 2019	Jun. 28, 2019	Oct. 31, 2018	Jul. 31, 2017	Mar. 31, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 27, 2019	Jun. 30, 2018	Dec. 31, 2013
Related Party Transaction [Line Items]
Fixed interest rate									10.16%		13.35%
Number Of Common Stock Need To Hold To Designate As Director				600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Proceeds from Issuance of Long-term Debt			$ 1,800							$ 1,500
Class Of Warrants Or Rights, Expiry Period				5 years
Royalty revenues						$ 46	$ 76	$ 113		274
MainPointe
Related Party Transaction [Line Items]
Proceeds from License Fees Received					$ 2,500
Asset Transferred, License Agreement					$ 309
Licensing Agreement, Royalty Percentage					7.50%
MainPointe \| Royalty [Member]
Related Party Transaction [Line Items]
Royalty revenues						3	$ 6	15		$ 14
Investor [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.528
Investor [Member] \| Private Placement [Member]
Related Party Transaction [Line Items]
Sale of Stock, Consideration Received on Transaction				$ 4,000
Sale of Stock, Number of Shares Issued in Transaction				8,912,655
Sale of Stock, Price Per Share				$ 0.4488
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.528
Sale Of Stock, Issue Price Description				85%
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 495		495
Proceeds from Issuance of Warrants								$ 4,000
Schutte
Related Party Transaction [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Fixed interest rate		7.50%
Share Price		$ 0.16
Debt Conversion, Converted Instrument, Warrants or Options Issued		10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Debt Conversion, Converted Instrument, Shares Issued		37,500,000
Proceeds from Issuance of Long-term Debt		$ 725							$ 650
Abuse Deterrent Pharma, LLC
Related Party Transaction [Line Items]
Proceeds from License Fees Received	$ 350	$ 350

LICENSE AND COLLABORATION AGREEMENTS (Details) - USD ($) $ in Thousands, shares in Millions				1 Months Ended				3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 02, 2019	Jun. 28, 2019	Oct. 09, 2015	Mar. 31, 2017	Mar. 17, 2017	Oct. 31, 2016	Apr. 30, 2014	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
License Development and Commercialization Agreement [Line Items]
Revenue from Contract with Customer, Including Assessed Tax								$ 46	$ 76	$ 113	$ 274
Amortization of Intangible Assets										103	$ 103
Finite-Lived Intangible Assets, Amortization Expense, Year Two								52		$ 52
Patents [Member]
License Development and Commercialization Agreement [Line Items]
Payment for Termination							$ 2,000
Schutte \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Percentage of common stock held		47.50%
Abuse Deterrent Pharma, LLC
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable	$ 350	$ 350
Abuse Deterrent Pharma, LLC \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable		$ 350
Period until which monthly license payment is receivable		18 months								5 years
MainPointe Pharmaceuticals, LLC \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Waiver of exercise price if exercise of option occurs by certain date		$ 500								$ 500
Period from effective date for exercise of option		5 years
Schutte
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued		10.0
Schutte \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued		10.0
Zyla
License Development and Commercialization Agreement [Line Items]
Payment for Termination							$ 2,000
Minimum Net Sales Reaching Description										one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description										Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla's launch of Oxaydo. Termination does not affect a party's rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla's supply of Oxaydo for a transition period.
Revenue from Contract with Customer, Including Assessed Tax			$ 5,000
Proceeds from Milestone Payment On Agreement			$ 2,500
Amortization of Intangible Assets												$ 208	$ 208
Finite-Lived Intangible Asset, Useful Life							9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Year Two								$ 208		$ 208
MainPointe
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 2,500
Licensing Agreement, Royalty Percentage				7.50%
License Agreement Option Products Description					In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
MainPointe \| UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 1,000
MainPointe \| JAPAN
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				500
MainPointe \| South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable						$ 3,500
Kempharm Agreement [Member] \| Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable						$ 1,000

RESEARCH AND DEVELOPMENT ACTIVITIES	6 Months Ended
RESEARCH AND DEVELOPMENT ACTIVITIES	Jun. 30, 2019
RESEARCH AND DEVELOPMENT ACTIVITIES
RESEARCH AND DEVELOPMENT ACTIVITIES	NOTE 5 – RESEARCH AND DEVELOPMENT ACTIVITIES Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at June 30, 2019 or December 31, 2018.

SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) - Non Vested Stock Options [Member] shares in Thousands	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning \| shares	232
Granted \| shares	0
Vested \| shares	0
Forfeited \| shares	0
Outstanding, ending \| shares	232
Outstanding beginning, Weighted Average Fair Value \| $ / shares	$ 0.10
Granted, Weighted Average Fair Value \| $ / shares	0
Vested, Weighted Average Fair Value \| $ / shares	0.00
Forfeited, Weighted Average Fair Value \| $ / shares	0.00
Outstanding ending, Weighted Average Fair Value \| $ / shares	$ 0.10

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Jun. 30, 2019
RECENT ACCOUNTING PRONOUNCEMENTS
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS New accounting standards which have been adopted on or before June 30, 2019 Leases In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. The classification of the lease will affect the pattern of expense recognition in the income statement such that operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842)-Targeted Improvements" (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840). The Company adopted ASC 842 using the modified retrospective transition approach during Q1 2019, which allows the Company to not adjust the comparative periods presented. The Company has elected to adopt the package of transition practical expedients and, therefore, has not reassessed whether existing or expired contracts contain a lease or the lease classification for existing or expired. The Company did not elect the practical expedient to use hindsight for leases existing at the adoption date. Upon adoption, operating leases was to be reported on the balance sheet as a gross-up of assets and liabilities, however the Company has elected, as an accounting policy, to not recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The adoption of ASC 842 did not have an impact on the Company’s financial statements as the Company has no leases with term of more than 12 months.

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2019	Feb. 10, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		21,650,294

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 208	$ 380,145	$ (380,380)	$ (27)
Balance (in shares) at Dec. 31, 2017	20,796
Net loss			(1,494)	(1,494)
Non-cash share-based compensation		62		62
Net distribution of common stock pursuant to restricted stock unit award plan	$ 2	32		34
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	238
Balance at Mar. 31, 2018	$ 210	380,239	(381,874)	(1,425)
Balance (in shares) at Mar. 31, 2018	21,034
Balance at Dec. 31, 2017	$ 208	380,145	(380,380)	(27)
Balance (in shares) at Dec. 31, 2017	20,796
Net loss				(2,755)
Balance at Jun. 30, 2018	$ 210	380,299	(383,135)	(2,626)
Balance (in shares) at Jun. 30, 2018	21,034
Balance at Dec. 31, 2017	$ 208	380,145	(380,380)	(27)
Balance (in shares) at Dec. 31, 2017	20,796
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Balance at Mar. 31, 2018	$ 210	380,239	(381,874)	(1,425)
Balance (in shares) at Mar. 31, 2018	21,034
Net loss			(1,261)	(1,261)
Non-cash share-based compensation		60		60
Balance at Jun. 30, 2018	$ 210	380,299	(383,135)	(2,626)
Balance (in shares) at Jun. 30, 2018	21,034
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Net loss			(788)	(788)
Non-cash share-based compensation		29		29
Net distribution of common stock pursuant to restricted stock unit award plan	$ 3	12		15
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	266
Balance at Mar. 31, 2019	$ 213	380,436	(385,010)	(4,361)
Balance (in shares) at Mar. 31, 2019	21,300
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Net loss				(4,129)
Balance at Jun. 30, 2019	$ 213	382,992	(388,351)	(5,146)
Balance (in shares) at Jun. 30, 2019	21,300
Balance at Mar. 31, 2019	$ 213	380,436	(385,010)	(4,361)
Balance (in shares) at Mar. 31, 2019	21,300
Net loss			(3,341)	(3,341)
Non-cash share-based compensation		29		29
Debt premium from debt modification		1,382		1,382
Issuance of warrant		1,145		1,145
Balance at Jun. 30, 2019	$ 213	$ 382,992	$ (388,351)	$ (5,146)
Balance (in shares) at Jun. 30, 2019	21,300

FAIR VALUE MEASUREMENTS	6 Months Ended
FAIR VALUE MEASUREMENTS	Jun. 30, 2019
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than our debt, are representative of their respective fair values due to their relatively short maturities. On June 28, 2019, we modified the $5.0 million related party loan and reported the debt using fair value for the changes to the loan resulting in the recognizing a $2.6 million loss on debt extinguishment.

LICENSE AND COLLABORATION AGREEMENTS	6 Months Ended
LICENSE AND COLLABORATION AGREEMENTS	Jun. 30, 2019
LICENSE AND COLLABORATION AGREEMENTS
LICENSE AND COLLABORATION AGREEMENTS	NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement. AD Pharma Agreement covering LTX-03 On June 28, 2019 we entered into with Abuse Deterrent Pharma, LLC ("AD Pharma"), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"), for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITxTM. Acura will receive a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019. AD Pharma will pay for and reimburse Acura for all outside development costs on LTX-03. If the NDA filing for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the Limitx intellectual property. AD Pharma does have the right to terminate the AD Pharma Agreement anytime for "convenience". AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones. We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. (See MainPointe Agreement covering Nexafed products). The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). On June 28, 2019 Mr. John Schutte assigned and transferred to AD Pharma his $6.0 million promissory note, the common stock purchase warrant for 10.0 million common shares, and the security agreement granting a security interest in all of the Company's assets. (See Note 8). Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of remaining common stock purchase warrants he holds). Mr. Schutte controls MainPointe and is the principal investor in AD Pharma. Zyla Agreement covering Oxaydo In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. We have recorded annual amortization expense of $208 thousand for each of the years 2018 and 2017. Amortization of the patent for the years 2019 through 2021 is expected to approximate $208 thousand each year and $52 thousand be quarter. In January 2015, we and Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, entered into a Collaboration and License Agreement (the “Zyla Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Zyla Agreement, we and Zyla formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions although no meetings were held in 2019 or to date in 2020. Zyla is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Zyla will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Zyla will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion. Zyla paid us a $5.0 million license fee upon signing of the Zyla Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla's royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor. The Zyla Agreement expires upon the expiration of Zyla’s royalty payment obligations in all countries. Either party may terminate the Zyla Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Zyla Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Zyla Agreement with respect to the U.S. and other countries if Zyla materially breaches its commercialization obligations. Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla’s supply of Oxaydo for a transition period. MainPointe Agreement covering Nexafed products In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country. MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. KemPharm Agreement Covering Certain Opioid Prodrugs In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free. The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

DEBT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 28, 2019	Oct. 31, 2018	Jan. 31, 2015	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 27, 2019	Dec. 31, 2013
Debt Instrument [Line Items]
Debt instrument principal amount									$ 10,000
Proceeds from Issuance of Long-term Debt		$ 1,800					$ 1,500
Debt instrument, interest rate, stated percentage								10.16%	13.35%
Debt instrument, fee amount				$ 50		$ 50
Gain (Loss) on Extinguishment of Debt	$ (2,600)	296		(2,600)		(2,600)
Debt consulting placement fee						100
Deferred debt issue costs				$ 0	$ 4	0	10
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Repayments of Debt							$ 1,220
Debt Instrument, Periodic Payment						$ 260
Debt Instrument, Interest Rate, Effective Percentage				10.16%		10.16%
Related party loans made to Company	$ 5,000			$ 5,000		$ 5,000
Term Loan [Member]
Debt Instrument [Line Items]
Deferred debt issue costs						231
Schutte Note [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 5,000
Proceeds from Issuance of Long-term Debt	725
Aggregate principal of promissory notes and accrued interest	6,000
Debt instrument, interest rate, stated percentage								7.50%
Gain (Loss) on Extinguishment of Debt	$ (2,600)
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Debt Conversion, Converted Instrument, Shares Issued	37,500
Debt Conversion, Converted Instrument, Warrants or Options Issued	10,000
Share Price	$ 0.16
Related party loans made to Company								$ 650
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									8.35%
Oxford Term Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 185
Repayments of Debt		$ 1,500
Maximum
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.98
Minimum
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52
Common stock purchase warrants
Debt Instrument [Line Items]
Debt instrument unamortized discount				$ 400		$ 400
Warrants to purchase common stock				60		60
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.52		$ 2.52
Warrants, expiry date						December 27, 2020
Additions To Debt Instrument Unamortized Discount			$ 33

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES Reglan®/Metoclopramide Litigation Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L‑3865‑10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC‑10‑004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. None of the plaintiffs in the lawsuits filed to date have confirmed that they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. All of these lawsuits have been effectively dismissed with the exception of less than ten pending Philadelphia cases that we expect will be finally dismissed without the need for any action by us. We expect that the Court will finally dismiss the small number of remaining Pennsylvania-based cases against us with prejudice by the end of the fourth quarter of 2019. Legal fees related to this matter have been covered by our insurance carrier. Based upon the current status and evaluation, we have not accrued for any potential loss related to these matters as of June 30, 2019.

SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended					3 Months Ended		6 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Nov. 30, 2017	Mar. 31, 2014
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested						$ 0	$ 0	$ 0	$ 0
Unrecognized compensation cost on unvested option awards outstanding						9		9
Allocated Share-based Compensation Expense						33	$ 66	$ 68	$ 142
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								8 months
Restricted stock units \| Director [Member]
Employee Benefit Plans Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 11				$ 9		$ 9
Restricted Stock Award Plan
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						219		219
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					60
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description								stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		492	67	200
Restricted Stock Award Plan \| January 4, 2016 Award Distributed [Member]
Employee Benefit Plans Disclosure [Line Items]
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution	83
Restricted Stock Award Plan \| Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	25
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant											400

SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	951	462
Granted	333	267
Distributed	(267)	(262)
Forfeited or expired		(8)
Outstanding, ending	1,017	459
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	459	262
Distributed	(267)	(262)
Vested	166	133
Outstanding, ending	358	133

FAIR VALUE MEASUREMENTS (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
FAIR VALUE MEASUREMENTS (Detail) - USD ($) $ in Thousands	Jun. 28, 2019	Oct. 31, 2018	Jun. 30, 2019	Jun. 30, 2019
FAIR VALUE MEASUREMENTS
Related party loan	$ 5,000		$ 5,000	$ 5,000
Loss on debt extinguishment	$ (2,600)	$ 296	$ (2,600)	$ (2,600)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
ACCRUED EXPENSES
Cost sharing expenses under license agreements	$ 300	$ 237
Other fees and services	26	36
Payroll, payroll taxes and benefits	7	6
Professional services	249	132
Financed premiums on insurance policies	36	102
Clinical, non-clinical and regulatory services	44	63
Property taxes	4	7
Franchise taxes	23	13
Total	$ 689	$ 596